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Abstract 
 
 
P2X7 is a member of the P2X purine receptor family and functions as an ATP-
gated non-selective cation channel. Expression is greatest in cells of the 
immune system where it plays a key role in the orchestration of IL1β 
maturation and release. Diabetic nephropathy (DN) is traditionally 
considered a ‘metabolic’ disease, but is increasingly recognized to have an 
important inflammatory component. The work in this thesis tests the 
hypothesis that P2X7 contributes to the pathogenesis of DN and, in 
particular, the development of renal inflammation in this disease. 
 
P2X7 expression was examined by immunohistochemistry in human kidney 
biopsy tissue; glomerular expression was identified in a subset of patients 
with early clinical DN. P2X7 expression was also upregulated at 12 weeks in 
glomeruli of rodents with both type 1 and type 2 diabetes.  After induction of 
diabetes with low dose STZ, GSK P2X7 KO mice exhibited a marked reduction 
in glomerular macrophage infiltration compared to WT, without impact on 
albuminuria or serum creatinine. A trend towards protection against 
induction of diabetes was also apparent in GSK KO mice; this protection was 
more pronounced in the Pfizer P2X7 KO strain and accompanied by reduced 
islet macrophage infiltration and preservation of β-cell mass. 
 
The mechanism linking P2X7 and glomerular macrophage infiltration was 
explored in vitro. A selective P2X7 antagonist, A438079, partially abrogated 
hyperglycaemia-induced secretion of the macrophage chemokine, MCP-1, 
from primary human mesangial cells (pHMC). MCP-1 secretion was enhanced 
by the ATP-hydrolysing agent, apyrase, as well as by application of 5-BDBD, a 
selective P2X4 antagonist, suggesting chemokine secretion from pHMCs may 
be modulated by multiple competing purinoceptor signals. 
iii 
 
In summary, P2X7 is upregulated at an early time-point in rodent diabetic 
glomeruli, and contributes to both glomerular and pancreatic inflammation 
in murine experimental disease. Comparable upregulation of P2X7 in 
glomeruli observed in human DN bodes well for future translational studies. 
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CHAPTER 1 
Introduction 
 
Part 1. Purinoceptor Signalling in the Kidney 
 
1.1 Overview 
 
Since the first observation in 1970 that adenosine triphosphate (ATP) may be 
released from nerve terminals in the gut and function as a neurotransmitter, 
receptors for extracellular nucleotides have been identified on almost every 
cell type within the body (Burnstock et al., 1970, Burnstock, 2006). Broadly, 
these are divided into P (for purine) 1 receptors that recognise adenosine, 
and P2 receptors that recognise ATP and related di- and tri-phosphate 
nucleotides. P2 receptors are further subdivided into P2Y, which are 
metabotropic G protein-coupled receptors, and P2X, which function as non-
selective cation channels (Figure 1.1) (Abbracchio et al., 2006, Khakh and 
North, 2006). Seven P2X receptors (P2X1-7) and eight P2Y receptors (P2Y1, 
2, 4, 6 and 11-14) are currently recognised (Abbracchio et al., 2006, Khakh 
and North, 2006). P2X receptors are trimeric channels with the potential for 
further complexity through heteromeric subunit assemblies between some 
family members (North, 2002). Each receptor can be characterised 
pharmacologically by its preference for certain endogenous and synthetic 
ligands. 
 
Both P2 receptor classes may couple to a wide range of intracellular second 
messenger systems with activation frequently provoking a rise in cytosolic 
calcium: through mobilisation of intracellular stores in the case of P2Y 
receptors, by direct calcium influx through P2X channels or via influx through 
voltage-gated calcium channels activated by cell depolarisation (Abbracchio 
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et al., 2006, Khakh and North, 2006). Signalling through different P2 
receptors may exert disparate and even antagonistic effects on cellular 
function (Solini et al., 2005).  
 
ATP is secreted in renal tubular fluid with concentrations measured at 
around 200nM in the proximal tubule (Vekaria et al., 2006). Any renal cell 
may be provoked to release ATP under conditions such as mechanical 
stimulation or osmotic stress, fluid flow or agonist stimulation, while red 
cells, platelets, and damaged or dying cells also represent important sources 
of nucleotide release (Praetorius and Leipziger, 2009a). P2 receptors are 
expressed differentially throughout the kidney and purinoceptor signalling 
appears to have important roles in water and sodium transport, control of 
the renal microcirculation, and in autoregulatory responses (Turner et al., 
2003, Unwin et al., 2003). In addition, ectonucleotidases can modulate 
agonist availability and the pattern of receptor activation in the local 
microenvironment (Shirley et al., 2009). 
 
From these observations it is reasonable to speculate that the P2 
purinoceptor system may function as a subtle autocrine or paracrine 
feedback system, integrating signals based on the local patterns of secretion, 
release and degradation of nucleotides. Moreover, it is becoming increasingly 
apparent that deleterious signals transduced via P2 receptors may contribute 
to disease within the kidney. One receptor which has generated particular 
interest in this setting is P2X7. 
 
 
1.2 The P2X7 receptor 
 
In the initial classification of P2 receptors, an additional class designated the 
‘P2Z’ receptor was included, recognised by its requirement for a high 
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concentration of extracellular ATP for channel activation and ability to form 
transmembrane aqueous pores permitting passage of solutes up to 900 Da, 
typically culminating in cell death (Pizzo et al., 1992). Subsequent discovery 
and cloning of a receptor with 40% sequence homology to the existing six 
P2X receptors and pharmacological profile compatible with P2Z led to 
rechristening as P2X7 (Surprenant et al., 1996). As for the other P2X 
receptors, P2X7 displays preference for the endogenous agonist ATP, with 
brief stimulation leading to a rapid transient current due to non-densitizing 
monovalent and divalent cation conductance (Wiley et al., 2011). Repeated 
receptor stimulation, however, leads to a more slowly developing secondary 
permeability pathway transmitting larger cations such as N-methyl-D-
glucamine and dyes including ethidium bromide (Surprenant et al., 1996, 
Wiley et al., 2011). This ‘large pore’ pathway is functionally dependent on the 
long intracellular carboxyl-domain of P2X7, which differentiates it 
structurally from other members of the P2X family (Figure 1.2A). 
 
 
1.2.1 Receptor structure and channel properties 
 
P2X receptors consist of 3 subunits, each comprising two transmembrane 
domains, an extracellular loop and intracellular N- and C- termini. P2X7 is 
thought to be homomeric, and while it can often be co-precipitated and co-
isolated with P2X4 from cell extracts, this does not appear to represent true 
heteromer formation (Antonio et al., 2011). Recent elucidation of the crystal 
structure of zebrafish P2X4, which shares functional similarities with P2X7 
including the capacity for large pore formation, has shed light on structure-
function relationships across the P2X family (Kawate et al., 2009). Individual 
subunits of the homomeric P2X4 receptor resemble a dolphin with the 
extracellular domain forming the ‘head’ and ‘body’ and transmembrane 
helices the ‘flukes’ (Figure 1.2B). The TM2 domains line the aqueous 
permeation pathway with rotation of subunits on agonist binding  
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Figure 1.2 Transmembrane topography and subunit structure of the P2X7 receptor. A: The
P2X7 receptor consists of three subunits, each comprising two transmembrane domains,
intracellular N- and C-termini, and a hydrophilic extracellular loop including an ATP binding-
pocket created by the interaction between neighbouring subunits. The position of putative
disulphide bridges (=) and N-linked glycosyl chains (blue circles) are marked. B: Extracellular
subunit structure of the related P2X4 receptor, as delineated by X-ray crystallography, which
shows resemblance to a dolphin emerging from the cell membrane. C: A more topographically
accurate representation of the ATP binding site of P2X4; ATP is shown in sphere configuration,
and the right-hand pane shows a close-up of the pertinent molecular interations. TM:
transmembrane; N: N-terminus; C: C-terminus. Part A adapted from Wesselius et al., 2007. Parts
B and C reproduced by permission from Macmillan Publishers Limited: Nature, Kawate et al.
2009, copyright 2009 (A) and Nature, Hattori et al. 2012, copyright 2012 (B).
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conjectured to realign these domains vertically to open the channel. Three 
ATP binding sites are thought to be located in the grooves between subunits. 
 
Mathematical modelling of P2X7 receptor gating has led to a suggested 
scheme for receptor function: binding of a single ATP molecule induces 
receptor asymmetry and discourages binding of a second ATP molecule; 
binding of a second ATP molecule at higher concentration triggers opening of 
the ‘small pore’ cationic conductance; binding of a third molecule leads to 
further pore enlargement (permitting conductance of larger cations such as 
NMDG) and triggers activity of the associated ‘large pore’ conductance (Yan 
et al., 2010, Pelegrin, 2011). Studies demonstrating dissociation of the small 
cationic and large solute currents, for instance after mutating the C-terminus 
of the channel, suggest that the receptor itself does not form the large pore 
(Wiley et al., 2011). 
 
The C-terminal domain of P2X7, which is 120-200 amino acids longer than 
the other P2X receptors, appears to be critical for large pore formation, 
interaction with adaptor proteins and receptor trafficking (Roger et al., 
2010). Interaction with the recently discovered protein pannexin-1 (panx-1) 
appears to underlie, at least in some cell types, the large pore conductance: 
panx-1 and P2X7 co-immunoprecipitated in HEK293 cells demonstrating 
their structural association, while siRNA knockdown or panx-1 channel 
inhibition with carbenoxolone abolished P2X7-dependent dye uptake but not 
small cation currents in HEK293 cells and human and murine macrophages 
(Pelegrin and Surprenant, 2006, Pelegrin and Surprenant, 2009).  
 
P2X7 can also be linked to other pore-forming pathways as demonstrated by: 
i) the existence of separate pathways for cationic and anionic dye 
conductance in mouse macrophages (panx-1 is permeable only to cationic 
dyes); ii) the existence of a MAPK-dependent dye uptake pathway 
independent of IL1β release or cytolytic pore formation; iii) and the finding 
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that colchicine can block P2X2- and P2X7-dependent dye uptake without 
affecting small cation conductance (panx-1 is not involved in the formation of 
P2X2-associated large pores) (Donnelly-Roberts et al., 2004, Schachter et al., 
2008, Pelegrin, 2011, Marques-da-Silva et al., 2011). 
 
 
1.2.2 Tissue distribution 
 
P2X7 expression varies considerably from tissue to tissue with the highest 
constitutive levels found in cells of the immune system, consistent with its 
well-defined role in inflammatory cytokine processing and release (see 
below). Within this system, highest expression is found in macrophages, 
followed by dendritic cells, monocytes, NK cells, and B and T lymphocytes, 
although there is some inter-species variability in this rank order (Gu et al., 
2000, Wiley et al., 2011). Neutrophils express minimal cell surface receptors 
but display abundant intracellular protein, as do all haemopoietic cells (Gu et 
al., 2000). 
 
Within the kidney and renal tract, P2X7 is expressed in cultured mesangial 
cells and has been demonstrated at low levels in distal tubular epithelium in 
human kidney biopsy tissue (Harada et al., 2000, Solini et al., 2007, Gauer et 
al., 2007). P2X7 is also expressed in other renal interstitial or infiltrating cell 
types including fibroblasts and tissue macrophages (Ponnusamy et al., 2011). 
In common with several other epithelial tissues including vaginal and uterine 
epithelium, alveolar epithelial cells and stratified squamous skin epithelial 
cells, P2X7 is also expressed in urothelial cells lining the ureter and bladder 
(Groschel-Stewart et al., 1999, Bardini et al., 2000, Lee et al., 2000, Mishra, 
2013). The function of P2X7 in epithelia is not fully understood, although it 
appears to contribute to regulation of surfactant production in alveoli, and 
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may contribute to mechanisms of epithelial turnover or pathogen defence 
(Wiley et al., 2011, Mishra, 2013). 
 
In other tissues, P2X7 has been identified in microglia and astrocytes within 
the brain as well as spinal neurons where it has been implicated in 
nociceptive signalling (Wiley et al., 2011, Burnstock, 2013). In bone, P2X7 is 
found in both osteoblasts (of mesenchymal origin) and osteoclasts (derived 
from cells of haematopoietic lineage) and appears to have an important 
physiological role in the mechanotransduction of skeletal loading to new 
bone formation (Li et al., 2005). 
  
 
1.2.3 Agonist and antagonists (Table 1.1) 
 
P2X7 activation requires a high concentration of extracellular ATP (EC50 >80-
100µM), one feature which distinguishes it from the other P2X receptors 
(North, 2002, Wiley et al., 2011). The ATP analogue BzATP is 10-30 times 
more potent than ATP (EC50 7µM) but lacks specificity, exerting stimulatory 
effects at other P2X receptors, as well as acting as an antagonist of P2Y 
receptors (North, 2002). ATPγS and ADP are essentially inactive at the 
channel in the resting state (Donnelly-Roberts and Jarvis, 2007). P2X7 
activity is potentiated by reducing the extracellular concentration of calcium 
or magnesium, possibly through allosteric effects (Michel et al., 1999, Wiley 
et al., 2011). This phenomenon has bearing on P2X7 activation in the distal 
nephron, where tubular calcium and magnesium concentrations are reduced 
due to proximal reabsorption. 
 
A recent study examining P2X7 agonist and antagonist responses using 
whole-cell patch clamp recordings in HEK 293 cells, suggests that 
intermediate activation states of P2X7 have altered nucleotide selectivity 
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(Browne and North, 2013). 'Tethering' of BzATP to P2X7, with consequent 
persistent membrane current, was achieved by coincident exposure to 
ultraviolet radiation. Both ADP and CTP stimulated membrane currents when 
applied to receptors with pre-'tethered' BzATP, while the same agonists 
proved ineffective when applied to receptors in the resting state. This finding 
suggests that our current schema for P2 receptor pharamacological 
responses likely underestimates the true complexity of receptor-agonist 
interactions in in vivo biological systems. 
 
The endogenous human cathelicidin-derived peptide LL37, produced 
predominantly by neutrophils and endothelial cells, also displays activity at 
the P2X7 receptor, and is capable of stimulating IL1β release from LPS-
primed monocytes in an ATP-independent fashion (Elssner et al., 2004). 
Mouse P2X7 can also be activated by ATP-independent ADP-ribosylation, an 
NAD-dependent process, although the physiological relevance to human 
P2X7 is questionable, as humans do not possess the requisite ADP-ribosyl–
transferase (ART-2) enzyme (Seman et al., 2003). 
 
A variety of compounds with inhibitory activity at P2X7 have been employed 
in pre-clinical studies. Oxidised ATP (oATP; 2’,3’ dialdehyde ATP) irreversibly 
inhibits receptor function, displaying highest potency at the human P2X7 
receptor, but also inhibiting other P2X receptors including P2X1 and P2X2, 
rendering it unsuitable for in vivo human use (Hibell et al., 2001, North, 
2002). The Ca2+/calmodulin-dependent protein kinase II (CamKII) inhibitor, 
KN62, exhibits inhibitory activity at P2X7 but with significant inter-species 
differences in efficacy (King, 2007). The polysulphonic dye Brilliant blue G 
(BBG) is an effective antagonist at the rat P2X7 receptor but stains proteins 
(leading to visible cutaneous discolouration when used in vivo.) 
 
High throughput in vitro screening of small molecule inhibitors using cation 
flux and pore formation assays has led to the identification of several new 
10 
 
Agonists EC-50
Nucleotides ATP
BzATP
Potentiated by:
↓[Ca2+]EC
↓[Mg2+]EC
↓[Na+]EC
↓[Cl-]EC
>80-100µM
7µM
Non-nucleotide LL-37
Alternative activation ADP-ribosylation
Antagonists IC-50
Ions Ca2+
Mg2+
Zn2+
Cu2+
H+
2900µM
500µM
11µM
0.5µM
0.4µM (≈pH 6.1)
Generic P2X antagonists Suramin
PPADS
Brilliant Blue G
Oxidised ATP
>300µM (R); 3µM (H)
50µM
10nM (R); 200nM (H)
25µM  (R); 3µM (H)
Organic cations Calmidazolium
KN-62
10nM (R)
30nM (H)
Novel small molecule 
inhibitors
Cyclic imides eg
AZ11645373
Disubstituted tetrazoles
eg A438079
Cyanoguanidines eg
A740003
10-90nM (H)
100nM (R); 300nM (H)
18nM  (R); 40nM (H)
Other 17β-oestradiol
Monoclonal αP2X7 Ab
Decanvanadate
(H2V10O28
−4)
Table 1.1 P2X7 receptor agonists and antagonists. The list of novel small molecule inhibitors is
not exhaustive. Collated from Michel et al. 1999, Hibell et al. 2001, North et al. 2002 and Donnelly-
Roberts and Jarvis, 2007. R: rat; H: human; EC: extracellular
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classes of selective P2X7 antagonists; for example, A438079, a disubstituted 
tetrazole compound which acts as a reversible inhibitor of P2X7 with IC50 of 
100nM and 300nM at rat and human P2X7 receptors, respectively, displays 
minimal activity at other P2 receptors (Donnelly-Roberts and Jarvis, 2007). 
The cyanoguanidine, A740003, shows similar properties.(Honore et al., 
2006) Selective P2X7 antagonists from several pharmacological classes have 
been successfully used in phase I and II clinical trials with a favourable 
adverse effect profile (Arulkumaran et al., 2011). 
 
 
1.2.4 Genetic polymorphisms and splice variants 
 
Human P2X7 is located at 12q24 and comprises 13 exons (Buell et al., 1998). 
Multiple splice isoforms exist with the full-length receptor designated P2X7A 
and further variants labelled B-J (reviewed recently in (Sluyter and Stokes, 
2011)). P2X7B lacks the C-terminal domain and consequently is unable to 
form the large pores characterstic of P2X7A and instead appears to stimulate 
trophic changes (Adinolfi et al., 2010). A and B are expressed at comparable 
levels at the mRNA level in those tissues which have been surveyed, and 
expression of P2X7B potentiates P2X7A responses when the two are 
coexpressed (Adinolfi et al., 2010). The truncated P2X7J receptor has been 
found at high levels in malignant cervical tissue and forms heteromeric non-
functional receptors with P2X7A which may interfere with apoptotic 
functions (Sluyter and Stokes, 2011). 
 
Multiple single nucleotide polymorphisms (SNPs) of the P2RX7 gene have 
been characterised, and can lead to both gain or loss of function effects 
(Sluyter et al., 2004). rs3751143 (Glu496Ala) is the best studied and leads to 
loss of function, with deficits in pore formation and dye uptake, reduced IL1β 
maturation and impaired killing of intracellular pathogens by macrophages 
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(Gu et al., 2001, Sluyter et al., 2004, Lees et al., 2010). Numerous clinical 
correlative studies have linked rs3751143 with an increased susceptibility to 
Mycobacterium tuberculosis, presumably due to defects in bacterial killing by 
macrophages (Sluyter and Stokes, 2011). A different SNP, rs591874, has been 
associated with an increased ambulatory blood pressure; the effect of this 
polymorphism on receptor function has not been investigated, although the 
lack of association between rs3751143 and blood pressure suggests 
rs591874 does not result in loss of function (Palomino-Doza et al., 2008). 
 
 
1.3 Cellular roles of P2X7 
 
1.3.1 IL1β and IL18 maturation 
 
Activation of P2X7 receptors in macrophages primed by exogenous bacterial 
peptides (eg. LPS) or TNFα leads to massive secretion of the leaderless 
inflammatory cytokines IL1β and IL18 (Ferrari et al., 1997, Solle et al., 2001, 
Franchi et al., 2009). This effect is dependent on the Nacht Domain-, Leucine-
Rich Repeat-, and PYD-Containing Protein-3 (NLRP3) inflammasome for 
upstream signal integration and subsequent caspase-1 activation leading to 
maturation of pre-formed pro-IL1β (Ferrari et al., 2006). In the absence of a 
second signal, stimulation with LPS leads to cytosolic accumulation of pro-
IL1β but only very muted release of mature peptide. Tissue damage, whether 
due to infection or ‘sterile’ injury, and additional non-lytic pathways lead to 
ATP exposure in the extracellular space, P2X7 binding and pro-IL1β  
processing and release; P2X7 hence appears to function as a ‘damage sensor’ 
transducing tissue injury to a local inflammatory response (Figure 1.3) (Di 
Virgilio, 2007, McDonald et al., 2010). 
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Both potassium efflux and large pore formation appear to be important in the 
mechanism for IL1β maturation (Ferrari et al., 1997, Ferrari et al., 2006). 
P2X7 may also play a role in disgorgement of IL1β-laden microvesicles upon 
entering the extracellular space, as vesicle exposure to ATP precipitates 
membrane breakdown (Bianco et al., 2005). 
 
 
1.3.2 Cell death 
 
Prolonged stimulation of cells with ATP frequently leads to cell death and 
P2X7 is a key mediator of this process (Di Virgilio et al., 1998). Depending on 
cell type and context, P2X7 activation can initiate cell death by either colloid-
osmotic lysis or apoptosis. The former mechanism appears to stem from the 
propensity of P2X7 to form large membrane pores on prolonged agonist 
stimulation, leading to gross cell membrane disruption. Receptor activation 
can also, however, lead to the full spectrum of apoptotic changes including 
nuclear fragmentation, membrane blebbing, cell shrinkage and apoptotic 
body formation which may putatively relate either to downstream effects of 
the small pore conductance or caspase-1 activation after shorter periods of 
receptor stimulation (Chow et al., 1997, Di Virgilio et al., 1998). 
 
Inter-species differences also impact on the cytotoxicity of P2X7; human 
P2X7 has lower affinity for ATP than rat, and consequently human 
macrophages are more susceptible to apoptosis than colloid-osmotic lysis 
after ATP stimulation, in contrast to their rat counterparts (Rassendren et al., 
1997, Di Virgilio et al., 1998).  Brief ATP stimulation of HEK293 cells stably 
transfected with P2X7 can lead to rapid alterations in cell morphology 
typically associated with apoptosis (eg. membrane blebbing, 
phosphatidylserine exposure and microvesicle release) which are then 
reversible with washing out of agonist, a process termed ‘pseudoapoptosis’, 
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which presumably represents an early but non-committed stage in the P2X7-
dependent cell death pathway (Mackenzie et al., 2005). 
 
 
1.3.3 Cellular proliferation 
 
While diffuse or prolonged P2X7 stimulation culminates in cell death, P2X7 
activation has also been linked to cell growth and proliferation in certain 
contexts. HEK293 cells stably transfected with P2X7 have a higher basal 
mitochondrial potential, intra-mitochondrial calcium levels and cellular ATP 
stores and are able to grow in serum-free conditions (Adinolfi et al., 2005).  
P2X7-mediated responses also appear important in proliferation of T-
lymphocytes and microglial cells (Baricordi et al., 1999, Bianco et al., 2006). 
P2X7 activation appears to able to modulate key components of aerobic 
glycolysis within the cell, potentially underlying the increased replicative 
vitality of P2X7 over-expressing cells (Amoroso et al., 2012). Of note, P2X7 is 
over-expressed in several human cancers while tumours induced in vivo 
using P2X7-transfected cell lines have accelerated growth as well as denser 
vascular networks and elevated amounts of secreted vaso-active endothelial 
growth factor (VEGF) (Adinolfi et al., 2012). 
 
 
1.3.4 Phospholipid signalling 
 
Numerous lipid derivatives, including diacylglycerol, arachadonic acid and 
phosphatidic acid, act as important secondary messengers in cellular signal 
transduction. P2X7 has been demonstrated to activate the phospholipase D 
pathway in macrophages and lymphocytes as well as certain epithelial cell 
types; this response requires a rise in intracellular calcium but cannot be  
15 
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replicated by calcium ionophores or mobilisation of intracellular calcium 
stores (el-Moatassim and Dubyak, 1992, Gargett et al., 1996, Pochet et al., 
2003, Garcia-Marcos et al., 2006). Activation of phospholipase A2 after P2X7 
stimulation has also been demonstrated in both monocytes and 
submandibular epithelial cells and appears to be a requisite step for 
lysosome exocytosis and final release of IL1β (Alzola et al., 1998, Andrei et al., 
2004). 
 
 
1.3.5 Phagocytosis 
 
Recent work has established a role for the P2X7 receptor in phagocytosis of 
non-opsonised particles, bacteria and apoptotic bodies (Wiley et al., 2011). 
P2X7 is closely associated with non-muscle myosin heavy chain-IIA 
(NMMHC-IIA) in its resting state and it is this protein interaction that appears 
to mediate receptor-led phagocytosis; ATP binding and  receptor activation 
leads to dissociation of NMMHC-IIA and attenuates phagocytosis (Gu et al., 
2009, Gu et al., 2010, Gu et al., 2011). Phagocytosis can also be inhbited by 
BzATP, P2X7 ectodomain and selective antagonists of the P2X7 receptor 
including A438079, suggesting a dissociation between this role and classical 
receptor activity (Gu et al., 2010). P2X7-deficient peritoneal macrophages do 
not show inhibition of phagocytosis by ATP while stable expression of P2X7 
in HEK293 cells confers the ability to phagocytose apoptotic cells (Gu et al., 
2011). P2X7 thus appears to act as a scavenger receptor while bound to 
NMHHC-IIA in the resting state, switching to more classical pro-inflammatory 
activation states in the present of ATP. 
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1.4 P2 receptors in renal health and disease 
 
Autocrine / paracrine P2 purinoceptor signalling contributes to several 
physiological mechanisms in the kidney including microcirculatory 
autoregulation, tubuloglomerular feedback and urinary concentration. Given 
these physiological roles of P2 receptors, together with the ubiquity of P2 
receptor expression, it is not surprising that deleterious signals transduced 
via P2 receptors or interruption of normal purinoceptor signalling may 
contribute to disease within the kidney. 
 
Renal diseases where P2 receptor pathways contribute signficantly to 
pathogenesis are discussed below, with reference to corresponding 
physiological roles where appropriate. 
 
 
1.4.1 Glomerulonephritis 
 
Inflammatory glomerular disease is common, potentially treatable, and is a 
major contributor to end-stage kidney disease (Byrne et al., 2010). Current 
treatment regimens depend on non-specific immunosuppression, often 
corticosteroid-based, and are associated with significant morbidity (Tam, 
2006). Interest in identifying more specific treatment targets has led to 
examination of P2 signalling as a candidate pathogenic mechanism with a 
major focus on the P2X7 receptor. 
 
A key role for P2X7 in glomerulonephritis has been suggested in experiments 
using the rodent nephrotoxic nephritis (NTN) model. This model uses 
injection of anti-glomerular basement membrane nephrotoxic serum to 
induce a lesion that histologically resembles human crescentic 
glomerulonephritis (McAdoo et al., 2010). A 3-fold upregulation of 
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glomerular P2X7 mRNA is seen by day 4 in rat NTN, correlating with the 
onset of significant proteinuria and peak macrophage infiltration (Turner et 
al., 2007b). Receptor upregulation, as assessed by immunostaining, is also 
seen by 24 hours in a mouse model of accelerated NTN, co-localising with 
caspase-3, a marker of apoptosis (Turner et al., 2007b).  
 
Disease induced in Glaxo P2X7 KO mice showed reduced glomerular 
thrombosis, reduced proteinuria, and improved renal function at day 8 
compared to WT animals (Taylor et al., 2009). This was associated with 
almost complete suppression of monocyte chemoattractant protein 1 (MCP-
1) measured in urine and reduced glomerular macrophage infiltration. The 
selective P2X7 antagonist, A438079, also led to attenuation of disease in rat 
NTN when used at a dose of 300µmol/kg body weight twice daily (Taylor et 
al., 2009). 
 
Glomerular and, to a lesser extent, tubular immunostaining for P2X7 has 
been observed in human renal tissue from patients with lupus nephritis, the 
hallmark of which is glomerular inflammation (Turner et al., 2007b). Orally-
active and well-tolerated selective antagonists exist for human P2X7, but 
have yet to be tested in renal disease (Keystone et al., 2011, Arulkumaran et 
al., 2011). 
 
The P2Y1 receptor, best characterised as a mediator of ADP-induced platelet 
aggregation, has also been studied in the murine NTN model (Leon et al., 
1999, Hohenstein et al., 2007). The disease is attenuated and mortality is 
reduced in the P2Y1 KO mouse compared with WT, with a reduction in 
glomerular and peritubular capillary rarefaction (Hohenstein et al., 2007). 
The absence of differences in bleeding time and glomerular and peritubular 
capillary platelet aggregation between P2Y1 KO and WT mice, suggests that 
this may be a platelet-independent effect, while differences observed in 
19 
 
endothelial proliferative activity may implicate P2Y1-mediated endothelial 
dysregulation as a component of disease pathogenesis in this model. 
 
The purinergic axis has also been studied in the anti-Thy-1 rat model of 
mesangial proliferative glomerulonephritis (Rost et al., 2002). Injection of a 
monoclonal anti-thymocyte antibody cross-reacting with a Thy-1 like antigen 
on mesangial cells results in initial complement-dependent mesangiolysis, 
followed by mesangial cell proliferation, exuberant ECM production and, 
contrary to human mesangial proliferative diseases, ultimate recovery and 
restoration of normal glomerular architecture (Bagchus et al., 1986, Hugo et 
al., 1997). The non-selective P2 receptor inhibitor pyridoxalphosphate-6-
azophenyl-2’,4’,-disulfonic acid (PPADS), administered twice daily at a dose 
of 15-60 mg/kg body weight, led to a selective reduction in mesangial cell 
proliferation, maximal at day 5, with no effect on initial mesangial cell injury 
or inflammatory infiltrate (Rost et al., 2002). P2Y2 receptor upregulation was 
observed in a mesangial pattern by immunostaining. These findings support 
a role for nucleotide-dependent mesangial cell proliferation in this form of 
nephritis, and complement in vitro studies showing proliferation of cultured 
mesangial cells in response to P2Y activation (Schulze-Lohoff et al., 1992, 
Harada et al., 2000). Further studies employing subtype-selective P2 receptor 
antagonists are required to realise any potential therapeutic benefit, 
particularly since P2X-mediated responses may be predicted to contribute to 
the inciting inflammatory insult. 
 
 
1.4.2 Fibrosis and chronic kidney disease 
 
The paracrine P2 receptor system is of proven importance in coordinating 
several physiological responses within the kidney: P2X1 activation in the 
glomerular afferent arteriole is pivotal for normal autoregulation of renal 
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microcirculatory blood flow, while regulation of GFR by tubuloglomerular 
feedback depends, at least in part, on ATP release and P2 receptor-mediated 
signalling for transmission of the spreading calcium wave within the 
juxtaglomerular apparatus that culminates in afferent arteriolar 
vasoconstriction (Ren et al., 2004, Peti-Peterdi, 2006, Toma et al., 2008, 
Osmond and Inscho, 2010, Sipos et al., 2010). This importance of renal P2 
signalling in health, together with the ubiquity of P2 receptor expression, and 
their ability to transduce mitogenic and apoptotic responses in resident renal 
cells have led to the candidacy of these receptors in the pathogenesis of 
chronic renal diseases such as diabetic nephropathy (Turner et al., 2003, 
Harada et al., 2000). A growing recognition that immune responses play a 
pivotal role in the perpetuation of these classically ‘non-inflammatory’ kidney 
diseases has directed attention to the part played by innate immunity, and 
particularly the pro-inflammatory P2X7 receptor (Navarro-Gonzalez and 
Mora-Fernandez, 2008, Vilaysane et al., 2010). 
 
 
1.4.2.i Diabetic nephropathy 
 
Diabetic nephropathy is characterised by excessive deposition of ECM 
proteins in the glomerular basement membrane, mesangium and 
tubulointerstitium, and is typified clinically by albuminuria and progressive 
loss of renal function (Mason and Wahab, 2003). While all resident 
glomerular cells contribute to glomerulosclerosis, mesangial cells are the 
main effector of ECM accumulation in response to the hyperglycaemic milieu 
(Qian et al., 2008). P2 receptors of both P2Y and P2X subclasses are 
expressed on mesangial cells and appear to exert opposite effects on cell 
turnover, with P2Y stimulating proliferation and P2X provoking apoptosis 
and necrosis (Harada et al., 2000, Rost et al., 2002, Solini et al., 2007). P2X7 is 
expressed at low levels on mesangial cells, but it can be upregulated by TNFα 
(Harada et al., 2000). 
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Rat mesangial cells exposed to a high glucose environment secrete increased 
amounts of ATP that appear to enhance ECM production via a TGFβ-
dependent mechanism in an autocrine/paracrine fashion (Solini et al., 2005). 
This response is replicated by the addition of 3’-O-(4-benzoylbenzoyl)-ATP 
(BzATP), a P2X7 receptor agonist, and blocked by oxidised ATP (oATP), an 
antagonist (although neither compound is highly selective for P2X7), 
suggesting P2X7 receptor involvement. Addition of UTP, a P2Y2 and P2Y4 
agonist, leads to reduced ECM protein expression in this model, although the 
recent finding that UTP can act as an agonist at intermediately-activated 
P2X7 receptors complicates the interpretation of this (Solini et al., 2005, 
Browne and North, 2013). Experiments in human fibroblasts also implicate 
P2X7 in diabetic cytopathy, since P2X7 activity is markedly enhanced in cells 
grown in high glucose media or obtained from a diabetic donor (Solini et al., 
2000, Solini et al., 2004). This is accompanied by rearrangement of P2X7 into 
ring-like structures at the periphery of the cell, and apoptosis when high 
concentrations of ATP (5mM) are applied (Solini et al., 2000). 
 
Minimal P2X7 expression can be detected immunohistochemically in the 
kidneys of normal rats, but the receptor is clearly upregulated by 6 weeks in 
the streptozotocin (STZ) model of type 1 diabetes (Vonend et al., 2004). Co-
labelling with cell-specific markers and immuno-electron microscopy both 
suggest predominant podocytic expression (Vonend et al., 2004). BzATP has 
been shown to augment glucose uptake into rat podocytes cultured in 
hyperglycaemic conditions, potentially priming the development of the 
podocytopathy which contributes to disease initiation (Reddy et al., 2008, 
Karczewska et al., 2011). 
 
The P2X4 gene is very close to P2X7 on human chromosome 12. The P2X4 
receptor shares physical properties with P2X7, including the potential for 
large membrane pore formation and a response to stimulation by BzATP. It is 
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expressed at significantly higher levels in mesangial cells than P2X7, and 
recent data suggest that P2X4 may be the dominant receptor mediating ATP-
induced apoptosis in human mesangial cells, a role previously attributed to 
P2X7 (Solini et al., 2007). Neither receptor has been studied in in vivo models 
of diabetic nephropathy, a prequisite step to determine whether either is 
functionally important in disease pathogenesis.  
 
 
1.4.2.ii Tubulointerstitial fibrosis 
 
Rodent unilateral ureteric obstruction (UUO) is a widely used model of 
tubulointerstitial fibrosis and progressive kidney disease; it is characterised 
by mononuclear cell infiltration, fibroblast differentiation and proliferation, 
increased ECM deposition, and tubular atrophy (Klahr, 2001, Goncalves et al., 
2006). Induction of disease in P2X7 KO mice leads to an attenuated 
phenotype, with less fibrosis and collagen deposition, reduced macrophage 
infiltration, reduced surface TGFβ staining, and a greatly diminished 
population of medullary interstitial myofibroblasts at day 14 (Goncalves et 
al., 2006). Similar benefits have been seen with P2X7 deletion in models of 
inflammatory fibrosing disease in other organ systems, including bleomycin-
induced lung fibrosis (Riteau et al., 2010). It is interesting to note that in vitro 
P2X7 receptors appear to mediate direct renal epithelial cell-fibroblast 
crosstalk under conditions of tubular damage, with necrotic tubular cells 
promoting fibroblast cell death by a P2X7-dependent mechanism 
(Ponnusamy et al., 2011). 
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1.4.3 Polycystic kidney disease 
 
Parenchymal cyst formation is common to several human renal diseases, the 
most common being autosomal dominant polycystic kidney disease (ADPKD). 
While the fundamental genetic defects underlying ADPKD are well defined 
(mutations in PKD1 and PKD2 encoding polycystin-1 and polycystin-2, 
respectively) the pathogenic mechanisms promoting cyst formation and 
expansion remain less clear (Yoder, 2007, Torres and Harris, 2009). Cyst-
lining epithelial cells are unable to maintain planar polarity; they express an 
abnormal secretory phenotype promoting fluid retention and display 
increased rates of proliferation and apoptosis (Torres and Harris, 2009). 
Knowledge that ATP is concentrated within the lumen of ADPKD cysts and 
can couple to chloride secretion via rises in intracellular calcium or cAMP, as 
well as trigger both proliferative and apoptotic pathways through P2 
receptor activation, has made the P2 system attractive for study in renal 
cystic disease (Mangoo-Karim et al., 1989, Wilson et al., 1999, Communi et al., 
2000, Schwiebert et al., 2002). 
 
Madin-Darby canine kidney (MDCK) cells grown in a three-dimensional 
collagen matrix proliferate and form microcysts when exposed to the cAMP-
forming adenylate cyclase stimulant, forskolin (Mangoo-Karim et al., 1989). 
The ectonucleotidase, apyrase, suppresses cyst growth when added to such 
cultures, demonstrating an ATP-dependence for cystogenesis in this model 
(Turner et al., 2007a). Cyst growth can also be retarded with the addition of 
non-selective P2 receptor antagonists, including reactive blue 2 (RB2) and 
suramin, although cyst growth in this model cannot be augmented by the 
addition of exogenous ATP. The pattern of antagonist responses suggest 
primacy of P2Y receptors in promoting cyst growth, but the lack of selective 
agents means that the specific P2 receptor dependence remains unclear 
(Turner et al., 2007a). Addition of ATP drives growth of cysts formed from 
enriched principal-like MDCK cells (with intercalated-like cells eliminated), 
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demonstrating clear ATP dependence for cAMP-mediated cyst formation in 
this subpopulation of cells (Buchholz et al., 2011). 
 
The role of P2X7 in cystogenesis has also been examined in vitro using cell 
cultures derived from the cpk/cpk mouse model of autosomal recessive 
polycystic kidney disease (ARPKD). P2X7 is expressed in renal collecting 
ducts of the cpk/cpk mouse as they undergo fulminant cystogenesis, and the 
receptor can also be detected in human fetal ARPKD tissue (Hillman et al., 
2002, Hillman et al., 2004). The P2X7 agonist, BzATP, caused a reduction in 
cyst number, but not in cyst size, when added to cultures derived from 
dissociated cpk/cpk kidneys (Hillman et al., 2004). The greater potency of 
BzATP over ATP in inhibiting cyst formation, together with the antagonising 
effect of oATP, was taken to support a role for P2X7 in this setting. However, 
an absence of classical downstream effects of P2X7 (eg. caspase activation), 
together with an appreciation that BzATP is also an antagonist at P2Y1 and 
P2Y4 receptors, raises the possibility that P2Y-mediated signalling may also 
underlie these findings (ie. P2Y responses promoting cyst growth). 
 
More recently, the role of P2X7 in cystogenesis has been tested in a zebrafish 
model of polycystic kidney disease generated by pkd2 knock-down with 
morpholinos. Here, exposure of zebrafish to the P2X7 antagonist oATP, 
together with the more selective antagonist A438079, and P2X7 knock-down 
using morpholinos, significantly reduced the frequency of the cystic 
phenotype. A reduction was seen in phosphorylated extracellular signal-
related kinase (phospho-ERK) activity and cell proliferation in pronephric 
kidneys suggests that P2X7 may couple to deleterious mitogenic signalling in 
this setting (Chang et al., 2011). 
 
All renal epithelial cells, with the exception of intercalcated cells, possess a 
primary cilium capable of transducing a flow response manifest as an 
intracellular calcium transient (Praetorius and Spring, 2001, Torres and 
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Harris, 2009). Polycystin-1 and -2 localise to the primary cilium and 
participate in mechanotransduction, making impaired ciliary function an 
important candidate pathogenic mechanism in ADPKD (Nauli et al., 2003, 
Yoder, 2007). Autocrine/paracrine purinoceptor signals amplify the flow-
mediated calcium response with ATP release seemingly dependent on the 
presence of the primary cilium (Jensen et al., 2007, Praetorius and Leipziger, 
2009b). The flow-mediated rise in intracellular calcium is impaired in ADPKD 
epithelial cells, and flow-induced ATP release is reduced in parallel, despite 
cells maintaining normal sensitivity to exogenous nucleotides and displaying 
enhanced resting and hypotonicity-induced ATP release (Xu et al., 2009). 
Loss of normal cilia-dependent flow responses in the tubules of patients with 
ADPKD is conjectured to contribute to cyst development by promoting 
dysregulated proliferation and dedifferentiation; whether blunted ATP 
release is a bystander or contributor to this process remains to be 
determined. The link between these findings of disturbed flow-sensitive ATP 
release, intracellular calcium signalling and pathological cystogenesis is 
currently unclear (Calvet, 2002). 
 
1.4.4 Disorders of water transport and hypertension 
 
While arginine vasopressin (AVP) has a primary role in the regulation of 
water transport in the collecting duct, other autocrine and paracrine factors, 
including purinoceptor signals, are important modulators. P2Y2 has received 
particular attention: stimulation of P2Y2 in the microperfused rat inner 
medullary collecting duct (IMCD) antagonises AVP-induced water 
permeability; in immortalised mouse collecting duct cells, P2Y2 activation 
leads to internalisation of aquaporin 2, and in rat IMCD suspensions P2Y2 
stimulation triggers release of prostaglandin E2 (PGE2), which is another 
modulator of collecting duct function (Kishore et al., 1995, Welch et al., 2003, 
Wildman et al., 2009a, Wildman et al., 2009b). P2Y2 expression is increased 
in the inner medulla of dehydrated rats and P2Y2 KO mice display enhanced 
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urinary concentration capacity, together with increased expression of the 
machinery for water conservation, including aquaporin 2 (Kishore et al., 
2005, Zhang et al., 2008). 
 
The potential pathophysiological correlate of these findings has been 
examined in rat models of lithium-induced nephrogenic diabetes insipidus 
(NDI), and in the diuresis of post-obstructive uropathy, both conditions 
involving PGE2-mediated water diuresis (Zhang et al., 2009, Zhang et al., 
2010). In the former study, enriched IMCDs from rats in which NDI had been 
induced with lithium were stimulated ex vivo with nucleotides, and PGE2 
release measured. PGE2 release was enhanced by 50-130% on exposure to 
nucleotides compared with control preparations (Zhang et al., 2009). 
Interestingly, and in contrast to control animals, IMCDs from lithium-fed rats 
responded to ADP, ATPγS, and UTP, suggesting a role for P2Y6 and/or P2Y1 
in promoting PGE2 release, in addition to P2Y2. RT-PCR revealed significant 
upregulation of P2Y4 receptor mRNA in lithium-fed rats, while P2Y6 
remained unchanged, and P2Y2 expression diminished (but was still the 
most abundant P2Y receptor). Similar analysis in the post-obstructive 
uropathy model revealed upregulation of P2Y2 and P2Y6 mRNA without a 
change in P2Y4 (Zhang et al., 2010). In this setting, nucleotide responses in ex 
vivo IMCDs  were suggestive of predominant P2Y2 involvement. The 
contribution of P2X receptors, which may also influence water transport, 
were not examined (Wildman et al., 2009b). While these studies suggest an 
important role for P2 receptor signalling in diseases of water transport, 
complementary studies with KO mice or selective antagonists will be needed 
to realise future therapeutic benefit. 
 
Purinoceptors have also been implicated in the aetiology of hypertension and 
consequent renal damage. Polymorphic variation in P2X7, P2X4 and P2Y2 
have been associated with essential hypertension (Palomino-Doza et al., 
2008, Wang et al., 2010). Both P2Y2 and P2X4 have been shown to regulate 
27 
 
function of the ENaC sodium channel in the distal nephron and KO mouse 
models of both receptors display a hypertensive phenotype (Yamamoto et al., 
2006, Rieg et al., 2007, Pochynyuk et al., 2008, Wildman et al., 2008). 
 
Upregulation of the P2X7 receptor has been shown in the glomerulus of 
hypertensive renin-overexpressing rats at 12 weeks of age, although the 
cellular location was not defined and the functional significance is 
unexplored (Vonend et al., 2004).  The P2X7 antagonist, Brilliant Blue G, has 
been shown to ameliorate hypertension, renal macrophage infiltration, 
albuminuria, and renal fibrosis when administered in vivo to Dahl rats 
rendered hypertensive through a high salt diet; a reduction in albuminuria 
and macrophage infiltration was also reported with the highly selective P2X7 
antagonist, A438079, in the same study (Ji et al., 2011). ATP levels are 
increased in the renal interstitial fluid of rats with angiotensin II-induced 
hypertension, and both clopidogrel (a selective P2Y12 antagonist), 
administered orally in drinking water at 20mg/kg daily, and 
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS; a non-
selective P2 receptor blocker), administered IP at a dose of 20mg daily, led to 
reduced phenotypic mesangial cell activation, afferent arteriolar wall 
thickness, macrophage infiltration, and renal cell proliferation in the early 
stages of this model (Graciano et al., 2008). 
 
Autoregulation of renal blood flow is dependent on local purinoceptor 
signalling and is disrupted in hypertensive nephropathy, leading to increased 
transmitted capillary pressures (Loutzenhiser et al., 2006). Attenuated 
afferent arteriolar vasoconstrictor responses to P2X1 stimulation have been 
documented in angiotensin II hypertensive rats fed a high salt diet, and are 
thought to underlie this phenomenon (Inscho et al., 2011). 
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1.5 Conclusion - purinoceptor signalling 
 
A growing body of evidence supports the view that ATP and related 
nucleotides, once recognised only in their capacity for cellular energy 
transfer, perform a crucial role as autocrine and paracrine stimuli when 
present within the extracellular space. Through the diverse repertoire of P2 
receptors, nucleotide signals appear to conduct a wide range of physiological 
responses within the kidney, and participate in the pathogenesis of 
numerous and disparate renal diseases. Dissecting the role of individual P2 
receptors in renal disease has proved difficult to date, because ligands may 
activate multiple receptors and selective antagonists exist for only a small 
number of receptors. However, the impact that clopidogrel (a P2Y12 
antagonist and anti-platelet agent) has had in cardiovascular medicine 
illustrates the potential therapeutic benefit to be reaped from continuing 
efforts to modulate the activity of this finely balanced system, with the 
ultimate goal of manipulating P2 signalling to ameliorate human renal 
disease (Yusuf et al., 2001). 
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Part 2. Diabetic nephropathy 
 
1.6 Overview 
 
Diabetic nephropathy (DN) is the commonest cause of chronic kidney disease 
(CKD) and end-stage renal disease (ESRD) worldwide, with an enormous 
projected increase in the burden of disease as the prevalence of diabetes 
continues to increase (Byrne et al., 2010, USRDS, 2012). Renal disease may be 
consequent to both type 1 and type 2 diabetes mellitus. Type 1 diabetes is an 
auto-immune disorder, often presenting in childhood or adolescence, 
characterized by cellular and humoral auto-immune destruction of 
pancreatic β-cells, leading to rapidly progressive insulin deficiency, weight 
loss and severe hyperglycaemia requiring immediate insulin replacement 
therapy. Type 2 diabetes, on the other hand, typically affects older 
individuals and co-segregates with other features of the so-called ‘metabolic 
syndrome’, including obesity, hypertension and hyperlipidaemia. The 
appearance of hyperglycaemia is initially attributable to peripheral insulin 
resistance, which overwhelms compensatory increases in pancreatic insulin 
secretion, although secondary β-cell degeneration and hypoinsulinaemia 
frequently develop as the disease progresses. 
 
 
1.7 Clinical manifestations 
 
The diabetic state pre-disposes to both ‘macro-vascular’ (such as coronary 
and cerebral vascular disease) and ‘micro-vascular’ end-organ complications, 
the latter group comprising nephropathy, neuropathy and retinopathy, the 
incidence of which increases with disease duration. Renal hyperfiltration, due 
to disruption of normal glomerular haemodynamics, with a consequent 
increase in glomerular filtration rate (GFR), is common in early diabetes and 
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precedes overt evidence of renal damage. Clinical renal disease classically 
follows a gradual progression through low-grade albuminuria 
(‘microalbuminuria’) indicative of early glomerulopathy, to overt proteinuria 
and finally loss of GFR, culminating ultimately in ESRD. This progression is 
not absolute, however, and as many as 50% of patients may present with loss 
of GFR in the absence of significant proteinuria, likely, in part, attributable to 
the widespread use of renin-angiotensin system (RAS) inhibition as first-line 
anti-hypertensive therapy (Halimi, 2012). 
 
 
1.8 Histopathological features of DN 
 
The renal histopathological findings of nephropathy due to type 1 or type 2 
diabetes are essentially indistinguishable and have thus been considered 
together in recent classifications (Tervaert et al., 2010). Early hyperfiltration 
is typically accompanied by glomerular enlargement which may translate to 
an increase in renal size of up to 15% (Feehally et al., 2007). Increased 
production and deposition of ECM proteins within the glomerulus initially 
manifests as glomerular basement membrane (GBM) thickening, best 
identified on electron microscopy, and increases with duration of disease 
(Perrin et al., 2006). Expansion of the supporting mesangial areas with ECM 
is the archetypal glomerular lesion of DN and is best appreciated on periodic 
acid-Schiff (PAS) or silver stains. Mesangial expansion is typically diffuse but 
mesangiolysis and focal exuberance may produce a nodular pattern 
(Kimmelstiel-Wilson lesions).  Increasing mesangial area correlates with 
worsening albuminuria, suggesting it represents a key structural-functional 
correlate in progressive disease (Fioretto et al., 1995). A high proportion of 
globally sclerosed glomeruli are observed in advanced DN with ESRD. 
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Other histological features include arteriolar hyalinosis, classically of the 
efferent arteriole, and thickening of tubular basement membranes due to 
ECM deposition, analagous to those of the glomerulus. Interstitial fibrosis and 
tubular atrophy progresses in parallel to glomerular disease and represents 
an important predictor of outcome (Okada et al., 2012). 
 
1.9 Cellular and molecular mechanisms in DN 
 
While hyperglycaemia represents the core clinical and diagnostic 
abnormality in diabetes, the consequent haemodynamic and metabolic 
perturbations which summate to produce renal injury are complex. All 
resident renal cell types are affected and contribute to development of 
disease. Abnormalities in podocyte architecture with subsequent cell death 
and detachment are observed early in disease, and the local, aberrant, 
podocyte response to GBM denudation may drive the onset of GBM 
thickening and albuminuria (Gnudi, 2012). Mesangial cells are chief effectors 
of the progressive glomerulosclerosis observed in DN, while tubular cell 
injury may lead directly to interstitial fibrosis through epithelial-
mesenchymal transition (EMT), or indirectly through deleterious cross-talk 
with other interstitial cell types. Once renal disease is established, many 
mechanisms of progressive injury are shared with non-diabetic CKD, 
including secondary hypertensive injury, activation of the renal-
angiotension-aldosterone system (RAAS) and proteinuria-induced tubular 
toxicity (Gnudi, 2012, Forbes and Cooper, 2013). 
 
The breadth of pathogenic mechanisms involved in DN is summarised in 
Figure 1.4. Initiators of cellular injury include increased glucose translocation 
into cells with subsequent deleterious channeling down polyol and 
hexosamine pathways; haemodynamic or stretch-related injury due to 
glomerular hypertension; and interaction with abnormally glycated proteins. 
Subsequent accumulation of reactive oxygen species (ROS) within the cytosol  
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triggers multiple stress-activated signalling pathways and activation of 
protein kinase C, an important intermediary event. Among the host of 
downstream signalling pathways and cytokines regulated by this response, 
transforming growth factor-β (TGFβ) and connective tissue growth factor 
(CTGF; induced by TGFβ) have cardinal roles in conducting ECM production, 
vasoactive endothelial growth factor (VEGF) is critical to disturbance of local 
blood flow and vascular permeability, angiotensin-II (AT2) provokes 
glomerular hypertension in addition to direct fibrogenic effects, and 
inflammatory cytokine release engages innate immune mechanisms in renal 
injury (Kanwar et al., 2011, Gnudi, 2012). 
 
Despite increasing knowledge of the pathways and interactions involved in 
the development of DN, clinical treatments remain limited to central 
strategies of good glycaemic and blood pressure control and RAAS blockade. 
Although these approaches are successful in prolonging renal survival in a 
proportion of patients, the fact that many patients continue to progress to 
ESRD despite this emphasises the need to develop novel approaches to 
treatment.  
 
 
1.10 Inflammation in DN 
 
While DN has traditionally been regarded as a corollary of the cardiovascular 
and metabolic disturbances contingent on the diabetic state, it has become 
increasingly evident over the last 20 years that immune mechanisms play a 
key role in initiation and progression of disease. Persistent low grade 
activation of innate immune pathways occurs within renal cells as a 
consequence of aberrant intracellular metabolism, generation of reactive 
oxygen species (ROS), exposure to advanced glycation end-products (AGEs) 
and haemodynamic stress, resulting in elaboration of pro-inflammatory 
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cytokines, recruitment of circulating inflammatory cells and ultimately an 
amplification loop of tissue injury driving fibrosis and nephron loss. This 
inflammatory facet of DN represents an important potential opportunity for 
clinical intervention and has been the subject of intensive research. Several 
recent in-depth reviews have synthesised the current experimental evidence 
in this area (Navarro-Gonzalez and Mora-Fernandez, 2008, Rivero et al., 
2009, Navarro-Gonzalez et al., 2011, Lim and Tesch, 2012, Wada and Makino, 
2013). 
 
 
1.10.1Inflammatory factors 
 
The immune network comprises a wide array of secreted and cell surface 
molecules, acting via specific cell surface receptors to transduce signals that 
are often tissue- and context-specific (Navarro-Gonzalez et al., 2011). The 
repertoire of immune cells is similarly complex with increasing recognition of 
multiple states of activation and, in the case of monocytes and macrophages, 
a plasticity allowing a change in phenotype over time (Geissmann et al., 
2010). The tools of cell biology have allowed for in-depth study of individual 
mediators in the context of DN, often by examining the consequences of 
selectively interfering with their function, allowing a gradual outline to 
develop of the full complexity of interactions (Figure 1.5). 
 
 
1.10.1.i Inflammatory cytokines 
 
The cytokines interleukin-1 (IL1), interleukin-18 (IL18), interleukin-6 (IL6) 
and tumour necrosis factor-α (TNFα) have received the most attention in the 
study of inflammation and DN. Incubation of peritoneal macrophages with 
GBM from STZ diabetic rats enhances secretion of IL-1 and TNFα, and levels  
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
of IL-1, IL-6 and TNFα mRNA increase in the renal cortex with time in the 
same model (Hasegawa et al., 1991, Navarro et al., 2006). In addition, all 
intrinsic renal cell types, including podocytes, mesangial cells, endothelial 
cells, tubular cells and fibroblasts are capable of synthesizing and secreting 
inflammatory cytokines (Rivero et al., 2009). 
 
Both IL1 and the related leaderless peptide IL18, induce upregulation of 
leukocyte adhesion molecules including intercellular adhesion molecule-1 
(ICAM-1) and E-cadherin, contributing to the influx of inflammatory cells into 
the diabetic kidney, as well as increasing local production of other cytokines 
(Park et al., 2000, Stuyt et al., 2003). IL-1 can directly induce proliferation 
and secretion of matrix proteins from mesangial cells, contributing to 
glomerulosclerosis (Melcion et al., 1982). IL-1 has also been demonstrated to 
act synergistically with TNFα to stimulate production of vasoactive 
eicosanoids such as prostoglandin E2 (PGE2) and phospholipase A2 (PLA2) 
from rat mesangial cells, increasing vascular endothelial cell permeability in 
vitro, and potentially contributing to intraglomerular haemodynamic 
abnormalities (Pfeilschifter et al., 1989, Royall et al., 1989, Navarro-Gonzalez 
et al., 2011). IL-18 is predominantly secreted from tubular cells and has been 
shown to have an important role in the pathogenesis of acute ischaemic 
nephropathy in mice (Melnikov et al., 2001). It can also act to increase the 
susceptibility of endothelial cells to TNFα-induced apoptosis (Marino and 
Cardier, 2003). Serum and urinary IL-18 is elevated in patients with type 2 
diabetes and correlates with albuminuria both at baseline and during follow-
up (Nakamura et al., 2005). 
 
A survey of IL6 mRNA in the diabetic kidney using in situ hybridisation has 
revealed expression in mesangial cells and glomerular epithelial cells as well 
as tubular and infiltrating cells; most cells in the vicinity of areas of mesangial 
proliferation stain strongly for IL-6 mRNA (Suzuki et al., 1995). In this study, 
IL-6 expression also correlated well with the degree of interstitial injury. IL-6 
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has been implicated in pathways governing mesangial proliferation, ECM 
protein synthesis and endothelial permeability, all relevant to pathogenesis 
of DN (Lim and Tesch, 2012). Serum IL-6 levels increase in the course of DN 
and are highest in those with overt proteinuria (Shikano et al., 2000). 
 
TNFα is an important, largely macrophage-derived, soluble cytokine with 
pleiotropic inflammatory and immunostimulatory effects (Wajant et al., 
2003). Its importance in the pathogenesis of inflammatory diseases such as 
rheumatoid arthritis and inflammatory bowel disease has been underlined by 
the efficacy of anti-TNFα monoclonal antibodies such as Infliximab in these 
conditions (Wada and Makino, 2013). TNFα expression increases in the renal 
cortex of diabetic rats, and serum and urine levels increase in humans with 
DN (Moriwaki et al., 2003, Navarro et al., 2006). Infliximab has been shown to 
reduce albuminuria in the STZ rat model of diabetes although the mechanism 
has not been further explored (Moriwaki et al., 2007). Potential toxic effects 
of TNFα include a contribution to leukocyte influx, stimulation of local 
production of ROS, effects on endothelial permeability and induction of 
apoptosis (Lim and Tesch, 2012). 
 
 
1.10.1.ii Cell adhesion molecules and chemokines 
 
Cell adhesion molecules play an important role in determining the location of 
leukocyte adherence to the vasculature and subsequent tissue infiltration, 
and may be upregulated by inflammatory cytokines such as TNFα (Navarro-
Gonzalez et al., 2011). Similarly, chemokines produce molecular gradients 
towards which leukocytes are attracted in order to concentrate immune cells 
at a site of tissue injury. Hence both classes of molecule have been 
investigated for their importance to the inflammatory state in DN. 
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ICAM-1 is an an endothelial glycoprotein which binds leukocytes via the 
ligand LFA-1 (Lim and Tesch, 2012). ICAM-1 levels are upregulated in renal 
tissue in rat models of DN and correlate with infiltration of mononuclear cells 
which can be prevented by administration of an anti-ICAM-1 monoclonal 
antibody (Sugimoto et al., 1997). Both type 1 (STZ) and type 2 (db/db) DN 
mouse models are attenuated when induced in mice genetically deficient in 
ICAM-1 (Okada et al., 2003, Chow et al., 2005). Analysis of serum ICAM-1 
levels in serum samples from patients in the Diabetes Control and 
Complications Trial (DCCT) demonstrated an increased risk of progressive 
nephropathy in those patients with ICAM-1 levels in the highest tertile; these 
patients also had an increased relative risk (RR 1.67) of developing new 
sustained microalbuminuria compared to patients in the lowest tertile (Lin et 
al., 2008). 
 
Levels of vascular cell adhesion protein-1 (VCAM-1), another important 
mediator of tissue-leukocyte interactions, are also increased in both human 
DN (predominantly on tubular epithelial cells) and rodent DN 
(predominantly venular endothelial cells and infiltrating leukocytes in the 
KKAy mouse model) and plasma levels of soluble VCAM-1 appear to correlate 
with albuminuria in hypertensive type 2 diabetics (Seron et al., 1991, Ina et 
al., 1999, Rubio-Guerra et al., 2009). Other adhesion molecules which have 
been linked to the pathogenesis of DN include endothelial cell-selective 
adhesion molecule (ESAM), which appears to have an important role in 
regulation of endothelial protein permeability, and E-selectin (Navarro-
Gonzalez et al., 2011). 
 
Monocyte chemoattractant protein-1 (MCP-1), an important chemoattractant 
factor for monocytes and macrophages, is the best studied chemokine in DN 
and has an important functional role in disease (discussed in section 1.7.2.a). 
Other chemokines which have been linked to renal injury, albeit less robustly, 
include CX3CL1 (fractalkine) and CCL5 (RANTES) (Navarro-Gonzalez et al., 
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2011). CX3CL1 is upregulated in the kidneys of STZ-treated rats and this 
increase can be suppressed by angiotensin converting enzyme (ACE) 
inhibition (Kikuchi et al., 2004). Although the functional role of CX3CL1 has 
not been directly tested in animal models of DN, an inhibitory monoclonal 
antibody to this molecule has been shown to attenuate renal injury in a 
mouse model of bovine serum overload proteinuria, although this was 
accompanied by only a modest and non-significant reduction in leukocyte 
infiltration (Donadelli et al., 2003). CCL5 is upregulated in the kidneys of 
patients with type 2 diabetes and nephropathy, predominantly in the tubules 
(as detected by in situ hybridisation and immunhistochemistry) with more 
prominent expression in those with interstitial cell infiltration and fibrosis 
(Mezzano et al., 2004). 
 
 
1.10.1.iii Pattern recognition receptors 
 
Both exogenous pathogen-derived molecules (pathogen-associated 
molecular patterns; PAMPs) and endogenous damage-associated molecules 
(danger-associated molecular patterns; DAMPs) are capable of directly 
acitvating innate immune mechanisms through interaction with cell 
membrane or cytosolic pattern recognition receptors (PRRs). DAMP-PRR 
interactions are now recognised as important initiators and perpetuators of 
tissue inflammation and injury in a range of non-infective kidney diseases  
(Rosin and Okusa, 2011). 
 
The cell membrane PRR, toll-like receptor (TLR) 4, is upregulated in proximal 
tubules and peritubular capillaries in human DN, and expression can be 
induced by hyperglycaemia in cultured human proximal tubular epithelial 
cells (PTECs) (Lin et al., 2012). Albuminuria and serum creatinine are both 
reduced in uninphrectomised STZ-diabetic TLR-4 KO mice compared to WT, 
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with reduced cortical macrophage infiltration and MCP-1 expression.  The 
TLR-4 antagonist, CRX-526, is also effective in attenuating DN and 
inflammation in STZ-diabetic eNOS KO mice in the absence of an effect on BG 
or blood pressure (Lin et al., 2013). The related PRR, TLR-2, is also 
upregulated in the kidney of STZ-diabetic rats, although corresponding 
upregulation could not be demonstration in kidney biopsy specimens from 
patients with advanced DN (Li et al., 2010, Lin et al., 2012). 
 
 
1.10.2 Inflammatory cells 
 
1.10.2.i Macrophages 
 
Macrophages are resident phagocytes derived from circulating mononuclear 
cells which have been recruited to the tissue compartment. Specialised for 
phagocytosis, macrophages play an important role in tissue maintenance and 
remodelling as well as host defence against micro-organisms, antigen 
presentation and local cytokine secretion (Gordon, 2002, Geissmann et al., 
2010).Macrophages are also recognised as important orchestrators and 
effectors of tissue injury in a range of non-infective human inflammatory 
diseases, including those of the kidney (Nelson et al., 2012). 
 
It is increasingly recognised that macrophages retain a significant degree of 
plasticity allowing for phenotypic sub-differentiation according to the 
context of the local prevailing cytokine environment. Although now generally 
regarded as an oversimplification, the concept of classically activated pro-
inflammatory ‘M1’ macrophages differentiating under the influence of IFNγ 
and alternatively activated ‘M2’ macrophages, directed primarily by the TH2 
cytokines IL-4 and IL-13, represents a useful conceptual dichotomy (Gordon 
and Martinez, 2010, Sica and Mantovani, 2012). 
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Macrophages are present in both the interstitial inflammatory infiltrate 
observed in human DN and also glomeruli where peak infiltration has been 
reported in association with moderate degrees of glomerulosclerosis (Bohle 
et al., 1991). Interstitial macrophage accumulation correlates strongly with 
clinical and histological parameters including serum creatinine, proteinuria 
and degree of interstitial fibrosis (Nguyen et al., 2006, Yonemoto et al., 2006).  
 
P- and E-selectin, leukocyte adhesion molecules involved in the recruitment 
and transmigration of monocytes to the periphery, are upregulated in both 
glomerular and interstitial capillaries in patients with DN (Hirata et al., 
1998). The important macrophage recruitment factor MCP-1 is upregulated 
in tubules and interstitial cells but not glomeruli of patients with DN as 
detected by in situ hybridisation, while urinary MCP-1 secretion increases 
with worsening clinical disease and correlates well with both the number of 
interstitial macrophages and clinical markers of disease progression (Wada 
et al., 2000, Tam et al., 2009). Tubulo-interstitial expression of another 
macrophage attractant factor, osteopontin, is also enhanced in DN and 
correlates with tubulo-interstitial fibrosis (Junaid and Amara, 2004). 
Experimental data describing the activation state of macrophages 
accumulating within the human diabetic kidney is scarce, although an 
increase in cells displaying active phosphorylated p38 MAPK in human 
diabetic kidney has been described, particularly within interstitial 
macrophages and myofibroblasts (Adhikary et al., 2004). 
 
In the STZ mouse model of type 1 diabetes, most glomerular and interstitial 
leukocytes recruited into the kidney are macrophages and an increase can be 
detected as early as 2 weeks (Chow et al., 2004b). Glomerular macrophage 
number correlates with indices of glomerular injury including renal function, 
albuminuria, glomerular hypertrophy and type IV collagen deposition, while 
interstitial macrophages also correlate with scores of tubular atrophy, 
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interstitial type IV collagen and alpha-smooth muscle actin (αSMA;Chow et 
al., 2004b). In this study, macrophages were frequently observed in 
proximity to proliferating interstitial fibroblasts suggesting deleterious 
cross-talk between the two cell types promoting interstitial fibrosis. Although 
significant renal macrophage accrual occurs later in the db/db type 2 
diabetes mouse model (4-6 months of age), similar correlation with markers 
of renal function and ECM deposition has been observed (Chow et al., 2004a). 
 
While macrophage infiltration correlates closely with markers of disease and 
tissue injury, it has been debated whether their presence is truly injurious or 
in fact reactive to tissue damage, in which case they may have a beneficial 
role such as phagocytosis of cellular debris. This debate has been informed 
by functional studies of macrophages in animal models. Induction of diabetes 
with STZ in mice genetically deficient in MCP-1 leads to diminished 
macrophage infiltration in both glomerular and interstitial compartments, 
reduced macrophage activation (as assessed by iNOS and sialoadhesin 
expression) and amelioration of albuminuria, glomerular hypertrophy and 
cellularity and interstitial fibrosis (Chow et al., 2006). Similar findings have 
also been reported in an MCP-1 deficient strain of db/db mouse where 
reduced renal macrophage infiltration and protection from renal injury was 
observed compared to control animals despite a lack of effect on 
development of obesity, diabetes or macrophage infiltration into adipose 
tissue (Chow et al., 2007). Beneficial effects have been reported in both type 
1 and type 2 diabetes disease models using antagonists of CCR2, the receptor 
for MCP-1 (Awad et al., 2011, Sayyed et al., 2011). Interestingly, while 
adoptive transfer of monocytes to diabetic CCR2 KO mice induces renal 
injury (where previously it was ameliorated) and leads to increased 
macrophage accumulation in the kidneys, this is true whether the transferred 
monocytes are CCR2 +/+ or CCR2 -/-, suggesting that this receptor may 
predominantly control monocyte mobilisation from the bone marrow rather 
than tissue infiltration (Awad et al., 2011). Induction of diabetes with STZ in 
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osteopontin KO mice also reduces macrophage infiltration and interstitial 
fibrosis but not markers of glomerular injury, suggesting greater relevance of 
this chemokine to the tubulointerstitial compartment (Nagao et al., 2012). 
 
Treatment of db/db mice for 6 weeks with a neutralising anti-c-fms (the 
receptor for colony stimulating factor-1) monoclonal antibody after the 
establishment of albuminuria (from 12 weeks) did not affect progression of 
albuminuria, but did attenuate tubular damage and markers of renal fibrosis 
in conjunction with the predicted reduction in macrophage accumulation 
(Lim et al., 2009). This is consistent with the hypothesis that progression of 
established human DN is accelerated by recurrent episodes of macrophage-
dependent inflammation and acute kidney injury (Kelly and Dominguez, 
2010). Adoptive transfer of M2 macrophages, polarised with IL-4 and IL-13, 
to mice subsequently made diabetic with STZ, reduced the development of 
tubular atrophy and interstitial fibrosis as well as attenuating pancreatic 
injury, suggesting this macrophage phenotype may exert a protective effect 
at least in early disease (Zheng et al., 2011). 
 
 
1.10.2.ii Lymphocytes 
 
Although less prominent than macrophage infiltration, accumulation of 
lymphocytes, predominantly T cells, within the diabetic kidney is well 
recognised (Wu et al., 2011). A minor component of the glomerular and 
interstitial  leukocytic infiltrate in rodent models of both type 1 and type 2 
DN is comprised of T cells, while an early T cell infiltrate in the 
juxtaglomerular apparatus has been reported in human type 1 diabetes 
(Moriya et al., 2004, Chow et al., 2004a, Chow et al., 2006). A recent study has 
reported a marked increase in the number of CD4, CD8 and CD20+ cells 
within the renal interstitium of patients with type 2 DN, with the numbers of 
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CD4 and CD20+ cells correlating with proteinuria (Moon et al., 2012). The 
proportion of circulating activated T lymphocytes is increased in diabetic 
patients with sub-nephrotic proteinuria compared to those with non-
proteinuric disease (Bending et al., 1988). T cells have been proven to play an 
important role in animal models of other ‘non-immunological’ renal disease 
such as ischaemia-reperfusion injury (Rabb et al., 2000). 
 
There is no clear evidence for classical antigen-dependent T cell activation in 
DN although the exposure of previously hidden epitopes due to renal damage 
or production of neoantigens due to protein modification has been 
hypothesised as a mechanism of immune activation (Lim and Tesch, 2012). 
CD4+ cells express receptors for AGEs which can directly stimulate the 
production of IFNγ, contributing both to local tissue inflammation and 
oxidative stress as well as macrophage activation (Imani et al., 1993, Lim and 
Tesch, 2012). 
 
The functional importance of lymphocytes in experimental DN has been 
tested by inducing diabetes with STZ in Rag1 deficient mice, which do not 
produce mature T or B lymphocytes (Lim et al., 2010). In this study 
lymphocyte deficiency prevented the development of albuminuria and 
partially protected against podocyte loss, while indices of interstitial injury, 
macrophage number and renal function were not affected. Selective 
depletion of regulatory T cells (Tregs) with a monoclonal antibody to CD25 
enhanced insulin resistance in the uninephrectomised db/db mouse model 
and worsened parameters of DN including albuminuria and glomerular 
hyperfiltration (Eller et al., 2011). Adoptive transfer of CD4+FoxP3+ Tregs  
from healthy donor animals had the opposite effect, strengthening the 
evidence that this subset of cells exert a beneficial effect, although the direct 
effects on renal injury and indirect effects due to changes in insulin 
resistance could not be separated in this study. While circulating immune 
complexes and glomerular deposition of IgG may be detected in DN, a direct 
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role for B lymphocytes in disease pathogenesis has not been proven (Lim and 
Tesch, 2012). 
 
1.11 Rodent models of diabetes and DN 
 
Animal models of human disease represent an important tool for study of 
natural history, molecular mechanisms of disease pathogenesis, and 
development and testing of novel therapeutic agents. Characteristics of ideal 
models include replication of most aspects of human disease, wide 
availability, ease of reproduction and cost-effectiveness (Alpers and Hudkins, 
2011). The latter considerations have led to rodents, and in particular mice 
and rats, being the most frequently used species for disease modeling in 
biomedical research. 
 
While acute disease can frequently be modeled in animals over a similar 
time-frame to the human illness, slowly-evolving diseases such as DN 
represent a greater challenge. Many established models of DN require aging 
of animals, often to >1 year to achieve full expression of renal lesions, and 
these are frequently variable and incomplete (Brosius et al., 2009). While 
genetic, pharmacological or surgical manipulations can compress the time-
line of disease this is often at the expense of elements of the full disease 
phenotype, or superimposition of a second injurious process, limiting the 
translational relevance of subsequent findings. Additional modifying factors, 
such as the genetic background or the age of the animal, also impact 
significantly on disease expression. 
 
The difficulties in establishing robust and reproducible models of DN led to 
the creation of the Animal Models of Diabetic Complications Consortium 
(AMDDC; www.diacomp.org), a network of researchers collaborating to 
identify and characterize new models of disease, standardize assessment and 
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reporting of disease metrics and share data on phenotyping and validation. 
This group has published criteria for validation of new disease models, 
providing a clear description of the desirable features of a model faithful to 
the human disease (Table 1.2). 
 
No model identified to date encapsulates all features of the AMDCC validation 
criteria and hence model selection is often dictated by local availability, 
experience and time-constraints as well as the planned application. Hence, 
interpretation of data must be in the context of the recognized limitations of 
the chosen model. 
 
 
1.11.1 Mouse models 
 
Mouse models of human disease are attractive due to the relative ease with 
which the effects of genomic manipulation, such as global or tissue-specific 
gene inactivation, can be tested on disease evolution. Moreover, a strategy of 
ingressing important pro-diabetic mutations onto mice with nephropathy-
susceptible genetic backgrounds has rapidly expanded the repertoire of 
disease models (Alpers and Hudkins, 2011). 
 
Limitations when compared to rat models include their smaller size, meaning 
smaller quantities of blood, urine or tissue available for analysis, and greater 
physiological differences from humans, often limiting studies of novel 
pharmacological agents (Huang et al., 2011). With respect to the current 
project, mouse, rat and human P2X7 receptors display important 
pharamacological and operational differences which bear relevance to 
interpretation and translation of experimental findings; for instance, BzATP 
is 10-fold more potent to activate human and rat P2X7 receptors, compared 
to mouse (Donnelly-Roberts et al., 2009). 
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1.11.1.i Effect of genetic background on disease expression 
 
Many different inbred mouse strains are available for experimental use and 
genetic background has an important modifying effect on disease expression. 
C57BL/6 mice are widely used due to the frequent availability of genetically-
engineered mutants on this background together with the fact they breed 
well and have a low frequency of spontaneous tumours (Breyer et al., 2005). 
However, this strain appears particularly resistant to the development of 
glomerulosclerosis, whether due to hyperglycaemia or reduction of renal 
mass (Zheng et al., 1998, Ma and Fogo, 2003). This is despite displaying 
relative susceptibility to the induction of hyperglycaemia with STZ and also 
to the metabolic complications of a high fat diet (West et al., 1992, Gurley et 
al., 2006).  
 
The DBA/2 mouse strain, however, appears to be more susceptible to the 
development of diabetic renal injury (Doi et al., 1989, Gurley et al., 2006). 
This is further reflected in the strain dependence of the db/db type 2 diabetes 
mouse model where the commonly used and susceptible C57BLKS 
background, which shares 84% of its alleles with C57BL/6 and 16% with 
DBA/2, shows more severe disease than animals on a pure C57BL/6 
background (Breyer et al., 2005). 
 
Other important strain effects are discussed with relation to the individual 
models below. 
 
 
1.11.1.ii Effect of age on disease expression 
 
While development of diabetic renal injury in mice is clearly time-dependent, 
there is also evidence that inducing disease in older animals may promote a 
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more severe disease phenotype. Induction of diabetes with repetitive low 
dose STZ in 18 month-old female C57BL/6 mice (a resistant sex and strain) 
produces a severe disease phenotype with marked glomerular, 
tubulointerstitial and vascular disease, and 10-fold higher albuminuria than 5 
month old comparator animals (Wu et al., 2010a). In this study, oxidative 
stress, markers of endoplasmic reticulum stress and inflammatory cytokines 
were all upregulated in the kidneys of aged non-diabetic mice while marked 
increases in these parameters were observed in aged diabetic animals along 
with the appearance of diffuse interstitial macrophage infiltration. This 
apparent synergism between aging and diabetes may hence provide a useful 
tool to accelerate the development of experimental renal injury (Zheng et al., 
2003, Wu et al., 2010a). 
 
 
1.12 Individual mouse models of DN 
 
Numerous mouse models of DN have been described, consequent to both 
type 1 and type 2 diabetes. The most commonly used models are discussed 
below, with emphasis on their individual stengths and weaknesses (Table 
1.3). 
 
1.12.1 Type 1 diabetes models 
 
1.12.1.i Streptozotocin-induced DN 
 
STZ is an antibiotic derived from Streptomycetes achromogenes used to 
induce a phenotype of type 1 diabetes in experimental animals (Szkudelski, 
2001). Taken up into pancreatic β-cells via the GLUT-2 receptor, it causes 
alkylation of DNA, overstimulation of poly-(ADP-ribose) polymerase (PARP) 
in an attempt to repair DNA, depletion of NAD+ and ATP and ultimately  
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Mouse models Strengths Weaknesses
Type 1 diabetes
High dose STZ ‘Pure’ hyperglycaemic
insult
Simple and low cost
STZ causes off-target 
nephrotoxicity
Carcinogen
Repetitive low dose STZ Minimal off-target 
nephrotoxicity
Early renal macrophage 
infiltration
Milder disease than high 
dose STZ
C57BL/6 relatively 
resistant to DN
Akit a mouse Spontaneous diabetes
‘Pure’ hyperglycaemic
injury with no off-target 
effects
Minimal interstitial 
disease
Glomerular IgA
deposition common
NOD mouse Spontaneous diabetes
Insulinitis closely models 
human type 1 disease
DN very slow to develop 
(> 1 year)
Insulin treatment often 
necessary
eNOS KO mouse Accelerates DN due to 
both type 1 (eg STZ) and 
type 2 (eg db/db) 
diabetes
Advanced 
glomerulopathy (nodular 
sclerosis)
Mechanism of early 
podocytopathy unclear
Prominent hypertension
Tubulointerstitial disease 
often mild or even 
ameliorated
OVE26 mouse Marked albuminuria and
glomerulosclerosis on 
FVB background
No need for exogenous 
insulin
Albuminuria markedly 
reduced on C57BL/6 and 
DBA/2 backgrounds
Type 2 diabetes
High fat diet Simple and low cost
Recapitulates human 
metabolic syndrome
Mild hyperglycaemia and 
consequently mild DN
Renal lipid accumulation 
common
Db/db mouse Spontaneous diabetes
Obese but not 
hypertensive
Advanced DN with eNOS
KO strain
Tubulointerstitial disease 
mild
C57BL/6 relatively 
resistant to DN
Table 1.3 Mouse models of diabetic nephropathy. NOD: Non-obese diabetic; eNOS: Endothelial
nitric oxide synthase
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cellular necrosis and death (Lenzen, 2008). STZ also inhibits β-cell O-
GlcNAcase, the protein responsible for export of O-linked N-
acetylglucosamine (O-GlcNAc) from the cell, leading to irreversible O-
glycosylation of proteins, which compounds cellular injury (Lee et al., 2006, 
Tesch and Allen, 2007). 
 
Injection of STZ is followed by a tri-phasic metabolic response, with an initial 
early hyperglycaemic phase (c. 1 hour) due to inhibition of insulin secretion, 
followed by hypoglycaemia (4-8 hours) due to β-cell necrosis and fulminant 
release of insulin into the circulation (Lenzen, 2008). Complications of 
hypoglycaemia, such as seizures, can be prevented by ensuring animals have 
free access to oral sugar solutions during this phase. Permanent 
hyperglycaemia develops by 12-48 hours after β-cell degranulation and 
necrosis is complete (Lenzen, 2008). 
 
STZ will potentially accumulate in any cell type expressing GLUT-2, activating 
the same injurious mechanisms elicited in β-cells. Off-target toxicity has been 
described in both liver and kidney, with the latter manifesting as proximal 
renal tubular injury and potentially confounding detection and assessment of 
metabolic kidney injury (Tay et al., 2005). These effects are particularly 
apparent when STZ is administered as one or two ‘high dose’ injections (eg. 
100-200 mg/kg).  
 
Repetitive low dose protocols (eg. 50mg/kg on five consecutive days) are 
also effective in inducing a diabetic phenotype, with initial milder β-cell 
injury followed by a secondary autoimmune insulinitis, not observed in the 
high-dose schedule, commencing at 5-6 days after the last injection (Like and 
Rossini, 1976). The inflammatory islet infiltrate comprises predominantly 
lymphocytes and macrophages and is not accompanied by circulating islet 
cell antibodies (Like et al., 1978). Achieved hyperglycaemia is comparable to 
that seen with high dose induction schedules while off-target toxicity is 
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typically diminished (Breyer et al., 2005). No direct podocyte injury is 
observed in the low dose model (Breyer et al., 2005). C57BL/6 and DBA/2 
strains exhibit more robust and sustained hyperglycaemia than BALB/C, 
MRL/Mp and 129 SvEv strains (Gurley et al., 2006). 
 
Albuminuria, seen variably from ~5 weeks post induction, is typically lower 
than with the high dose schedule, although this may in part reflect reduced  
STZ nephrotoxicity. The evolution of advanced DN lesions (mesangial 
expansion and nodule formation) occurs late (> 15 weeks), and also has a 
strong dependence on background genetic strain, with DBA/2 animals 
exhibiting the highest levels of albuminuria and greatest mesangial 
expansion on head-to-head testing (Gurley et al., 2006). Diabetes may require 
partial correction of hyperglycaemia with insulin to sustain mice for the 
requisite duration to induce histological changes of DN (Roxburgh et al., 
2009). 
 
 
1.12.1.ii Akita mouse 
 
Originally identified as the result of a chance mutation in a C57BL/6 colony in 
Japan, Akita mice develop spontaneous type 1 diabetes by 3-4 weeks of age 
through β-cell loss in the absence of insulinitis (Yoshioka et al., 1997). The 
responsible Ins2C69Y mutation disrupts a disulphide bond between insulin A 
and B chains, leading to misfolding, retention within the endoplasmic 
reticulum and β-cell proteotoxicity (Wang et al., 1999, Ron, 2002). While 
homozygote mice die in infancy, mice carrying a heterozygote mutation 
manifest a dominant phenotype, as expression of the mutant misfolded 
protein interrupts secretion of normal insulin expressed from the wild-type 
allele (Ron, 2002). 
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Blood glucose is similar or higher than that seen in the STZ model and the 
absence of off-target effects and non-metabolic nephrotoxicity potentially 
make it an attractive model for study of microvascular complications (Breyer 
et al., 2005, Gurley et al., 2010). When the phenotype of C57BL/6 Akita mice 
was compared directly to that of low dose STZ on the same genetic 
background, a similar, but more uniform, degree of mesangial expansion was 
observed in Akita mice and albumin excretion was higher (Gurley et al., 
2010). Albuminuria is enhanced when the Akita mutation is imposed on a 
DBA/2 or 129/SvEv background, although mesangial expansion is only a 
feature of disease in C57BL/6 or 129/SvEv Akita mice (Gurley et al., 2010). 
Interstitial disease is not a feature and no study has reported changes of 
advanced DN such as mesangial nodule formation (Alpers and Hudkins, 
2011). Akita mice have a propensity for glomerular IgA deposition by 20 
weeks, complicating the interpretation of experimental interventions on 
mesangial expansion. 
 
 
1.12.1.iii Non-obese Diabetic (NOD) mouse  
 
First described in Japan in 1980, the NOD mouse exhibits a spontaneous 
diabetic phenotype present in 80% of female animals by 30 weeks of age 
(Makino et al., 1980). NOD mouse shares many important pathogenic and 
genetic features to human autoimmune type 1 diabetes including an 
exuberant insulinitis comprising antigen presenting cells, T cells and B cells, 
MHC-dependent and -independent genetic susceptibility, and development of 
anti-islet cell antibodies, meaning the model has been used extensively to 
study events underlying autoimmune β-cell injury (Atkinson and Leiter, 
1999, Breyer et al., 2005, Thayer et al., 2010). Although they exhibit other 
extra-pancreatic phenotypic features (eg. deafness, complement 
abnormalities, T cell accumulation in peripheral lymphoid organs) target 
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organ damage can be assumed to arise from metabolic disturbance, as 
opposed to non-specific nephrotoxicity (Atkinson and Leiter, 1999). 
 
NOD mice do develop features of early nephropathy including albuminuria, 
GBM thickening and mesangial expansion, albeit with some variability in the 
time of onset (Doi et al., 1990). The strain has been used successfully to 
demonstrate the effect of therapeutic interventions on histological and 
biochemical parameters of DN, although partial treatment of diabetes with 
insulin is needed to maintain animals for the requisite experimental time that 
may be in excess of 1 year (Zheng et al., 2002). Production of genetically-
engineered congenic NOD stock with deletions or modifications to genes of 
interest in DN is feasible, but multiple genetic loci must be preserved in order 
to maintain development of diabetes and identification of suitable non-
diabetic control mouse strains can be difficult (Breyer et al., 2005). 
 
 
1.12.1.iv Endothelial Nitric Oxide Synthase (eNOS) knockout models 
 
Endothelial dysfunction represents an early and important component of the 
glomerular injury in both type 1 and type 2 diabetes (Badal and Danesh, 
2012). Nitric oxide (NO), produced locally by eNOS, is an important mediator 
of both vascular tone and vascular permeability, with inhibition or genetic 
deletion of eNOS leading to opening of interendothelial junctions and 
albumin leak in multiple murine microvascular beds (Predescu et al., 2005, 
Zhao et al., 2006). Endothelial NO availability is reduced in diabetes and 
polymorphisms in the human NOS3 gene (encoding eNOS) have been 
demonstrated both to be functional, corresponding to lower measured levels 
of NO, and to predict development of advanced nephropathy in patients with 
both type 1 and type 2 diabetes (Tsukada et al., 1998, Zanchi et al., 2000, Du 
et al., 2001, Ezzidi et al., 2008, Brosius et al., 2009). 
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Induction of diabetes with a low dose STZ protocol in eNOS KO animals leads 
to 10 fold-higher albuminuria by week 20, increased mesangiolysis and 
thicker GBM on electron microscopy, compared to diabetic WT animals 
(Kanetsuna et al., 2007). Mesangial expansion is not increased compared to 
WT, tubulointerstitial pathology is mild, and blood pressure is elevated in 
eNOS KO animals (Kanetsuna et al., 2007). The phenotype is more severe 
with a higher dose STZ schedule: around 20-fold higher albuminuria by 5 
months compared to WT, increased mesangial expansion and occasional 
mesangial nodular sclerotic changes (Nakagawa et al., 2007). Similar 
potentiating effects on albuminuria, mesangial expansion, glomerulosclerosis 
and mesangiolysis were seen in a study of the F1 cross between 
heterozygous 129S6/SvEvTac eNOS +/-  mice and heterozygous C57BL/6J 
eNOS +/- mice carrying the Akita mutation, with eNOS -/- having more 
severe disease than +/- and, in turn, +/+ progeny (Wang et al., 2011). Of note, 
tubulointerstitial fibrosis, as assessed by Masson’s trichrome staining, was 
ameliorated in eNOS KO Akita mice compared to eNOS WT animals (Chen et 
al., 2005). 
 
A similar enhancement of renal pathologic changes by eNOS deficiency has 
also been observed in a model of type 2 diabetes, where eNOS +/- mice on a 
C57BL/6 background were backcrossed for 10 generations on to the 
nephropathy-sensitive C57BLKS/J strain and then crossed with db/db mice 
(Zhao et al., 2006). By 26 weeks, eNOS KO mice had dramatically more 
albuminuria, increased mesangial expansion and GBM thickness, early 
nodular sclerotic changes and, strikingly, a >50% reduction in GFR. Although, 
at face value, these changes appear more robust and severe than those 
observed with the low dose STZ model, this may in part be explained by the 
background genetic strains used in the relevant experiments (Brosius et al., 
2009). 
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While genetic eNOS deficiency appears to overcome many of the 
shortcomings of traditional mouse models of DN, the precise mechanisms 
underlying the acceleration of renal pathology have not been clear. A recent 
study examining the effect of a VEGF receptor blocker, Vatalanib, after 
induction of diabetes with low dose STZ in eNOS KO mice, has shed some 
light on this (Yuen et al., 2012). In this study, Vatalanib, administered by daily 
oral gavage commencing 2 weeks after induction of diabetes, inhibited 
glomerular capillary enlargement in both eNOS KO and WT diabetic animals, 
but only attenuated albuminuria in WT mice. In eNOS KO animals an acute 
podocytopathy was evident by 2 weeks after diabetes induction, concomitant 
with onset of marked albuminuria, not apparent in WT animals and 
preventable with RAAS blockade. As podocytes do not express significant 
amounts of eNOS, this suggests that deleterious endothelial cell-podocyte 
crosstalk may in part explain the amplified diabetic phenotype observed in 
the absence of eNOS. 
 
1.12.1.v OVE26 mice 
 
OVE26 transgenic mice over-express calmodulin in pancreatic β-cells, leading 
to cell toxicity and a type 1 diabetic phenotype (Epstein et al., 1989). When 
expressed on an FVB background, OVE26 mice exhibit marked albuminuria, 
far in excess of that seen in any other diabetes mouse model, reaching levels 
200-fold greater than control mice by 9 months (Zheng et al., 2004). This is 
accompanied by mesangial expansion, progressing to more global 
glomerulosclerosis, podocyte loss and mild tubulointerstitial fibrosis (Alpers 
and Hudkins, 2011). Mice can maintain body weight and survive for over a 
year without the need for exogenous insulin therapy (Zheng et al., 2004). The 
primary limitation of OVE26 mice is the marked strain-dependence of DN 
development: while OVE26 transgenic mice bred onto a C57BL/6 or DBA/2 
background still develop marked hyperglycaemia, albuminuria and 
mesangial expansion are signficantly reduced (Xu et al., 2010). As a result, it 
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is challenging to ingress additional genetic mutations onto this model (Alpers 
and Hudkins, 2011). 
 
 
1.12.2 Type 2 Diabetes Models 
 
1.12.2.i High-fat diet 
 
Feeding mice a high-fat diet has been used as an approach to model type 2 
diabetes and the metabolic syndrome (Surwit et al., 1988, Panchal and 
Brown, 2011). High fat diet promotes obesity, dyslipidaemia, insulin 
resistance, impaired glucose tolerance and hypertension as well as end organ 
damage including cardiac hypertrophy and hepatic steatosis (Panchal and 
Brown, 2011). Hyperglycaemia is modest with random BG values of 8-14 mM 
by 12 weeks of feeding (West et al., 1992, Deji et al., 2009). Susceptibility to 
high fat diet shows strain-dependence with greatest success using C57BL/6 
and AKR/J inbred genetic backgrounds (West et al., 1992). 
 
Obese animals manifest a mild renal phenotype comprising albuminuria (3-4 
fold higher than control animals), glomerular hypertrophy, mesangial 
expansion and irregular GBM thickening, together with interstitial 
macrophage accumulation (Deji et al., 2009). Of note, these abnormalities 
could be prevented by feeding a restricted volume high fat diet, matching 
body weight to low fat diet controls. Lipid accumulation in renal tissue is also 
observed, driven by accelerated local lipogenesis and depressed lipolysis, 
which may contribute to the development of kidney injury (Kume et al., 
2007). 
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1.12.2.ii Db/db mouse 
 
The db/db (db referring to diabetes) mouse was first described as a chance 
mutation in C57BLKS stock at the Jackson Laboratory in the 1960s and is a 
commonly used model of obese type 2 diabetes (Hummel et al., 1966). A 
point mutation in the gene encoding the hypothalamic leptin receptor leads 
to aberrant splicing and production of defective protein; transmitted by 
autosomal recessive inheritance, this leads to hypothalamic resistance to the 
adipocyte-derived satiety hormone leptin, with consequent hyperphagia and 
obesity (Tesch and Lim, 2011, Panchal and Brown, 2011). In C57BLKS mice, 
hyperglycaemia develops by 4 weeks, albuminuria may be observed by 8 
weeks, and mesangial expansion by 12-16 weeks of age (Sharma et al., 2003). 
Subsequent β-cell degeneration means intermittent insulin administration is 
required to keep animals alive for longer periods (Tesch and Lim, 2011). 
Significant interstitial fibrosis is not a feature (Breyer et al., 2005). 
 
Db/db mice on a C57BL/6 background have a lower incidence of diabetic-
range hyperglycaemia and delayed onset of renal injury compared to 
C57BLKS. They also manifest β-cell hypertrophy rather than degeneration 
meaning maintenance insulin replacement is not required (Sharma et al., 
2003, Chow et al., 2007). Nephropathy can be accelerated by uninephrectomy 
(Bower et al., 1980, Tesch and Lim, 2011). Male mice of both strains are more 
susceptible to diabetes than females (Tesch and Lim, 2011). 
 
Ob/ob mice carry a mutation in the gene for leptin (as opposed to the 
receptor) which is transmitted by autosomal recessive inheritance (Panchal 
and Brown, 2011). While the overall phenotype of these animals is similar to 
db/db, renal disease is mild and mainly comprises diffuse and nodular 
lipohyaline glomerular changes, limiting their use for interventional studies 
(Sharma et al., 2003).  
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1.13 Rat models of DN 
 
As with mice, rat models of both type 1 and type 2 diabetes have been used to 
study DN . The most commonly used models are discussed below, with 
emphasis on their individual stengths and weaknesses (Table 1.4). 
 
1.13.1 Type 1 diabetes models 
 
1.13.1.i Streptozotocin-induced DN 
 
As with mice, STZ is commonly used to induce type 1 diabetes in rats through 
direct pancreatic β-cell toxicity (Tesch and Allen, 2007). Sprague-Dawley and 
Wistar are the most commonly used strains. The majority of animals develop 
diabetes after a single IV or IP dose and, unlike in the mouse, off-target acute 
kidney injury is minimal or absent (Junod et al., 1967). DNA damage and 
resultant proliferative responses do occur within the kidney, however, these 
have typically resolved by 3 weeks post-administration (Kraynak et al., 
1995). It is generally felt advisable to wait for this 3 week window to elapse 
after STZ injection before beginning treatment with potential therapeutic 
agents. 
 
Albuminuria may be observed from 2 weeks after diabetes induction 
increasing to 5-10 times control values by 24 weeks (Osicka et al., 2000, 
Kalantarinia et al., 2003). However, histological abnormalities are mild, even 
after prolonged hyperglycaemia, and are limited to modest mesangial 
expansion, interstitial fibrosis and deposition of ECM proteins (Sanai et al., 
2000, Nakamura et al., 2007). Many investigators superimpose an additional 
insult to accelerate the development of nephropathy, such as 
uninephrectomy or hypertension (Kelly et al., 1998, Huang et al., 2009). A 
model has recently been described in which STZ diabetes is induced in a rat  
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Rat Models Strengths Weaknesses
Type 1 diabetes
STZ ‘Pure’ hyperglycaemic
injury
Low cost
DN can be accelerated by 
UNx or inducible 
hypertension
Mild renal phenotype
Cataracts common
Insulin treatment 
necessary
Obese Type 2 diabetes
Zucker diabetic fatty rats Spontaneous diabetes
Recapitulates human 
metabolic syndrome
Dominant renal 
abnormality is 
hydronephrosis
OLETF rats Spontaneous diabetes
Recapitulates human
metabolic syndrome
DN onset very slow 
(proteinuria 20 weeks, 
GBM thickening 40 
weeks)
Insulin treatment often 
required
Lean type 2 diabetes
GK rats Spontaneous diabetes
Dyslipidaemic but not 
hypertensive
Insulin treatment not 
required
DN onset very slow (mild 
albuminuria by 1 year, 
glomeruosclerosis at 2 
years)
Table 1.4 Rat models of diabetic nephropathy. OLETF: Otsuka Long-Evans Tokushima fatty; GK:
Goto-Kakasaki
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harbouring the Ren2 renin gene under the control of the cytochrome 
P4501a1 promoter. In this rat hypertension can be induced by the dietary 
administration of indole-3-carbinol (Conway et al., 2012). This permits 
hypertension to be induced after the onset of diabetes (as opposed to being 
present from the outset in non-conditional Ren2 transgenics) and titrated to 
the desired level, more closely modelling the biology of human disease. 
 
 
1.13.2 Obese type 2 diabetes rat models 
 
1.13.2.i Zucker diabetic fatty rats (ZDF/Drt-fa) 
 
ZDF/Drt-fa rats develop spontaneous hyperglycaemia in the context of 
obesity and hyperlipidaemia driven by a mutation in the leptin receptor 
(Panchal and Brown, 2011). Outbred obese Zucker rats do not exhibit 
hyperglycaemia; the diabetic variant was identified as a chance mutant in a 
Zucker colony, transmitted in an autosomal dominant fashion, and selectively 
inbred for 16 generations (Clark et al., 1983, Vora et al., 1996). Obesity and 
increased body weight is apparent by 6 weeks of age while hyperglycaemia 
and hyperinsulinaemia manifests by 8-12 weeks together with 
hypercholesterolaemia and hypertriglyceridaemia (Vora et al., 1996). While 
albuminuria is increased by 6 weeks in obese animals compared to lean 
controls, and increases progressively thereafter, the dominant 
histopathological finding in animals with prolonged hyperglycaemia is of 
hydronephrosis, presumed to be of neurogenic origin, and complicating the 
interpretation of experimental findings (Vora et al., 1996). 
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1.13.2.ii Otsuka Long-Evans Tokushima Fatty (OLETF) Rats 
 
OLETF rats display spontaneous hyperglycaemia in the context of mild 
obesity and were derived from a mutation in a colony of Long-Evans rats in 
Tokushima, Japan, in the early 1980s (Kawano et al., 1992). Rats exhibit 
hyperglycaemia at ~18 weeks of age, followed by  hyperinsulinaemia and 
then pancreatic degeneration by 40 weeks of age, often requiring insulin 
replacement. Renal complications develop with time, with increased 
proteinuria by 20 weeks, mesangial expansion and GBM thickening apparent 
by 40 weeks, and glomerular nodular changes developing by 60-70 weeks 
(Kawano et al., 1992, Yagi et al., 1997). Compared to lean controls, animals 
exhibit hypertension from 10 weeks of age, which may contribute to the 
development of nephropathy (Yagi et al., 1997) 
 
 
1.13.3 Lean type 2 diabetes rat models 
 
1.13.3.i Goto-Kakizaki (GK) rat 
 
The GK rat represents a model of lean type 2 diabetes and was produced by 
repeated inbreeding of Wistar rats selected through oral glucose tolerance 
testing (Goto et al., 1976). The mechanism of diabetes onset is consequently 
complex, including impairment in gestational β-cell neogenesis and abnormal 
β-cell differentiation (Panchal and Brown, 2011).  Hyperglycaemia is evident 
by 4-6 weeks of age and supplemental insulin is not required for long-term 
maintenance as blood sugars remain only modestly elevated (<20mM). By 35 
weeks, renal abnormalities are limited to glomerular hypertrophy and GBM 
thickening with no accompanying increase in albuminuria (Phillips et al., 
2001). Interstitial macrophage infiltration is observed from 12 weeks, 
increasing up to 35 weeks, and an excess of glomerular macrophages is 
63 
 
present by 35 weeks (Phillips et al., 2001). An increase in type IV collagen 
and αSMA expression is observed by 1 year but glomerular sclerotic changes 
and tubulointerstitial fibrosis only appear after 2 years of diabetes (towards 
the end of the animal’s life) (Sato et al., 2003). 
 
1.14 Conclusions - diabetic nephropathy 
 
Despite the panoply of molecules and pathways now identified as 
contributing to the pathogenesis of DN, there have been no major therapeutic 
advances in the last 10 years, and a substantial proportion of sufferers 
continue to progress to end-stage renal disease (ESRD). Recognition that 
innate immune mechanisms, classically associated with infective or 
inflammatory diseases, contribute to progression of DN, has presented a new 
avenue for investigation, and potentially the development of novel 
therapeutic agents. Any proposed anti-inflammatory or immuno-modulatory 
treatment for DN will, however, require careful target selection and thorough 
evaluation in pre-clinical disease models, to ensure both efficacy and 
specificity of action. 
 
A number of animal models of DN have been discussed, resulting from both 
type 1 and type 2 diabetes. Common to all of these, with the possible 
exception of diabetic eNOS KO mice, is a mild renal phenotype, failing to 
recapitulate the features of advanced human DN. This is further complicated 
by differences in reported severity of renal disease between different strains, 
ages and sex of mice, increasing heterogeneity of published data and 
hindering replication of important findings. Ultimately, investigators should 
select a model of DN to test their specific research question by considering 
which features are most desirable eg. presence of associated hypertension or 
obesity, early robust albuminuria or interstitial disease, or presence of a well-
developed inflammatory response. 
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Part 3. Hypothesis and aims 
 
1.15 Hypothesis 
 
The central research question addressed in this project is: 
 
Does the P2X7 receptor contribute to the pathogenesis of diabetic 
nephropathy? 
 
As reviewed above, circumstantial evidence already exists which connects 
P2X7 to DN, including upregulation of glomerular expression observed at an 
early timepoint in the STZ diabetic rat, and a potential contribution to ECM 
synthesis in rat MCs exposed to hyperglycaemia (Vonend et al., 2004, Solini et 
al., 2005). To date, no studies have directly explored the functional 
importance of P2X7 in development of DN. Given the established role of P2X7 
in secretion of IL1β/IL18 from macrophages and its proven importance in 
the pathogenesis of inflammatory and fibrotic kidney diseases, a key aim of 
this project is to examine the contribution of P2X7 to renal inflammation in 
DN. An increasing body of evidence has linked activation of innate immune 
mechanisms to progressive kidney injury in diabetes, making interruption of 
these pathways an important focus for development of new therapies. 
 
1.16 Experimental aims and rationale 
 
The specific goals of the study are: 
 
1) To examine the expression of P2X7 in human kidney biopsy tissue 
from patients with DN by immunohistochemistry and assess the 
relationship between expression and clinical parameters of disease. 
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2) To study the functional importance of P2X7 to DN by comparing 
renal outcomes and measures of renal inflammation in WT and GSK 
P2X7 KO mice made diabetic by repetitive low dose STZ injection. 
 
3) To complement the murine study of genetic P2X7 deficiency by 
examining the effect of a selective P2X7 antagonist on the 
development of kidney disease in the uninephrectomised STZ rat 
model of DN. 
 
4) To further investigate the potential mechanism by which P2X7 
signalling may promote glomerular inflammation in DN, through in 
vitro studies of human glomerular cells exposed to hyperglycaemia. 
 
In addition, a supplementary study has been conducted to specifically 
examine the role of P2X7 in the development of insulinitis and β-cell injury 
after STZ, by comparing pancreatic outcomes in WT and Pfizer P2X7 KO mice. 
 
The low dose STZ mouse model of DN was selected for use on the following 
grounds: 
 
1) The model is established and well characterised, and manifests an 
early and robust macrophage infiltrate, providing a good model for 
study of early inflammatory events in DN. 
 
2) Although low dose STZ results in milder renal disease than a high 
dose induction schedule, it is associated with minimal bystander 
nephrotoxicity, a problem with high dose regimes. 
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3) STZ-induced diabetes offers the opportunity to look at the renal 
consequences of hyperglycaemia without confounding effects of 
hypertension, obesity and dyslipidaemia, common to most type 2 
diabetes mouse models. 
 
4) STZ can also be used to induce diabetes in rats, facilitating 
comparison between the mouse and rat models of DN used in this 
study. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 General materials 
 
All laboratory chemicals were purchased from Sigma-Aldrich (Poole, UK) 
unless otherwise specified. Tissue culture plasticware was manufactured by 
Corning (New York, USA), cell scrapers by Greiner (Frickenhausen, Germany) 
and scalpels by Swann-Morton (Sheffield, UK). Microcentrifuge tubes were 
supplied by Eppendorf (Hamburg, Germany). Specific materials and their 
source are described in the relevant sections below. 
 
 
2.2 Animal husbandry 
 
Mice and rats were maintained in a pathogen-free animal facility at Imperial 
College London (Hammersmith Hospital campus) in individually-ventilated 
cages with free access to water and standard laboratory diet. Maximum cage 
occupancy was five for mice and two for rats. All experimental animals were 
male. All animal procedures were licensed by the Home Office Science Unit: 
personal license 70/23327 and project licenses 70/7250 (Prof Roger Mason) 
and 70/7104 (Prof Charles Pusey). 
 
2.3 Breeding of genetically modified mice 
 
Two strains of P2X7 KO mice were used in experiments: one generated by 
GlaxoSmithKline (GSK; Harlow, UK) and the other by Pfizer (Groton, USA). 
Both were provided as kind gifts for use in this project. GSK KO mice were 
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bred in-house from heterozygote breeding pairs, with WT animals used as 
experimental controls. Pfizer KO mice were bred from homozygote KO 
breeding pairs and unrelated WT C57BL/6 animals were used as controls for 
experiments using these mice. 
 
2.3.1 Background: Generation of GSK P2X7 KO mice 
 
The GSK mouse was generated by targeted insertion of a lacZ gene at the 
beginning of exon 1 of the P2RX7 gene (Sim et al., 2004, Chessell et al., 2005); 
(Figure 2.1A and B). To achieve this, the P2X7R gene was isolated from a 
genomic library obtained from 129/Sv mice, the 5’ exons partially sequenced, 
and two fragments ligated into a neomycin-resistant ‘knock out vector’ 
plasmid. Homologous recombination of the resulting plasmid DNA into 
embryonic stem cells resulted in P2X7 gene disruption. Chimaeric mice were 
created by injection of transformed embryonic stem cells into C57BL/6 host 
embryos. These were subsequently crossed with C57BL/6 females to 
generate heterozygotes and then intercrossed to create healthy mutant 
offspring. Loss of channel function was confirmed by testing IL1β production 
from peritoneal macrophages in response to ATP and LPS, which was 
abolished in KO animals (Chessell et al., 2005). 
 
2.3.2 Background: Generation of Pfizer P2X7 KO mice 
 
The Pfizer mouse was generated by insertion of a neomycin resistance 
cassette into the P2X7R gene after the Arg505 codon (Solle et al., 2001); 
(Figure 2.1C). This insertion led to deletion of Cys506 to Pro532 in the long 
intracellular C-terminal region of the P2X7R gene product. Using 
methodology similar to that described for the GSK KO, a targeting vector 
(plasmid) was constructed and used for transformation of embryonic stem 
cells with the disrupted gene. Chimaeric mice derived from transformed  
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embryonic stem cells were subsequently mated with C57BL/6 mice. 
Northern blot analysis in bone marrow-derived mast cells confirmed absence 
of the transcript for P2X7 in KO animals, while Western blot of membrane 
preparations from KO macrophages suggested no intact or truncated forms 
of the receptor were expressed. Loss of channel function and biological 
activity were confirmed in macrophages by dye-uptake and cytokine release 
assays (Solle et al., 2001). 
 
 
2.4 Genotyping of genetically-modified mice 
 
All genetically-modified mice underwent confirmatory genotyping prior to 
use in experiments. This was achieved by extracting DNA from mouse tissue 
and performing PCR using oligonucleotide primers designed to discriminate 
between the native and disrupted forms of the P2RX7 gene. 
 
 
2.4.1 Extraction of DNA 
 
Tissue for DNA extraction was collected by ear punching and DNA was 
extracted using the QIAamp DNA Mini and Blood Mini Kit (Qiagen, Crawley, 
UK). Tissue was lysed by incubating at 56oC in a mixture of proprietary lysis 
buffer (buffer ATL) and proteinase K (600mAU/ml). Samples were vortexed 
intermittently and tissue lysis, as judged by disintegration of all visible tissue, 
was typically complete within 1-3 hours. Samples were then incubated in a 
further lysis buffer (buffer AL) for 10 minutes at 70oC to enhance protein 
degradation before adding 100% ethanol to precipitate DNA. Samples (and 
any DNA pellet precipitated by addition of ethanol) were then transferred to 
the QIAamp Mini spin column before centrifugation wash steps with buffers 
AW1 and AW2. DNA was then eluted from the membrane of the spin column 
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in 200µl buffer AE by centrifuging at 6000 x g for 1 minute at room 
temperature. 
 
 
2.4.2 PCR 
 
PCR was used to amplify fragments of the P2RX7 gene using primers 
designed to discriminate between WT and KO mice (Table 2.1). PCR was 
performed using the GoTaq HotStart Polymerase kit (Promega, Madison, 
USA). This system employs a high performance DNA polymerase bound to a 
proprietary antibody which blocks polymerase activity at temperatures 
<70oC; this activity is restored on heating samples to 94oC for the initial 
denaturation step. This system hence facilitates preparation of reactions at 
room temperatures and minimizes formation of non-specific products. 
 
 
Each PCR reaction was assembled as follows: 
 
  5 x PCR buffer   5 l 
  10mM dNTP mixture  0.1l 
  25mM MgCl2    1.5l 
  10μM Primers (5’ and 3’)  1.25l 
  Taq DNA polymerase  0.25l 
  Distilled H2O    9.4l 
  Ear punch DNA   5l 
  TOTAL    25l (per reaction) 
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The subsequent PCR thermal cycling program was: 
 
 1. 94oC for 5 mins   Activation of Taq DNA polymerase 
 2. 94oC for 1 min   Denaturation of DNA 
 3. 63oC for 1 min   Annealing of primers 
 4. 72oC for 1 min   Extension of PCR products 
 Cycling: repeat steps 2 to 4, 34 times 
 5. 72oC for 10 mins   Final extension step 
6. 4OC indefinitely Holding step until sample 
collection 
 
PCR products were stored at 4oC prior to gel electrophoresis. 
 
 
2.4.3 Agarose Gel Electrophoresis 
 
PCR products were analysed by electrophoresis on a 2% agarose gel. This 
technique allows separation of amplified DNA based on fragment size. The 
2% gel was prepared by placing ultrapure agarose in TAE buffer (40mM Tris 
base, 20mM acetic acid, ImM EDTA, pH 8), microwaving for 2 minutes to 
solubilise and stirring for 5 minutes. Ethidium bromide (33µl/l) was added 
during cooling. Once cool, the gel was poured into a casting tray, a sample 
comb inserted and left to set for 60 minutes. 
 
Once set, the gel was removed from the casting tray, combs were removed 
and the gel was transferred to an electrophoresis tank and covered with TAE 
buffer. PCR reaction products (15µl) were loaded into wells with a 100 base-
pair resolution DNA ladder (New England Biolabs, Ipswich, USA) used as a 
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reference marker. Electrophoresis was performed at 150V for ~40 minutes. 
Ethidium bromide intercalates between DNA base pairs and fluoresces when 
exposed to ultraviolet light allowing visualisation of DNA bands of different 
sizes when the gel is viewed under these conditions. 
 
Predicted band sizes for amplified DNA from wild-type and KO mice were: 
 
  GSK wild-type   568 bp 
  GSK KO heterozygote  568 bp and 393 bp 
  GSK KO homozygote   393 bp 
 
  Pfizer wild-type   280 bp 
  Pfizer KO heterozygote  280 bp and 363 bp 
  Pfizer KO homozygote  363 bp 
 
Sample data is presented in Figure 2.2. 
 
 
2.5 Induction of Type 1 diabetes in mice 
 
Mice aged 8 months or older, either WT or KO, were randomly divided into 
two groups: Group A, treated with streptozotocin (STZ, 2-deoxy-2(3-(methyl-
3-nitrosoureido)-d-glucopyranose) dissolved in 100mM sodium citrate 
buffer at pH 4.5; or Group B, treated with citrate buffer alone (all groups n=8; 
Figure 2.3). STZ was dissolved in citrate buffer at the point of use, and 
50mg/kg was injected intraperitoneally (IP) on 5 consecutive days after a 4-6 
hour fast (repetitive low-dose protocol; http://www.diacomp.org). 
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STZ is an antibiotic derived from Streptomycetes achromogenes used to 
induce a phenotype of type 1 diabetes in experimental animals (Szkudelski, 
2001). Taken up into pancreatic beta cells via the GLUT-2 receptor, it causes 
alkylation of DNA and activation of poly-ADP ribosylation, processes which 
ultimately lead to irreversible cellular damage and necrosis. When 
administered as multiple low dose injections in the mouse this effect is 
augmented by a subsequent autoimmune ‘insulinitis’ with consequent 
destruction of pancreatic beta cells (Tesch and Allen, 2007). 
 
Random blood glucose (BG) was measured at 3 weeks after the last injection. 
Mice were immobilised in a restrainer, a tail vein ‘prick’ performed with a 23 
gauge needle and a OneTouch glucometer (Lifescan, Milpitas, USA) used for 
glucose measurement. A BG of greater than 16mmol/l was regarded as 
diabetic. WT and GSK KO mice with a BG of 16-33.3 mmol/l were 
subsequently maintained for a total of 12 weeks. BG was measured at 3 
weekly intervals during the study, and animals with readings falling outside 
of the desired range were excluded. Urine was collected at baseline and week 
12 and terminal collection of blood and kidney tissues was made at week 12. 
 
A sub-study was conducted with WT and Pfizer KO mice to examine the 
susceptibility of this mutant strain to induction of diabetes with STZ. Animals 
were randomly divided into the following groups: WT, repetitive low dose 
STZ (n=8), WT, citrate buffer vehicle (n=4), Pfizer KO, repetitive low dose STZ 
(n=7) and Pfizer KO, citrate buffer vehicle (n=4). BG was measured at 3 
weeks and pancreas tissue taken for immunohistochemistry at this time 
point. 
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2.6. Uninephrectomy, induction and maintenance of type 1 diabetes and 
administration of a selective P2X7 antagonist in rats 
 
An initial pilot experiment (Experiment 1) was performed using Sprague 
Dawley rats (Charles River, Margate, UK). In this experiment, rats weighing 
200-250g were randomly assigned either to group A, single intravenous (IV) 
injection with STZ (50mg/kg) in citrate buffer or B, citrate buffer alone 
(n=5/group), and followed for 21 weeks with periodic urine collections and 
terminal collection of blood and kidney tissue. 
  
Subsequent experiments were performed using Wistar Han IGS rats (Charles 
River). An initial pilot experiment (Experiment 2) was performed to establish 
an effective dose of STZ for induction of diabetes. A further experiment 
(Experiment 3) was performed to establish the duration of diabetes required 
to provoke albuminuria (as the earliest sign of diabetic nephropathy) in 
animals which had undergone a uninephrectomy. In this experiment, rats 
weighing 200-250g underwent right uninephrectomy (UNx) followed by 
either A, single IV injection of STZ (40mg/kg) (n=6) or B, citrate buffer alone 
(n=4), one week later. Animals were followed for 16 weeks with urine 
collections made at baseline, weeks 4, 8, 12 and 16 and collection of blood 
and kidney tissue at week 16. In this experiment, the time of onset of robust 
albuminuria was established to be 8 weeks. 
 
The main rat experiment (Experiment 4) was designed to test the effect of a 
highly selective P2X7 receptor antagonist (AZ11657312; AstraZeneca, 
Alderley Park, UK) on the evolution of DN in uninephrectomised diabetic 
animals. Right UNx was performed in rats weighing 200-250g and a single 
injection of IV STZ (40mg/kg) or vehicle was administered one week later.  
Antagonist or drug vehicle (see below) was administered IP twice-daily for 
28 days starting from week 8. Animals were divided into 5 groups (n=8-9 per 
group) (Figure 2.4):  
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A:  Sham UNx + IV citrate buffer 
B:  UNx + IV citrate buffer 
C:  UNx + IV STZ 40mg/kg + IP drug vehicle 
D:  UNx + IV STZ 40 mg/kg + IP AZ11657312 10mg/kg 
E:  UNx + IV STZ 40mg/kg + IP AZ11657312 50mg/kg  
 
The doses of AZ11657312 chosen for study were based on previous 
published experience with the antagonist in the streptococcal cell wall model 
of inflammatory arthritis (Cruwys et al., 2007) and unpublished 
pharmacokinetic data supplied by AstraZeneca. Urine collections were made 
at baseline, week 4, 8 and 12. Terminal blood and kidney tissues were 
collected at week 12. 
 
 
2.6.1 Right Uninephrectomy 
 
Procedures were performed in a clean, purpose-built operating theatre in the 
animal facility. The right flank was shaved prior to anaesthetization with 
isofluorane. Once anaesthetised, a 1.5-2cm incision was made in the right 
flank and the subcutaneous tissue and the muscle layer divided using 
dissecting scissors. The right kidney was identified (lying deep to the liver in 
the retroperitoneal compartment) and manipulated through the flank 
incision. The capsule was divided and a cross-clamp placed over the vascular 
pedicle and ureter. A silk tie was used to ligate the vessels and ureter 
proximal to the clamp and the kidney removed. The clamp was subsequently 
removed and silk tie cut to a short length. The muscle layer was sutured 
closed using an absorbable stitch in a continuous pattern. 3-4 clips were 
applied to the skin (removed one week later). Animals undergoing sham 
nephrectomy were shaved and anaesthetized but underwent a flank incision 
only with the fully-functional kidney left in situ. 
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Animals received a single subcutaneous (sc) dose of buprenorphine analgesia 
(0.02mg/kg) at the end of the operation. Enrofloxacin (Baytril; Bayer, 
Leverkusen, Germany) was added to drinking water for 48 hours post-
operatively as antibiotic prophylaxis against wound infection. 
 
 
2.6.2 Induction and maintenance of type 1 diabetes 
 
STZ was dissolved in 100mmol/l citrate buffer (pH 4.5) at the point of use. 
Animals were placed under light anaesthesia with isofluorane and STZ or 
vehicle injected intravenously (IV) via the dorsal penile vein. Water in 
drinking bottles was replaced with 10% sucrose for 48 hours after injection 
to combat the risk of early hypoglycaemia due to insulin release from injured 
beta cells. 
 
Venous BG was checked at one week post-injection using a OneTouch 
glucometer (Lifescan). Light anaesthesia was induced with isofluorane and a 
tail vein ‘prick’ performed with a 23 gauge needle. Animals with a blood 
glucose of >33.3 mmol/l were administered slow-release sc insulin pellets 
(Linshin, Toronto, Canada) to prevent ketoacidosis and maintain weight. To 
do this, the animal’s scruff was shaved and a 16 gauge needle used to make a 
small sc incision. A metal trocar was inserted through the incision into the sc 
space and 1/8 of a pellet pushed through the trocar with a stylet. The skin 
was pinched over the incision site for 1 minute after removal of the trocar to 
ensure contraction of the skin defect. 
 
1/8 insulin pellet provides approximately 0.25 units insulin/day. BG was 
retested one week after insertion and a further 1/8 pellet inserted if 
persistently >33.3 mmol/l. This cycle was continued until BG had been 
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titrated to <33.3 mmol/l. Diabetic animals with BG in the desired range had 
repeat tests at two weekly intervals. Control animals were tested every 4 
weeks. 
 
2.6.3 Administration of highly selective P2X7 antagonist 
 
AZ11657312 was dissolved in a vehicle of 5% DMSO/95% 2-hydroxypropyl-
beta-cyclodextrin (HPBCD) solution. HPBCD was reconstituted as a 20% 
solution in distilled water. A 30mg/ml solution of drug was used for 
administration of high dose (50mg/kg) treatment with an approximate dose 
volume of 0.4 – 0.5 mls. A 6mg/ml solution was used to administer the low 
dose (10mg/kg) treatment ensuring dose volumes equivalent to the high 
dose injections. Injection volumes for vehicle-treated animals were 
calculated to ensure weight-based equivalence to both treatment groups. 
 
Antagonist or vehicle injections were administered IP twice daily under light 
anesthesia using a 1ml syringe and 25 gauge needle. 
 
2.6.4 GK rats 
 
Kidney tissue from GK rats and age-matched Wistar controls was provided by 
Dr Edward Debnam (UCL, London). GK rat kidney tissue used for P2X7 
immunohistochemistry was fixed overnight in neutral-buffered formalin, 
while tissue for gene expression analysis was stored in RNAlater prior to 
mRNA extraction. 
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2.7 Collection of biological specimens from mice and rats 
 
2.7.1 Urine collection 
 
Mice and rats were housed in individual metabolism cages for collection of 
urine samples. Mice were left in cages overnight while rats were kept in cages 
during daytime only. Due to significant polyuria in diabetic rats, urine 
collection containers were emptied midway through the collection period to 
prevent overflowing and ensure accurate measurement of urine volume. 
 
At the end of the collection, total urine volume was measured and an aliquot 
centrifuged at 240 x g for 5 minutes to sediment macroscopic debris. Urine 
glucose was measured semi-quantitatively using reagent strips (IND 
Diagnostics, Delta, Canada) before aliquoting samples for storage at -80oC. 
 
 
2.7.2 Collection of terminal blood and tissue specimens 
 
At the end of the study, animals were placed under isofluorane anaesthesia 
for collection of blood and tissues. Blood was obtained by cardiac puncture 
using a 1 ml syringe and 25 gauge needle. Tissues were dissected out after 
the animal had been culled by exsanguination. 
 
For mice, the right kidney was divided longitudinally and one half kidney 
placed in neutral-buffered formalin together with specimens of liver, lung 
and spleen. Specimens were left in formalin fixative overnight before transfer 
to 70% ethanol, prior to paraffin embedding and sectioning. Remaining 
kidney tissue was divided and used as follows i) placed in RNAlater ii) snap-
frozen in a cryovial in liquid nitrogen iii) placed in OCT embedding matrix 
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(Thermo Fisher Scientific, Loughborough, UK)  on a cork disc and frozen by 
immersion in isopentane cooled in liquid nitrogen iv) placed in periodate-
lysine-paraformaldehyde (PLP) fixative (see below). In the Pfizer KO 
substudy, a specimen of pancreas was obtained and fixed in neutral-buffered 
formalin. 
 
For rats, the left (remaining) kidney was dissected out. A coronal mid-pole 
section was placed in neutral-buffered formalin together with a specimen of 
spleen. A neighbouring coronal section was placed in RNAlater. The upper 
pole was divided longitudinally with one half placed in PLP fixative. The 
lower pole was divided into 4 quarters, one of which was placed in OCT 
embedding matrix on a cork disc and snap frozen, and the other three 
quarters snap frozen in a cryovial. 
 
Paraffin-embedded kidney tissue was cut at 4 μm thickness on a rotary 
microtome and stained with haematoxylin and eosin (H+E), periodic acid 
Schiff (PAS) or picrosirius red (sectioning and staining performed by Mrs L 
Lawrence, Department of Leukocyte Biology, Imperial College London). 
 
 
2.7.2.i Preparation of PLP fixative 
 
PLP fixative contains paraformaldehyde 1%, lysine 0.075M, sodium 
periodate 0.01M and phosphate buffer 0.037M. This fixative provides 
enhanced morphological preservation in comparison to frozen tissue, but 
facilitates use of some antibodies, in particular monoclonal preparations, 
which will not recognize their target epitope in formalin-fixed paraffin-
embedded tissue. 
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A lysine stock solution of 0.2M lysine monohydrochloride and 0.1M disodium 
hydrogen orthophosphate was prepared and pH adjusted to 7.4 with 
concentrated HCl. 4% paraformaldehyde in distilled water was prepared by 
prolonged stirring at 60oC, with the addition of a few drops of 1M NaOH to 
clear the solution. On the morning of use, lysine and paraformaldehyde stock 
solutions were mixed in a ratio of 3 vols : 1 vol and sodium metaperiodate 
0.214g/100mls was added. The solution was aliquoted and placed on ice, 
ready for tissue specimens to be placed in during retrieval. 
 
Tissues were fixed in PLP for 4 hours at 4oC and then transferred to 7% 
sucrose in PBS overnight to dehydrate. The following morning, the tissue was 
removed from sucrose and placed in OCT embedding matrix on a cork disc 
and frozen by immersion in isopentane cooled in liquid nitrogen before 
storage at -80oC. 
 
 
2.8 Serum and urine biochemical analysis 
 
2.8.1 Measurement of urinary albumin excretion 
 
Concentration of urinary albumin was measured in both rats and mice using 
a specific indirect 'sandwich' ELISA (Bethyl Laboratories, Montgomery, TX). 
(See Section 2.14 for detailed description of sandwich ELISAs and Table 2.5 
for materials used in this protocol). All steps were performed at room 
temperature. 
 
Urine specimens were thawed and allowed to equilibrate at room 
temperature. Samples were then mixed, centrifuged at 10,600 x g for 5 
minutes and supernatant decanted to clean tubes. Typical dilutions required 
for measurement were 1:1000 for control samples and 1:100-1:1000 for STZ-
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treated animals, depending on the timepoint of disease. Rat or mouse 
reference serum was serially diluted in sample diluent to produce a reference 
series ranging from 1.95 - 125 ng/ml in the rat and 7.8 - 500 ng/ml in the 
mouse, allowing a standard curve to be plotted (Figure 2.5A). 
 
Mouse urinary albumin concentration values (transformed from ODs using 
the standard curve and expressed in mg/l) were divided by paired urinary 
creatinine (see below; expressed in mmol/l) yielding the urine 
albumin:creatinine ratio (uACR; mg/mmol creatinine). This manoeuvre 
corrects albumin levels for urine concentration allowing inter-animal 
comparison. Calculation of timed albumin excretion rates was not possible 
with mice due to inaccuracies in ascertainment of urine collection volume 
due to urine frequently bypassing the collection container. 
 
Rat urinary albumin concentration values were normalized to the collection 
volume to provide an albumin excretion rate (expressed as µg/hr). 
 
 
2.8.2 Measurement of urinary creatinine 
 
Urinary creatinine was measured in both rats and mice using the Jaffe 
reaction. This works on the principle that addition of an alkaline picrate 
solution to creatinine yields a bright orange-red complex. Intensity of the 
colour as measured by spectrophotometry at 490nm corresponds to the 
concentration of creatinine in the sample. 
 
Samples were diluted with distilled water prior to measurement. Control 
samples were diluted by a factor of 1:20 and samples from diabetic animals 
by 1:5. A solution of creatinine was serially diluted with distilled water to 
produce a reference series with concentration ranging from 0.03125 - 2  
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mmol/l. Standard or sample (50µl) were added to each well of a 96 well 
plate. Each sample was measured in duplicate.  
 
An alkaline picrate solution was prepared by adding 2.5ml of 1N sodium 
hydroxide to 12.5mls of picric acid, and 100µl of this solution added to each 
well. The plate was then incubated for 30 minutes at room temperature. The 
optical density (OD) of each well was determined using a plate reader 
(ELx800; BioTek, Potton, UK) at a wavelength of 490nm and ODs averaged 
for the two replicates. ODs were corrected for background absorbance by 
subtraction of the measured OD for a ‘blank’ sample (distilled water alone). A 
standard curve was created by plotting the log of the concentration of the 
standards against the log of the ODs (Figure 2.5B). Using this standard curve, 
ODs for sample wells could be transformed to creatinine concentration 
values. Results were then multiplied by sample dilution to achieve a final 
value. 
 
 
2.8.3 Measurement of serum creatinine 
 
Whole blood samples from animals were centrifuged at 240 x g for 5 minutes. 
The serum (supernatant after centrifugation) was collected and used for 
analysis. Creatinine was measured by the modified Jaffe reaction in an 
Olympus AU600 analyser (Olympus, Watford, UK) by the clinical 
biochemistry laboratory at the Hammersmith Hospital (London, UK) 
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2.9 Morphometric analysis of rodent kidney tissue 
 
2.9.1 Measurement of glomerular size 
 
Glomerular size was measured on PAS-stained sections. Working 
systematically from one corner of the tissue section, the first 30 glomeruli 
encountered were digitized using a scientific grade digital colour camera 
(Olympus, Tokyo, Japan) at x400 magnification. Subsequent image analysis 
was conducted using ImagePro software (Media Cybernetics, Bethesda, USA). 
 
Measurements were calibrated by photographing and measuring an etched 
graticule of known diameter. The ‘polygon’ tool was then used to carefully 
outline and isolate each glomerular tuft and the surface area calculated. The 
mean value of 30 glomerular areas for each animal was calculated. 
 
 
2.10 Quantification of tissue fibrosis 
 
Tissue fibrosis in rodent kidney tissue was assessed on picrosirius red-
stained sections, viewed under polarized light. Picrosirius red staining is 
highly specific for detection of fibrillar collagen when viewed under polarized 
light; type 1 collagen fibrils display a yellow-orange birefringence while type 
3 collagen fibrils show green birefringence.(Junqueira et al., 1979) 
 
For each section, 5 randomly selected cortical fields viewed under polarized 
light were photographed and digitized at x200 magnification. Blood vessels 
larger than neighboring tubules were systematically excluded from selected 
fields to prevent skewing of results due to collagen component of vessel 
walls. Using ImagePro, images were converted to grayscale, rendering 
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birefringent collagen fibrils light grey or white. The ‘measurement’ tool was 
used to highlight all picro-sirius red stained areas, pixel by pixel. The 
highlighted area could then be measured and expressed as a fraction of the 
area of the section: 
 
 Area of picrosirius red staining 
  
         Total area of section 
 
The mean value for 5 cortical fields of view was calculated for each animal. 
 
 
2.11 Immunohistochemistry in rodent and human tissue 
 
2.11.1 General principles 
 
Immunohistochemistry (IHC) is the process by which discrete protein 
epitopes in a tissue specimen are labelled using a specific antibody, and 
visualized using a secondary detection system with consequent colour 
reaction. IHC provides information on the location of protein expression in a 
tissue (eg glomerular vs tubular in kidney tissue) as well as the degree of 
expression. 
 
IHC can be performed on tissue fixed in a variety of ways; different fixation 
methods may modify protein structure and alter antibody binding, meaning 
the optimal fixation protocol must be established for each antibody used. 
Formalin-fixed, paraffin-embedded tissue is frequently used for IHC as tissue 
architecture is preserved well with this fixation method. Formaldehyde 
preserves tissues by cross-linking amino groups in proteins with other 
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nearby nitrogen atoms in protein or DNA producing methylene bridges and 
other types of bridging links (Fox et al., 1985). These cross-links must usually 
be broken either by thermal or enzymatic means (‘epitope retrieval’) before 
primary antibody may be applied (Shi et al., 1991). 
 
‘Frozen sections’ are not treated with fixative at the time of collection, 
preserving native protein structure and circumventing the need for epitope 
retrieval. Freshly harvested tissue is immersed in liquid-nitrogen cooled 
isopentane and then ‘snap-frozen’ in liquid nitrogen before storage at -80oC. 
Once thawed and sectioned, the tissue is fixed for 5 - 10 minutes in a 
‘precipitating’ (or ‘denaturing’) fixative (such as cooled 50:50 
acetone:methanol) and left to air dry prior to staining. Precipitating fixatives 
act to dehydrate and reduce the solubility of protein molecules, as opposed to 
cross-linking proteins, and hence native epitopes are retained. Precipitating 
fixatives do not, however, preserve three-dimensional tissue structure and 
limit appreciation of native architecture. 
 
Other fixative techniques have been developed in an effort to combine the 
benefits of formalin fixation (preservation of architecture) and frozen 
sectioning (preservation of epitope conformation). One example is periodate-
lysine-paraformaldehyde (PLP) fixation (see section 2.6.2.a for method). 
Tissue is immersed in PLP fixative at the time of collection and snap-frozen 
and sections cut with a cryostat before air-drying. This technique extends the 
spectrum of antibody-epitope binding over formalin fixation (including some 
monoclonal antibodies) and tissue architecture preservation is superior to 
standard frozen sections. 
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2.11.2 Tissue sectioning and mounting 
 
Paraffin wax embedding and sectioning of formalin-fixed animal tissues was 
performed by Mrs Lorraine Lawrence (Department of Leukocyte Biology, 
Imperial College London). Sections were cut on a rotary microtome to a 
thickness of 4µm. 
 
Frozen and PLP-fixed animal tissue were sectioned using a cryostat. Sections 
(5µm thickness) were cut and collected onto poly-L-lysine coated slides. All 
sections were allowed to air-dry overnight before use. The following 
morning. frozen sections were immersed in 4oC 50:50 acetone:methanol 
fixative for 10 minutes. PLP sections did not require this step. 
 
Human renal biopsy specimens were paraffin sections retrieved from the 
histology archive at Hammersmith Hospital (approval was granted by the 
local research ethics committee). 
 
 
2.11.3 Pretreatment of paraffin sections 
 
Paraffin-embedded sections require removal of wax prior to performing IHC. 
Sections were placed in two sequential baths of xylene, before passage 
through graded ethanol concentrations and finally water. The latter steps 
serve to remove xylene and rehydrate the tissue. 
 
Dewaxed sections subsequently underwent heat-induced epitope retrieval 
(HIER). Sections were placed in boiling 0.01M sodium citrate buffer (pH 6.0) 
and transferred to a 95oC water bath for 20 minutes. Sections were then 
cooled under running water for 5 minutes before placing in PBS. 
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2.11.4 Blocking endogenous peroxidase activity and non-specific binding 
sites 
 
All sections underwent steps to reduce false positive colour reactions either 
due to endogenous peroxidase activity or non-specific (epitope-independent) 
binding of antibody. A wax pen (Dako, Glostrup, Denmark) was used to 
encircle tissue sections on the slide to minimize ‘run-off’ when solutions were 
applied. The sections were covered with 0.3% hydrogen peroxide for 10 
minutes before tapping off and washing three times in PBS. Depending on the 
primary antibody being employed a solution of either 10% dry powdered 
milk (Marvel; Premier Foods, St Albans, UK) or 20% normal goat serum 
(Dako) was applied for 30 minutes (See Table 2.2). 
 
 
2.11.5 Primary antibody and controls 
 
Primary antibodies were reconstituted and diluted as per the manufacturer’s 
instructions. Blocking solution was tapped off the slide and a tissue used to 
carefully blot residual solution. Antibody at the appropriate dilution was then 
applied in sufficient volume to cover the section (typically 100-200µl) (Table 
2.2). Slides were placed in a covered, humidified staining chamber to 
minimize evaporation and left to incubate for the appropriate duration. 
 
For exploratory P2X7 IHC, negative controls comprised omission of primary 
antibody, addition of polyclonal normal rabbit immunoglobulin at an 
equivalent concentration to the primary antibody, and use of primary 
antibody pre-incubated with the cognate immunizing peptide at a 1:1 ratio. 
Omission of primary antibody was used for established IHC protocols (eg. 
CD68, insulin). 
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2.11.6 Detection 
 
A commercial secondary antibody detection system (EnVision, Dako) was 
used.  The EnVision reagent consists of a peroxidase-conjugated polymer 
backbone which carries secondary antibody molecules raised in goat and 
directed against rabbit or mouse immunoglobulins. When applied to primary 
antibody-treated tissue, this complex will bind immunoglobulin adherent to 
the target epitope, permitting subsequent visualisation. The combination of 
several peroxidase molecules and several secondary antibody molecules on 
the same polymer increases detection sensitivity. 
 
Primary antibody was tapped off and slides washed 3 times for 5 minutes in 
PBS. Sufficient EnVision reagent was then added to completely cover the 
tissue section and the slide placed in the humidified incubation chamber for 
30 minutes. The reagent was then tapped off and a further 3 PBS washes 
performed. A 3,3’-diaminobenzidine (DAB) chromagen solution was 
prepared by mixing DAB+ chromagen with DAB+ substrate buffer in a ratio of 
1:50. This was applied to tissue sections for 3-5 minutes depending on the 
primary antibody; oxidation of DAB by peroxidase / H2O2 yields a dark 
brown pigment signifying positive staining. The appropriate duration of DAB 
exposure was determined by comparison of staining intensity in positive and 
negative control sections. Reaction was terminated by placing slides in PBS. 
 
Slides were then rinsed in water and counterstained by immersion for 30 
seconds in 0.1% Harris haematoxylin (a nuclear stain). After rinsing, excess 
stain was removed by brief (<1 second) immersion in acid-alcohol solution 
(0.1% HCl in 70% EtOH). Sections were then dehydrated by sequential 
passage through ascending alcohol concentrations to xylene. Slides were then 
mounted with DPX (Distrene, Plasticiser, Xylene; VWR, Lutterworth, UK) and 
glass coverslips and allowed to dry before examination. 
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2.12 Quantification of immunostained tissue 
 
2.12.1 Renal macrophages (CD68 staining) 
 
Glomerular macrophage number was counted for 20 glomeruli in each 
section and the mean value obtained. The same starting point was used in 
each section and the first 20 randomly encountered glomeruli were included. 
 
Interstitial macrophage number was counted for 5 randomly selected fields 
of view (x200 magnification) and the mean value obtained. 
 
 
2.12.2 Islet macrophages (Mac-2 staining) 
 
Macrophage infiltration in pancreatic islets was assessed using ImagePro. 
Islets were digitized at x400 magnification. Using ImagePro the image was 
scaled so that the entire islet could be seen on the screen. The ‘polygon’ tool 
was then used to carefully outline and isolate each islet allowing 
measurement of islet area. The isolated islet was then resized to 150-200% 
to allow precision when setting the colour threshold. 
 
The ‘measurement’ tool was then used to carefully highlight all Mac-2-stained 
areas of the islet, pixel by pixel. This overlay was then saved as a ‘template’ to 
apply to subsequent islets. The highlighted, Mac-2-stained area was then 
measured and the fractional stained area calcuated. All islets present in the 
section (9.85 ± 4.44) were scored and the mean value taken. 
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2.12.3 Islet insulin 
 
For each animal, islet insulin staining was assessed semi-quantitatively using 
the following scoring system: 
 
 1 = <50% surface area stained 
 2 = 50-70% 
 3 = 70-90% 
 4 = >90% 
 
Very few islets had insulin staining reduced significantly below 50% hence 
the scoring system was adjusted to maximize sensitivity within the observed 
range. All islets within the section were scored and the mean value obtained. 
 
 
2.12.4 Glomerular type 4 collagen 
 
Type 4 collagen was assessed using ImagePro. Glomeruli were outlined and 
area measured and type 4 collagen calculated as percentage stained area per 
glomerular area (Figure 2.6). Fifteen glomeruli in each section were scored 
and the mean value taken (AMDCC protocols suggest averaging fifteen 
glomeruli when assessing mesangial expansion). 
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2.13 Quantitative PCR 
 
2.13.1 General principles 
 
The core principle of PCR is the specific detection and amplification of a 
chosen gene sequence. This is achieved through use of specific 
oligonucleotide primer pairs which can anneal to the region of interest when 
DNA is denatured, and DNA polymerase which synthesises new nucleotide 
chains based on these specificities. Repeating multiple cycles of DNA 
denaturing, primer annealing and new nucleotide synthesis permits 
exponential amplification of the region of interest. In classical ‘end point’ PCR 
techniques, the final product is typically visualized by electrophoresis on an 
agarose gel; as well as confirming presence or absence of the target gene, this 
allows confirmation of identity based on expected product length (compared 
to a standard nucleotide ‘ladder’)  and assessment of specificity (absence of 
other, unanticipated, bands of different molecular weight). 
 
End-point PCR is not suitable, however, for measurement of the relative 
abundance of a gene of interest in an experimental sample. Although the 
concentration of PCR product correlates well with the concentration of 
genetic starting material during the exponential phase of the PCR reaction, 
the final end-point product concentration does not. This is in part explained 
by the loss of efficiency which occurs towards the end of the PCR reaction 
due to reduced primer and free nucleotide concentrations, reduced primer 
annealing probability (as DNA strands are in excess by the latter stages, 
favouring strand reannealing) and reduced DNA polymerase activity. 
 
Quantitative or ‘real time’ PCR (qPCR) has sought to overcome the limitations 
of the end-point method to allow accurate quantitation of gene expression in 
experimental samples. By using a fluorescent intercalating nucleic acid stain, 
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a PCR machine incorporating a sensitive fluorimeter can measure the 
increase in fluorescence intensity on a cycle-by-cycle basis. By selecting a 
threshold fluorescence intensity in the exponential amplification phase, the 
abundance of a gene of interest can be compared between experimental 
samples. Accurate comparison requires normalization of abundance to that 
of one or a number of ‘housekeeping’ genes, the expression of which is not 
regulated by the experimental conditions. 
 
To attain good quality qPCR data requires careful attention to detail and 
quality control. RNA, once extracted, should be assayed both for purity (by 
spectrophotometry) and also integrity, as comparison of samples with 
different degrees of degradation will yield unreliable results. Conversion of 
RNA to cDNA should be efficient and ideally the PCR reaction should be 
performed on a rotary machine, to avoid the uneven heating and cooling in a 
plate based system. The highest accuracy is attained by measuring gene 
abundance relative to a standard series and normalizing expression to a 
panel of housekeeping genes which have been assayed for their stability 
under the prevailing experimental conditions (Vandesompele et al., 2002). 
 
 
2.13.2 RNA extraction from whole kidney tissue 
 
RNA was extracted from animal kidney tissue using the RNEasy Mini Kit 
(Qiagen). This kit employs columns containing selective RNA-binding silica 
membranes which enable RNA purification from tissue lysates. Rat or mouse 
kidney was stored at -20oC in RNAlater RNA preservation solution after 
harvest. Samples were thawed and a 3mm3 piece of tissue dissected and 
placed into a microtube containing proprietary buffer RLT, a highly 
denaturing guanidine-thiocyanate-containing buffer supplemented with 2-
mercaptoethanol. Microtubes were then placed in a TissueLyser bead mill 
102 
 
(Qiagen) and homogenized at 50Hz using 5mm steel beads for four 2-minute 
blocks. 
 
Samples were then centrifuged at 10,600 x g  for 3 minutes before removing 
the clear supernatant (lysate) and mixing with 1 volume of 70% ethanol to 
provide appropriate binding conditions for the RNA. This mixture was then 
transferred to an RNeasy spin column and centrifuged for 15 seconds at 
>8000 x g to enable RNA binding to the silica membrane. Successive 
centrifugation wash steps were then performed using proprietary buffers 
RW1 and RPE. A final centrifugation was performed (2 minutes at >8000 x g) 
to dry the membrane and ensure no carryover of ethanol during RNA elution. 
RNA was then eluted from the column by adding 50µl nuclease-free water 
directly to the membrane and centrifuging for 1 minute at >8000 x g. Samples 
were aliquoted for subsequent concentration and integrity testing and stored 
at -80oC. 
 
2.13.3 Measurement of RNA concentration and integrity 
 
Once extracted, total RNA concentration and purity was measured using a 
microspectrophotomer (Nanodrop; Thermo Fisher Scientific). Absorbance at 
260nm (A260) correlates directly with RNA concentration in the sample and 
can be used to quantitate this. The ratio of readings at 260 and 280 nm (A260 
/ A280 ratio) provides a measure of RNA purity, with a ratio of 1.9-2.1 
suggesting pure RNA. Lower values typically reflect protein contamination 
which absorbs in the UV spectrum. A260 / A280 ratios >1.8 were deemed 
acceptable for further analysis. 
 
RNA integrity was assayed using a bioanalyzer (2100 Bioanalyzer; Agilent 
Technologies, Wokingham, UK). This uses chip-based technology 
incorporating a series of microchannels through which nucleic acid 
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fragments are separated based on size as they are driven through it 
electrophoretically. (Figure 2.7) As the various RNA species elute they pass a 
fluorescence detector which provides a read out of the peaks and troughs of 
fluorescence intensity, corresponding to the abundance of different sized 
fragments in the sample. By comparing the abundance of 18S and 28S 
ribosomal RNAs, an RNA integrity number (RIN) is generated. 
 
The RNA gel matrix was was filtered and mixed with dye concentrate to 
produce a working gel-dye mix. This was then injected into the RNA chip to 
prime it ready for sample measurement. RNA marker was pipetted into all 
wells, followed by 1 µl of either ladder or sample RNA. The chip was then 
vortexed for 1 minute at 2400 rpm using a customised chip vortex (Agilent) 
before running immediately on the bioanalyser. RIN values of >7 were 
deemed acceptable for further analysis.  
 
2.13.4 Synthesis of cDNA 
 
Although measurement of gene expression using qPCR assesses the 
abundance of transcribed mRNA, RNA templates must first be converted into 
cDNA. This process requires a viral reverse transcriptase enzyme derived 
from viruses with an RNA genome (retroviruses) such as Avian 
myeloblastosis virus (AMV) or Moloney murine leukaemia virus (MMLV) 
which have an RNA-dependent DNA polymerase activity. Priming for this 
reaction can either be gene specific or using random oligonucleotides which 
bind to RNA throughout its length and give an unbiased, full representation 
of the RNAs expressed. 
 
The Superscript VILO system (Invitrogen, Paisley, UK) was used. A 20µl 
reaction mixture was assembled comprising 4µl of 5x VILO reaction mix 
(containing random primers, MgCl2 and dNTPs in a buffer formulation  
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optimized for qPCR), 2µl of 10x SuperScript enzyme mix  and 1µg of purified 
RNA,  with the remaining volume nuclease-free water.  Samples were then 
incubated at room temperature for 10 minutes (primer annealing), 42oC for 
60 minutes (cDNA synthesis), 85oC for 5 minutes (heat inactivation) before 
cooling to 4oC. Samples were then diluted 10 fold using a solution of yeast 
tRNA (10 µg/ml) before aliquoting and storing at -20OC. tRNA acts as a 
carrier to minimize adsorption of cDNA onto surfaces and cannot be 
amplified by PCR. 
 
 
2.13.5 Preparation of cDNA standards 
 
Although gene expression can be measured and expressed solely as an 
amount relative to the expression of one or more housekeeping genes, 
greater precision is obtained by measuring absolute copy number for each 
gene studied. To do this requires comparison between each unknown sample 
and a standard curve generated from samples containing known 
concentrations of cDNA. Six-point standard curves were generated with 
serial 10-fold dilutions from 107 to 102 molecules (Figure 2.8A and B). 
 
To make standards for each gene, a quantitative PCR assay was performed 
using one sample measured in 6 replicates. Melt curves were inspected to 
assess specificity of priming and formation of primer-dimers; primer pairs 
were rejected if multiple peaks were apparent. (Figure 2.8C) Products were 
then pooled and added to blue 5x pre-mixed gel loading buffer before 
electrophoresing on a 2% agarose gel run at 80V for 30 minutes. Gels were 
inspected under UV light to confirm the presence of a solitary product band 
of the expected size as a further check of primer specificity. 
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cDNA was purified using the Geneclean spin kit (MPBiomedicals, Solon, USA). 
Gel bands were excised under UV light and melted at 55oC in an aqueous 
suspension of silica matrix ('Spin Glassmilk'). DNA binds to silica in the 
presence of high concentrations of chaotropic salt, presumed to be due to 
chaotropic disruption of water structure around negatively-charged silica 
allowing cation bridge formation between the silica matrix and the 
phosphate backbone of DNA. Samples were then centrifuged inside a spin 
filter at 14000 x g to promote binding of silica-DNA to the membrane. After 
two centrifugation wash steps using a buffer containing 100mM NaCl and 
50% EtOH ('Geneclean Spin wash solution'), DNA was eluted by lowering the 
salt concentration and rehydrating the silica matrix, breaking the attraction 
between matrix and DNA. 
 
The concentration of purified DNA was measured using a Nanodrop 
microspectrophotomer. The number of DNA copies in 1 µl of solution could 
then be calculated using the following series of equations: 
 
 Mean molecular weight of amplicon  =  660 x amplicon length (bp) 
 
 Where 660 is the mean MW of 1bp 
 
 Number of copies of amplicon in 1ng  =    6.02 x 1023 (Avogadro’s 
       constant)      x109 
                         ____________________________________ 
              Molecular weight of amplicon  
 
 Number of copies in 1 µl      =      cDNA/uL    x   copies of amplicon/ng 
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cDNA was then sequentially diluted to a stock solution of 108 copies/2 µl 
(sample volume used in qPCR reactions) and a six-point standard curve 
prepared by serial 10-fold dilutions using tRNA 10µg/ml as diluent 
 
 
2.13.6 Quantitative PCR reaction 
 
Quantitative PCR was performed using the Sybr green fluorophore as a DNA 
intercalating agent. Sybr green dye binds double-stranded DNA non-
selectively and, once bound, emits green light after excitation. Fluorescence 
levels hence increase as DNA product accumulates during the PCR reaction 
and can be monitored in real-time. By specifying a threshold detection level 
of fluorescence during the linear phase of amplification, absolute abundance 
of starting template can be assessed by comparison with reference samples 
used to create a standard curve. 
 
10 µl reactions were prepared by adding 2 µl of cDNA to 5 µl of 2x Sensimix 
Sybr Green mastermix (containing heat-activated DNA polymerase, dNTPs, 
6mM MgCl2 and Sybr Green I dye; Bioline, London, UK), 2µl nuclease-free 
water and 0.5µl each of forward and reverse oligonucleotide primers, specific 
for the gene of interest (0.5µM concentration). Specific primers for each gene 
of interest are listed in Tables 2.3 and 2.4. PCR was performed using a 
Rotorgene 6000 cycler (Qiagen), a rotary qPCR system, using the following 
template PCR program: 
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95oC for 10 mins (activation of DNA polymerase) 
 40 cycles of: 
- 95oC for 10s (denaturation) 
- 60oC for 15s (annealing) 
- 72oC for 20s (extension) 
 Melt curve, rising from 72 to 95 oC by 1oC every 5s 
 
Adequacy of the qPCR run was confirmed by inspecting standard curve 
linearity (accepting r2 >0.99), reaction efficiency (ideally 0.9 – 1.1) and melt 
curve morphology (single peaks). RT negative samples and ‘no template’ 
samples (ie. tRNA diluent alone) were run as controls. Copy number was 
obtained by comparing the cycle number (CT) at which a sample reached 
threshold fluorescence to the standard curve. Samples were run in duplicate 
and the mean copy number for each replicate pair calculated. 
 
 
2.13.7 Calculation of final copy number in genes of interest 
 
Copy number of any gene of interest measured in a sample requires 
correction for the abundance of a housekeeping gene which is not 
significantly regulated by the experimental conditions employed. Increased 
accuracy can be achieved by using more than one housekeeping gene for this 
normalization process. 
 
Four housekeeping genes were measured in both rat (HPRT, SDHA, RPL13a 
and YWHAZ) and mouse (28S ribosomal RNA, βactin, HPRT and YWHAZ). 
Genorm software was used to measure the stability of each housekeeping 
gene under experimental conditions by determining the pairwise variation 
with all other control genes as the standard deviation of the logarithmically-
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transformed expression ratios (Vandesompele et al., 2002). This process 
results in an ‘M value’ which expresses the average pairwise variation of a 
particular gene with all other control genes. This analysis works on the 
principle that expression level of two ideal internal control genes should be 
identical in all samples regardless of the experimental conditions imposed. 
Lower M values reflect increased stability and an arbitrary cut-off of 1.5 is 
frequently used to decide if a control gene displays adequate stability to be 
used for reference purposes. 
 
Having selected stable control genes, the relative expression of each gene of 
interest compared to all stable housekeeping genes was calculated and the 
geometric mean computed. From this a ‘normalisation factor’ was 
determined for each individual sample, allowing the most accurate correction 
for control gene abundance and a final copy number was obtained by 
applying this factor to the raw copy number data. 
 
 
2.14 ELISAs for cytokine analysis 
 
2.14.1 General principles 
 
Concentrations of cytokines (eg. MCP-1) in cell culture supernatants and 
urine were measured by specific capture or ‘sandwich’ ELISAs. The ELISA 
microplate technique was first described in 1971 by Engvall and Perlmann 
(Engvall and Perlmann, 1971). The general principle of all ELISAs is to detect 
and quantify a protein of interest by using a specific antibody coupled 
directly or indirectly to a signal-generating enzyme or fluorophore. In a 
standard ‘indirect’ ELISA, samples are incubated in a 96-well microplate 
allowing proteins to be adsorbed on the wall of the plate. A specific primary 
antibody is then applied, followed by a secondary enzyme-linked antibody. In 
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contrast, in a sandwich ELISA, the microplate is first coated with a target-
specific ‘capture’ antibody meaning only the protein of interest is 
immobilized on the wall of the wells. This protein is then ‘sandwiched’ 
between the capture antibody and an enzyme-linked secondary antibody to 
facilitate detection (Figure 2.9). Sandwich ELISAs are particularly useful 
when assaying complex protein solutions (eg. urine) as they isolate 
immobilisation of the protein of interest thereby increasing assay sensitivity 
and specificity. Addition of enzyme substrate yields a colour reaction 
proportional to the concentration of bound antigen, allowing quantification 
when compared to a ‘standard’ dilution series of the target cytokine. 
 
The steps below refer to the assay for human MCP-1 to exemplify the general 
principles of a sandwich ELISA. Specific details of the antibodies and 
solutions used for other assays can be found in Table 2.5. All steps were 
performed at room temperature. 
 
2.14.2 Coating 
 
An optically clear, high protein-binding capacity 96-well plate (Nunc 
‘Maxisorp’, Thermo Fisher Scientific) was coated with 100µl of an affinity-
purified mouse anti-human MCP-1 antibody (R+D Systems, Abingdon, UK) at 
a concentration of 2µg/ml diluted in PBS. The plate was covered with an 
adhesive strip (Appleton Woods, Birmingham, UK) and placed at 4oC 
overnight to allow adsorption of antibody to the walls of the microplate. The 
following morning the contents of the plate were expelled and wells were 
washed 3 times with 0.05% Tween 20 in PBS (wash buffer) before blotting 
on a tissue to remove excess fluid. 
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2.14.3 Blocking and addition of samples 
 
A blocking solution of 5% sucrose in PBS with 1% BSA was prepared and 
300µl added to each well. The BSA acts to block non-specific protein binding 
sites on the surface of the plate. 
 
While blocking, standard protein and cell culture supernatant samples for 
analysis were thawed, mixed and allowed to equilibrate at room 
temperature. A diluent solution of 0.1% BSA, 0.05% Tween 20 in PBS pH 7.3 
was freshly prepared. Recombinant human MCP-1 (R+D Systems) was used 
to create a reference concentration series. From a stock concentration of 10 
µg/ml, recombinant protein was diluted in diluent solution to form a 9-point 
standard series with concentration ranging from 9.76 - 2500 pg/ml. A ‘blank’ 
sample comprising diluent alone was also included. 
 
The plate was inverted to remove blocking solution, washed 3 times with 
washing buffer and excess solution blotted. Reference standard or sample 
(100µl) was then added to each well in a pre-determined plate layout and the 
plate incubated for 2 hours at room temperature on a plate shaker. Each 
sample was measured in duplicate to decrease variability. For human MCP-1 
measurement of cell culture supernatants no pre-dilution of samples was 
required. 
 
 
2.14.4 Secondary antibody and detection 
 
The plate was washed 3 times with washing buffer and excess solution 
removed. An affinity-purified biotinylated polyclonal goat anti-human MCP-1 
antibody (100μl; R+D systems) at a concentration of 100ng/ml diluted in 
diluent solution was added to each well. This antibody has been validated by 
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the company for use as a detection antibody in conjunction with its partner 
capture antibody. The plate was then incubated for 2 hours before washing 3 
times with washing buffer and blotting excess solution. 
 
A streptavidin-HRP conjugate (100µl), diluted in PBS as per the 
manufacturer's instructions (typically 1:200), was then added to each well. 
Streptavidin binds with high affinity to biotin, bringing the HRP enzyme into 
close proximity with the secondary antibody, facilitating a subsequent 
detection step. The plate was incubated for 20 minutes before washing 3 
times with wash buffer. 
 
A solution of 3,3’,5,5’-tetramethylbenzidine (TMB; Cambridge Bioscience, 
Cambridge, UK) and hydrogen peroxide, was prepared and 100 µl added to 
each well. TMB is colourless in solution in basal conditions but forms a blue 
product when oxidized by HRP in the presence of hydrogen peroxide, the 
colour intensity of which is proportional to the degree of HRP activity and, in 
turn, the amount of bound secondary antibody. The plate was incubated in 
the dark for approximately 10 minutes before stopping the reaction by 
adding 50 µl of 2N sulphuric acid. This final step yields a yellow colour 
change, proportionally identical in intensity to its blue counterpart. 
 
 
2.14.5 Data capture and analysis 
 
The plate was transferred to an ELx800 spectrophotometric microplate 
reader (Biotek, Winooski, USA) and the absorbance measured at 450nm. 
Adjusted absorbances were calculated by subtracting the background 
absorbance of the ‘blank’ sample. 
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A best-fit standard curve was generated from the absorbances of the 
recombinant MCP-1 reference series using 4 variable non-parametric 
regression modeling (Figure 2.10). Concentrations of MCP-1 in samples could 
then be calculated from the raw blank-subtracted absorbances using the 
resultant regression equation. A co-efficient of variance of <10% between 
sample replicates was accepted. 
 
 
2.15 Western blotting 
 
2.15.1 General principles 
 
Western blotting provides a method by which specific proteins, and, to some 
degree, their relative abundance, can be detected in biological samples or 
solutions. Samples are homogenised using a cell or tissue lysis buffer and the 
total protein concentration measured. A known quantity of protein solution 
is then separated on a sodium lauryl sulphate (SDS) – polyacrylamide gel, 
typically in the presence of the denaturing agent 2-mercaptoethanol. The 
ladder of separated proteins is then transferred from the gel to a 
nitrocellulose membrane which can be probed with a primary antibody 
specific to the protein of interest. An enzyme-linked secondary antibody is 
then applied, followed by a substrate solution, the chemiluminescent reaction 
of which can be visualised using standard photographic methodology. The 
identity of the labeled bands can be confirmed by comparing the position 
with protein of a known molecular weight run in parallel. 
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2.15.2 Protein extraction 
 
All steps during harvest of proteins from cell culture monolayers were 
performed on ice. Cells were washed twice with ice-cold PBS before adding 
100µl of a proprietary cell lysis buffer (Invitrogen; Constituents: 10mM Tris 
pH 7.4, 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM NaF, 20mM Na4P2O7, 
2mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate) 
supplemented with 1mM phenylmethanesulfonylfluoride (PMSF; a serine 
protease inhibitor) and protease inhibitor cocktail (P2714, Sigma). 
Monolayers were agitated for 2-3 minutes before scraping and collecting the 
lysate into microcentrifuge tubes. 
 
Tubes were rested on ice for 30 minutes, vortexing at 10 minute intervals, to 
ensure complete lysis of cell membranes and solubilisation of proteins. The 
extract was then centrifuged at 18,000 x g for 10 minutes at 4oC to pellet 
insoluble cellular debris. Supernatant was transferred to a fresh 
microcentrifuge tube and stored at -80oC. A 6 µl aliquot of each sample was 
removed before freezing for quantification of total protein concentration. 
 
 
2.15.3 Quantification of total protein concentration 
 
Total protein concentration of lysates were quantified using the Pierce 
bicinchonic acid (BCA) assay. The cornerstone of this assay is the Biuret 
reaction, whereby protein in an alkaline medium reduces Cu2+ to Cu1+ and 
forms a coloured chelate complex. In the subsequent colour development 
reaction, biocinchonic acid reacts with the Cu1+ cation in a ratio of 2:1 to form 
an intense purple-coloured soluble reaction product. Spectophotometric 
absorbance at 562nm is linearly proportional to the total protein 
concentration within the solution. 
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BCA assay reagent A (biocinchonic acid and tartrate in an alkaline carbonate 
buffer) was mixed in a 50:1 ratio with reagent B (4% copper sulphate 
pentahydrate solution). A reference protein series (BSA) was prepared by 
diluting from a concentration of 1400 µg/ml down to 0.1 µg/ml in distilled 
water; lysis buffer was added to each reference solution in order to constitute 
20% by volume. A ‘blank’ sample consisted of 20% lysis buffer in distilled 
water alone. Sample aliquots were thawed and diluted 1 in 5 in distilled 
water. Ten µl of sample or standard was then added to each well of a 96-well 
microplate followed by 200 µl of assay mixture. The plate was incubated for 
30 minutes at 37oC before cooling to room temperature and measuring the 
absorbance at 562nm on a plate reader. 
 
A standard curve was created by linear regression of blank-subtracted 
absorbances for the reference protein series (Figure 2.11). Total protein 
concentrations of the samples could then be calculated using the consequent 
regression equation, and multiplying by the dilution factor (ie. x 5). 
 
 
2.15.4 SDS-Polyacrylamide gels 
 
Ten millilitres of 10% resolving gel was prepared by mixing the following 
constituents: 4 mls distilled water, 3.4 mls 30% acrylamide/methylene 
bisacrylamide solution (Protogel; National Diagnostics, Charlotte, USA), 2.5 
mls 1.5M Tris-HCl (pH 8.8), 0.1 mls 10% SDS. Immediately before pouring, 
0.1 mls of 10% ammonium persulfate (APS) and 4 µl 1% N,N,N’,N’ 
tertramethylethylenediamine (TEMED) were added to induce gel 
polymerization; APS decomposes to sulphate free-radicals, a process 
accelerated in the presence of TEMED, and these free radicals initiate gel 
polymerization. Ten % polyacrylamide gels are versatile and can resolve 
proteins in the range of 20-200 kDa; higher percentage gels have a smaller  
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pore size and are hence better suited to resolving lower molecular weight 
proteins. 
 
Gels were prepared and electrophoresis performed using the Mini-Protean II 
system (Biorad, Berkeley, USA). Two clean glass plates were apposed in a 
casting block, separated by 1.5mm diameter spacers. The resolving gel was 
poured between the plates and left for 20 minutes to set. Immediately after 
pouring, the gel was covered by a shallow depth of water-saturated butan-2-
ol to exclude air and level the surface. 
 
Five millilitres of 5% stacking gel were prepared by mixing the following 
components: 3.4 mls distilled water, 0.83 mls 30% acrylamide/methylene 
bisacrylamide solution, 0.63 mls 1.5M Tris-HCl (pH 6.8). Once polymerized, 
the stacking gel has a large pore size allowing proteins to concentrate rapidly 
at the stacking gel – resolving gel interface, allowing proteins to separate by 
size in the resolving gel. The butan-2-ol was poured off and the gel surface 
washed with distilled water before blotting dry. Immediately before pouring, 
50µl APS and 5µl 1% TEMED were added to the stacking gel to catalyse 
polymerization. A 1.5mm, 10 well comb was carefully inserted into the 
stacking gel before leaving to set for 1 hour. The comb was then removed, 
excess gel carefully cleaned away with a needle and the casting block placed 
into the gel electrophoresis tank submerged in running buffer diluted from a 
10x stock (50mM Tris pH 8.3, 500mM glycine, 0.2% SDS). 
 
 
2.15.5 Sample preparation and electrophoresis 
 
Samples were thawed and kept on ice. Samples containing 10-40 µg of 
protein were mixed with 7µl 5x sample buffer (constituents: 4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue and 0.125M 
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Tris HCl) and sufficient distilled water added to bring the sample buffer to its 
working dilution and maintain a constant volume across all samples (35µl). 
2-mercaptoethanol acts, in tandem with sample heating, as a potent reducing 
agent, breaking disulphide bonds and linearising proteins so that subsequent 
electophoretic separation is governed by molecular weight alone. 
 
Samples were then heated at 95oC for 10 minutes before cooling rapidly on 
ice and centrifuging briefly to ensure the full volume could be recovered. A 
marker protein ladder mixture (‘Full range rainbow marker’; GE healthcare, 
Amersham, UK) was reconstituted to the working dilution with distilled 
water and sample buffer. Negative controls consisted of sample buffer diluted 
with distilled water alone. 
 
Samples and ladder were loaded onto the gel taking care not to cross-
contaminate between lanes. The gel tank was connected to a power supply 
and the gel run at 80V for approximately 2.5 hours. 
 
 
2.15.6 Transfer to nitrocellulose membrane 
 
Adequate separation of proteins was confirmed by inspection of the coloured 
ladder markers before halting electrophoresis. The MiniProtean wet tank 
transfer system (Biorad) was used for transfer of proteins to nitrocellulose. 
The glass plates were removed from the casting block and immediately 
submerged in transfer buffer (48mM Tris, 39mM glycine, 0.037% SDS, 20% 
methanol). A sheet of nitrocellulose membrane with pore size 0.45μm 
(Hybond ECL; GE Healthcare) was cut to size and ‘activated’ by briefly 
submerging in methanol before soaking in transfer buffer. 4 sheets of filter 
paper, cut to the size of the gel, were also soaked in transfer buffer. The 
stacking gel was discarded and a ‘sandwich’ formed within the gel-holder 
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cassette comprising: 1 foam pad, 2 sheets of filter paper, nitrocellulose 
membrane, resolving gel, 2 sheets of filter paper, 1 foam pad. Any trapped air 
bubbles were removed by rolling with a plastic pipette. 
 
The cassette was then inserted into the transfer tank adjacent to a cooling 
unit, the tank filled with transfer buffer, and a charge of 100 Volts applied for 
~1 hour 10 minutes. The membrane was removed and transferred to wash 
buffer solution (0.1% Tween 20 in TBS; TBS/T). Adequate transfer of protein 
was confirmed by visual inspection of coloured ladder protein transfer and, if 
necessary, by reversible staining of protein with Ponceau S solution. 
 
 
2.15.7 Blocking and antibody application 
 
The membrane was transferred to a solution of 5% milk in TBS/T and placed 
on a rocker for 1 hour in order to block non-specific protein binding sites. 
The blocking solution was poured off and the membrane washed briefly with 
wash buffer before adding the relevant primary antibody diluted in 5% BSA 
in TBS/T and placing on a rocker for a variable period of time optimized for 
each antibody (see Table 2.6). The membrane was then washed 3 times for 5 
minutes each in wash buffer before incubating with a species-specific HRP-
linked secondary antibody diluted in 5% dry milk in TBS/T for 1 hour. The 
membrane was then washed 3 times for 5 minutes each in preparation for 
the detection step. 
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2.15.8 Chemiluminescence and signal detection 
 
The chemiluminescence reaction was used for detection of bound antibody. 
The enhanced chemiluminescence kit (ECL; GE Healthcare) used in this step 
consists of two reagents: hydrogen peroxide and luminol. These were mixed 
in a 1:1 ratio prior to use and applied directly to the membrane lying on a 
cellophane sheet. The membrane was incubated in ECL medium for 
approximately 1 minute before gently tapping off and wrapping the 
membrane in the cellophane sheet. The membrane was placed in a 
photographic cassette and transferred to the dark room where it was 
exposed against x-ray film (Hyperfilm ECL; GE Healthcare) and developed 
using an automatic film processor (SRX-101A; Konica Minolta, Tokyo, Japan). 
 
In the presence of an oxidising agent (produced by decomposition of 
hydrogen peroxide by HRP), luminol is converted to an excited state and 
chemiluminesces as this species decays. This chemiluminescence is 
proportional to the amount of HRP present, and consequently the abundance 
of target protein, and can be detected with great sensitivity using high 
performance x-ray film. After development of the exposed x-ray film, the 
target protein(s) can be seen as discrete bands and the identity confirmed by 
comparing the molecular weight with those of the marker ladder proteins. 
Relative abundance of protein between samples was assessed by visual 
comparison of band size and density and by densitometry using image 
analysis software (ImageJ, Bethesda, USA). 
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2.16 In vitro studies of human glomerular cells 
 
2.16.1 Background 
 
Transformed human mesangial cells (tHMCs) were kindly provided by Dr 
Xiong Ruan (UCL, UK) and their generation has been described previously 
(Sraer et al., 1996); in brief this line was created by taking human mesangial 
cells cultured from normal human kidney unsuitable for transplantation and 
immortalising them by transfection with the viral oncogene large T-SV40 and 
H-ras. The cells maintain many of the phenotypic characteristics of primary 
HMC including cytoplasmic projections, stellate shape and microvilli and 
express α-smooth muscle actin (αSMA), a protein present in HMC but absent 
in glomerular epithelial and endothelial cells. 
 
Primary human mesangial cells (pHMCs) were purchased from Lonza (Lonza 
Biologics, Slough, UK).  
 
A conditionally-immortalized human podocyte line was kindly provided by 
Prof Moin Saleem (University of Bristol, UK), and generation of their line has 
been described in detail (Saleem et al., 2002). The line was created by 
isolating podocytes from a nephrectomy specimen from a 3 year old child 
with reflux nephropathy and transfecting a temperature sensitive SV40-T 
gene. These cells proliferate at the ‘permissive’ temperature of 33oC but 
transfer to 37oC leads to growth arrest, differentiation and expression of 
mature podocyte markers including nephrin and podocin, together with 
morphological changes including development of fine processes and slit 
diaphragm-like structures rendering them a good model of mature human 
podocytes. 
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2.16.2 Maintenance of proliferating cultures 
 
2.16.2.i Transformed human mesangial cells 
 
tHMCs were cultured in a medium composed of RPMI 1640 supplemented 
with 4mmol/l D-glucose, 1% penicillin-streptomycin and 5% foetal calf 
serum (FCS). Cells were maintained in a humidified incubator at 37oC with 
5% CO2. Medium was changed every 2-3 days and cells inspected daily using 
an inverted phase-contrast microscope. Cells were subcultured when 90-
100% confluent. 
 
 
2.16.2.ii Primary human mesangial cells 
 
pHMCs were cultured in a proprietary basal medium (Lonza) supplemented 
with 5% FCS and gentamicin / amphotericin-B. Cells were maintained in a 
humidified incubator at 37oC with 5% CO2. Medium was changed every 2-3 
days and cells inspected daily using an inverted phase-contrast microscope. 
Cells were subcultured when 90-100% confluent and cells used for 
experiments at passage 7-12. 
 
 
2.16.2.iii Transformed human podocytes 
 
Podocytes were cultured in a medium composed of RPMI 1640 
supplemented with 4mmol/l D-glucose, 1% penicillin-streptomycin and 5% 
FCS. Cells were maintained in an incubator at 33oC with 5% CO2. Medium was 
changed every 2-3 days and cells inspected daily using an inverted phase-
contrast microscope. Cells were subcultured when 90-100% confluent. 
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For experiments, cells were subcultured into plates with the appropriate 
number of wells at a seeding density of 0.5-2 x105 cells / ml. Plates were then 
transferred to a humidified incubator at 37oC with 5% CO2 to allow 
differentiation over a 14 day period, in growth medium as before. Cells were 
inspected daily to confirm their anticipated change in morphology and 
medium was changed every 2 days. 
 
 
2.16.3 Subculture of cells and cell counting 
 
For subculture of cells, medium was removed and cells washed with a small 
quantity of pre-warmed 0.05% trypsin-EDTA (Invitrogen). For 75cm2 (T75) 
flasks, 1-2 mls of trypsin-EDTA was then added to cover the monolayer and 
the flask incubated at 37oC for 3 minutes to allow cell detachment. The flask 
was then tapped firmly and cell detachment confirmed by microscopy. An 
excess of culture medium supplemented with 5% FCS was then added to the 
flask to inactivate the trypsin and a homogeneous cell suspension created by 
repeated pipetting against the base of the flask. The cell suspension was then 
divided into 3-5  T75 culture flasks and an appropriate volume of culture 
medium added. Cell adhesion was confirmed by microscopy after 24 hours. 
 
When sub-culturing to multi-welled cell culture plates for experiments, cells 
were counted after detachment to ensure seeding at a consistent density 
within and between experiments. To do this, a 50 µl aliquot of homogeneous 
cell suspension was removed from the trypsinised suspension, and mixed 
with an equal volume of trypan blue. Trypan blue dye is taken up through the 
cell membrane of dead cells, staining them blue, but is not taken up into 
living cells. Ten µl of this mixture was then place on each of two graticules of 
a haemocytometer and covered with a cover slip before transferring to the 
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stage of a microscope for counting. The haemocytometer is constructed such 
that the volume of fluid captured between slide and coverslip overlying one 
large graticule square is known precisely (in this case 0.1 mm3). By counting 
the number of cells overlying each large square (four per graticule over two 
graticules) and taking the mean, an estimate of the number of cells in solution 
was obtained. Cells stained with trypan blue were excluded from the count. 
The final cell concentration was obtained by correcting for dilution with 
trypan blue (multiplication factor of two). Cells were plated at a density of 
0.5-2 x105 / ml depending on the cell type and experiment. 
 
 
2.16.4 Freezing of cells for long-term storage and cell recovery 
 
Cells were detached from their substrate using trypsin-EDTA as described 
above, and culture media used to neutralize enzymatic activity. Cell mixture 
was then transferred to a 15ml plastic tube and centrifuged at 1000 x g for 
five minutes. Medium was carefully aspirated off and the cell pellet 
resuspended in 1 – 1.5 mls of proprietary cell culture cryopreservation media 
(Recovery media; Life Technologies; contains 10% DMSO) before 
transferring to a cryovial. The cryovial was placed at -80oC in a polystyrene 
container overnight before moving to liquid nitrogen for long term storage. 
 
When recovering cells, the cryovial was removed from liquid nitrogen and 
warmed in a 37oC water bath. When only a small ice pellet remained, the tube 
was transferred to the laminar flow hood. When fully thawed, the cell 
suspension was quickly pipetted into an appropriately sized flask containing 
pre-warmed culture medium, the contents mixed and transferred to a 
humidified incubator at the correct temperature for the cell-type in question. 
Culture media was changed after 24 hours in order to remove DMSO-
containing cryopreservation media. 
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2.16.5 Confirmatory phenotyping of podocytes  
 
Culture conditions used for podocytes during proliferation and 
differentiation differed from previous published protocols; cells were 
routinely cultured in a low glucose (4mM) basal medium without the 
addition of the insulin / transferrin / selenium (ITS) supplement. As such, the 
following tools were used to characterize the phenotype of the cells and 
confirm podocyte differentiation prior to use: assessment of cell morphology 
by phase-contrast microscopy; immunofluorescent cytostaining for nephrin 
and podocin expression; Western blot analysis of SV40 T-antigen expression. 
 
 
2.16.6 Treatment of cells 
 
The core cell culture model used to simulate the diabetic milieu was the same 
for all cell types (Figure 2.12). Experiments were performed after cells had 
been plated into multi-well plates and had reached >70% confluence. In the 
case of podocytes, cells had also undergone a 2 week period of differentiation 
at 37oC. 
 
Medium was removed and replaced in all cases with glucose-free RPMI 1640 
supplemented with 4mM D-glucose with no serum. Unstimulated serum-free 
conditions were maintained for 24 hours to induce cell cycle synchronization 
and quiescence prior to treatment. All subsequent media used for 
experiments were serum-free. 
 
Hyperglycaemic conditions were recreated by supplementing glucose-free 
RPMI 1640 with 30mM D-glucose, whereas ‘normoglycaemic’ media 
contained 4mM D-glucose. L-glucose, the metabolically inactive stereoisomer 
of D-glucose, was added to normoglycaemic media at a concentration of  
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26mM to act as an osmotic control for hyperglycaemic media. Cells were 
maintained in these conditions for 48 hours without a medium change, 
before collection of supernatants for cytokine analysis or cell monolayer 
lysates for protein extraction. 
 
The effects of a selective P2X7 antagonist, A438079 (Tocris Bioscience, 
Bristol, UK), a P2X7 agonist BzATP, a selective P2X4 antagonist, 5-BDBD 
(Tocris), a P2Y2 / P2Y4 agonist UTPγS (Tocris) and an ATP-hydrolyzing 
agent, apyrase, on MCP-1 production were tested both in the presence and 
absence of hyperglycaemia by supplementing normoglycaemic and 
hyperglycaemic media respectively with the appropriate reagent 
concentration. The effect of ATP on pHMC IL1β release was tested by 
growing cells for 48 hours in either normoglycaemic or hyperglycaemic 
conditions and then replacing the medium with identical fresh medium 
supplemented with 5mM ATP. Cells were stimulated for 30 minutes before 
collecting supernatants. 
 
 
2.16.7 Cell viability assay 
 
Viability of pHMCs cultured in the presence of small molecule receptor 
inhibitors was assessed using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) 
assay (CellTiter 96; Promega, Madison, USA). Viable and metabolically active 
cells reduce MTS to a coloured soluble formazan product, the absorbance of 
which at 490nm is directly proportional to the number of living cells present 
in the culture system. It can thus be employed to assess viability or 
proliferative responses to substances under test. 
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pHMCs were subcultured in a 96-well plate at a seeding density of 2 x 
104/well. Cells were allowed to proliferate to >70% confluence before 
replacing medium with serum-free medium for 24 hours. This was then 
replaced with normoglycaemic RPMI 1640 supplemented with the 
appropriate concentrations of inhibitor or drug vehicle and cultures 
incubated at 37oC for 48 hours. 
 
Medium was then removed and replaced with 100µl of MTS reagent and the 
plate returned to the 37oC incubator for 1-2 hours, checking regularly for 
appropriate maturation of the colour reaction. The spectrophotometric 
absorbances of each well at 490nm were then analysed using a plate reader, 
and cell viability assessed by comparing the relative absorption compared to 
cells grown in basal medium alone in the absence of inhibitor or drug vehicle. 
 
 
2.16.8 Immunofluroescent cytostaining 
 
Immunofluorescent labelling was used for the detection of P2X7 protein in 
pHMCs and nephrin and podocin in podocytes. The core principles of this 
technique are similar to those described for immunohistochemical analysis of 
tissue sections (Section 2.10): a specific primary antibody is applied to bind 
the protein of interest, before adding a species-specific anti-immunoglobulin 
secondary antibody, in this case coupled to a light-emitting fluorophore. 
Fluorescence microscopy can then be used to detect and visualise expression 
of the protein of interest. 
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2.16.8.i Culture of cells for immunofluorescence 
 
Standard tissue culture plastic autofluoresces between 360 and 620nm, the 
excitation range  for commonly used fluorescent dyes, and is hence not 
suitable for this application. Cells must therefore be grown on a glass surface 
to circumvent this. Glass coverslips were coated with poly-L-lysine to 
improve cell adherence, and sterilised by baking at 200OC for 3 hours in an 
oven. Coverlips were then placed into the bottom of wells of a plastic 24-well 
plate before subculturing cells to the plate as normal. Once cell adhesion had 
occurred, further cell culture, experimental treatments and initial 
immunofluorescence protocol steps were performed with the cell-coated 
coverslips remaining inside the culture plate. 
 
 
2.16.8.ii Cell fixation and permeabilisation 
 
After completing experimental incubations, medium was removed and cells 
washed twice with PBS. A solution of 4% paraformaldehyde (PFA) in PBS 
was then added to wells, the plate covered and left for 5 minutes in the fume 
cupboard. PFA acts as a fixative to preserve cellular morphology during 
subsequent steps. PFA was then aspirated from wells and the cells washed a 
further 3 times with PBS.  
 
To permit access of primary antibody to the intracellular compartment in 
addition to the exterior surface of the cell membrane, a permeabilisation step 
is required. To achieve this, 1ml 0.1% Triton x100 in PBS was added to cells 
and incubated for 10 minutes before washing twice with PBS. Triton is a 
detergent and has a non-selective disruptive effect on membrane lipid, 
producing holes through which antibody may pass. 
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2.16.8.iii Blocking and antibody application 
 
Non-specific binding sites were blocked by incubation with 5% BSA in 0.1% 
Triton in PBS for 1 hour at room temperature. This was aspirated and the 
primary antibody or control (polyclonal IgG or diluent alone) applied for a 
duration optimised for each antibody (Table 2.7). Cells were then washed 3 
times in PBS for 5 minutes each before incubating with a fluorochrome-
conjugated secondary antibody diluted in 5% BSA in 0.1% Triton in PBS for 1 
hour in the dark. 
 
2.16.8.iv Mounting and microscopy 
 
Cells were washed 3 times in PBS for 5 minutes each. One drop of mounting 
media with DAPI (a nuclear stain; Vector labs, Peterborough, UK) was placed 
on a microscope slide and the glass coverslip was carefully transferred on to 
it. Nail varnish was used to seal the edges of the coverslip ready for 
microscopy viewed through the appropriate narrow-band filter. 
 
2.17 Statistical analysis 
 
All values described in the text and figures are expressed as mean ± standard 
deviation. Statistical analysis was carried out by GraphPad Prism 6.02 
(GraphPad Software, San Diego, CA). Numerical data comparing two groups 
were analyzed by the Student’s t-test for parametric data and Mann-Whitney 
U test for non-parametric data. Categorical data comparing two groups were 
analysed with Fisher's exact test. 
 
Data comparing more than two groups were analysed by one-way ANOVA 
with post-tests corrected by the Bonferroni method for multiple  
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comparisons for parametric data, and Kruskal-Wallis with Dunn's post-test 
for non-parametric data. Outlying values, clearly inconsistent with a 
population's distribution, were confirmed as such using the robust 
regression and outlier removal (ROUT) method (Graphpad Software), and 
excluded from subsequent analysis. Where oulying values have been 
excluded this is clearly described in the figures and/or text. 
 
 P < 0.05 was considered to be significant. *,** and ***, used in figures, denote 
p values of <0.05, <0.01 and <0.001 respectively. NS (not significant) denotes 
a p value >0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
 
CHAPTER 3 
 
Expression of P2X7 in human diabetic nephropathy 
 
 
3.1 Introduction 
 
P2X7 is expressed at very low levels in rodent kidney under normal 
conditions (Turner et al., 2003). Upregulation in glomeruli has been 
demonstrated in the mouse model of nephrotoxic nephritis, where P2X7 has 
been shown to play an important role in pathogenesis of glomerular 
inflammation (Turner et al., 2007b, Taylor et al., 2009). Glomerular 
upregulation, predominantly within the podocyte, has also been shown in 
STZ-induced diabetes in the rat and ren-2 transgenic hypertensive rats, 
although the functional significance of these findings has not yet been tested 
(Vonend et al., 2004). 
 
Few studies, however, have examined P2X7 expression within the human 
kidney. In this chapter, I have sought to examine the expression of P2X7 in 
human renal biopsy tissue using a specific and contemporary anti-P2X7 
antibody, and, in particular, in renal tissue from patients with biopsy-proven 
DN, to test the hypothesis that P2X7 may be upregulated in human disease in 
a manner analogous to that seen in animal models.  
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3.2 Results 
 
3.2.1 P2X7 is constitutively expressed in human renal tubular epithelium 
 
Renal biopsy tissue from 4 patients with thin basement membrane (TBM) 
lesion was probed with a rabbit polyclonal antibody raised against an epitope 
in the C-terminal domain of P2X7 (Table 3.1 and Figure 3.1). TBM typically 
represents the carrier state for autosomal recessive Alport Syndrome, a 
hereditary nephropathy due to a mutation in basement membrane collagen, 
but which is only rarely associated with progressive renal impairment 
(Savige et al., 2013). TBM represents a benign lesion in the majority of 
patients, manifesting as isolated microscopic haematuria with normal renal 
function and normal renal architecture other than GBM thinning.  
 
Glomerular immunoreactivity for P2X7 was observed in only 1 of 4 patients 
with TBM, while no P2X7-positive cells were identifiable in the interstitium 
in any biopsy (Figure 3.1A). Of note, the patient in whom glomerular P2X7 
staining was apparent had a reduced eGFR, proteinuria (urinary PCR 
33mg/mmol) and evidence of mild mesangial expansion, suggesting possible 
occult DN. Three of 4 patients had pronounced tubular staining which 
appeared morphologically to be restricted to distal tubules (Figure 3.1B).  
 
Renal tissue from one patient with class IV proliferative lupus nephritis was 
also examined and showed focal glomerular staining for P2X7 (Figure 3.1C), 
corroborating published data  (Turner et al., 2003). 
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A B
C
Figure 3.1. Immunohistochemistry for P2X7 in Thin Basement Membrane disease
and Lupus Nephritis A: Typical appearance of a glomerulus from a patient with TBM
lesion, with no appreciable P2X7 staining. B: Tubular appearance in TBM disease. Marked
P2X7 expression (brown) was seen in a subset of tubular epithelial cells with
characteristics of distal tubule (thin cuboidal epithelium with little brush border and
open lumens), while minimal proximal tubular staining was seen. C: Glomerulus from a
patient with class IV proliferative lupus nephritis. Numerous P2X7 positive cells were
present, scattered focally within the glomerulus, consistent with a previous published
report.(Turner et al., 2007b) D: Control with omission of primary antibody.
(Magnification: x200)
D
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3.2.2 P2X7 expression is upregulated in glomeruli and interstitial cells in a 
subset of patients with DN 
 
Renal biopsy tissue from 30 patients with biopsy-confirmed DN, 
predominantly due to type 2 diabetes, was also examined for P2X7 
expression (Table 3.1 and Figure 3.2). Twenty-seven of 30 patients showed 
evidence of distal tubular staining, in keeping with that observed in patients 
with TBM (Figure 3.2A). Glomerular immunoreactivity was present in 16/30 
patients, either as granular circumferential deposits around capillary loops 
or more focally within the glomerulus (Figure 3.2B). The intensity of 
glomerular P2X7 staining frequently varied between glomeruli within the 
same biopsy. The majority of patients (23/30) had evidence of P2X7-positive 
cells within the interstitum, often in areas of established tubular atrophy 
where a significant number of infiltrating inflammatory cells were apparent 
(Figure 3.2C). Glomerular and interstitial P2X7 staining were not mutually 
exclusive, co-existing in 11/30 patients. 
 
Immunohistochemistry for CD68, a macrophage marker, was performed on 
two patient biopsies, one with significant glomerular P2X7 immunoreactivity 
and the other with predominantly interstitial P2X7 expression, to compare 
the relative pattern and extent of staining (Figure 3.3). In both cases, P2X7 
staining was substantially more widespread than CD68, suggesting that P2X7 
expression is not explained solely by infiltration of P2X7-positive 
macrophages. 
 
 
3.2.3 Glomerular P2X7 expression is a feature of early clinical DN 
 
Clinical and histological makers of disease severity were compared between 
patients with or without evidence of appreciable glomerular or interstitial  
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cell P2X7 staining. (Table 3.2 and Figure 3.4). A trend towards lower values 
of proteinuria, serum creatinine, and % interstitial fibrosis on biopsy was 
apparent in patients with positive glomerular immunoreactivity compared to 
those with absent glomerular staining (Figure 3.4A,C,E and G). The opposite 
trend was seen in those patients where interstitial P2X7-positive cells were 
present, with  higher values of the same variables compared to those with 
absent interstitial staining, reaching statistical significance for serum 
creatinine (Figure 3.4B,D,F and H). 
 
Six % of patients with positive glomerular P2X7 expression had a serum 
creatinine >250µmol/l compared to 43% of those without glomerular P2X7 
staining. Similarly 11% of patients with glomerular P2X7 expression had a 
uPCR ≥300 mg/mmol, compared to 56% without, while 6% of patients with 
glomerular P2X7 staining had an interstitial fibrosis score of ≥50% compared 
to 50% of patients without. 
 
 
3.3 Discussion 
 
In this chapter, the expression of P2X7 within the human kidney has been 
examined by immunohistochemistry, employing an antibody specific to the 
intracellular C-terminal receptor domain. By this approach, near-ubiquitous 
constitutive expression of P2X7 in human distal tubule was observed, 
comparable to that found in both mice and rats (see Chapters 5 and 6). No 
appreciable glomerular expression was present in the majority of subjects 
with TBM, while P2X7-positive cells were found in both the glomerulus and 
interstitium in a subset of patients with DN. 
 
Few studies have previously examined the expression of P2X7 in human 
kidney. In one study, a small number of nephrectomy specimens from  
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Glomerular
staining
Positive Negative P value
% Type 2 
DM
88.9%
(n=9)
91.7%
(n=12)
N/A
Creatinine
(μmol/l)
164.1 ± 59.1
(n=16)
222.9 ± 122.3
(n=14)
0.098
eGFR
(mls/min)
44.8 ± 22.6
(n=16)
37.6 ± 25.0
(n=14)
0.411
uPCR
(mg/mmol)
194.8 ± 301.8
(n=9)
765.0 ± 735.9
(n=9)
0.047
% Fibrosis 24.1 ± 17.3
(n=16)
46.8 ± 31.8
(n=14)
0.063
Interstitial 
staining
Positive Negative P value
% Type 2 
DM
93.8%
(n=16)
80%
(n=5)
N/A
Creatinine
(μmol/l)
210.8 ± 100.6
(n=23)
128.3 ± 47.6
(n=7)
0.042
eGFR
(mls/min)
36.9 ± 23.3
(n=23)
56.4 ± 19.0
(n=7)
0.032
uPCR
(mg/mmol)
639.6 ± 710.9
(n=12)
160.5 ± 98.5
(n=6)
0.567
% Fibrosis 37.6 ± 28.3
(n=23)
25.0 ± 22.6
(n=7)
0.312
Table 3.2 Clinical disease parameters in patients with DN with or without
appreciable P2X7-positive glomerular or interstitial cells. Glomerular and
interstitial staining were not mutually exclusive, co-existing in 11/30 patients
studied. Complete datasets were available for serum creatinine and eGFR;
unattainable data for uPCR and diabetes category analyses are reflected in
reduced n values. Statistically significant p values are shown in bold.
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Figure 3.4 Clinical disease parameters in patients with DN with or without
appreciable P2X7-positive glomerular or interstitial cells. A, C, E, G: Comparing
patients with (positive) or without (negative) P2X7-positive glomerular cells. B, D, F,
H: Comparing patients with or without P2X7-positive interstitial cells. A,B: Serum
creatinine; C,D: eGFR; E,F: uPCR; G,H: % Interstitial fibrosis. . *: p<0.05; NS: Not
significant.
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patients with carcinoma and cadaver donor kidneys unsuitable for 
transplantation, were probed with an antibody raised against the C-terminal 
domain of P2X7 (a different antibody to that used in the current study), and 
‘very little immunoreactivity’ was reportedly detectable in tubules or 
glomeruli (Turner et al., 2003). Nine patients with lupus nephritis (6 
‘proliferative’ and 3 ‘membranous’) were also examined with the same 
antibody and receptor protein expression was found in all patients, 
predominantly within glomeruli. P2X7 expression has also been 
demonstrated in human foetal ARPKD renal cyst epithelium (Hillman et al., 
2002). Of note, P2X7 is highly expressed in a number of immune cells in 
humans, including the macrophage, capable of infiltrating the kidney during 
injury (North, 2002). 
 
Another recent study has investigated the expression of P2X7 in kidney 
specimens from patients with type 2 diabetes (Solini et al., 2013). This study 
examined P2X7 expression in nephrectomy specimens from 6 patients with 
metabolic syndrome, DN and concomitant renal cancer, and 3 non-diabetic 
controls. A different antibody (Ab48871, Abcam) was used, recognising an 
'internal region' of P2X7, and for which 'human kidney tissue' is stated on the 
datasheet as a positive control. Increased renal cortical and glomerular 
expression of P2X7 was observed, pictured in a focal distribution. No 
appreciable staining, either glomerular or tubular, was seen in the pictured 
control specimen. 
 
In the present study, the finding that P2X7 is upregulated within the 
glomerulus of some patients with DN is consistent with published data 
examining expression during experimental diabetes in the rat (Vonend et al., 
2004). The preponderance of glomerular staining in patients with early 
clinical DN also corresponds well with rodent experimental findings 
presented in this thesis, where glomerular expression is upregulated at an 
early time-point in rat models of DN due to both type 1 and 2 diabetes, and 
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also DN due to type 1 diabetes in the mouse (Chapters 5 and 6). Glomerular 
staining was typically granular and located circumferentially around 
capillary loops in patients with DN, as opposed to the more focal reactivity 
observed in proliferative lupus nephritis, although focal staining was also 
apparent in some diabetic subjects. Although the cell types expressing P2X7 
have not been formally established, the widespread glomerular distribution 
compared to the relatively sparse presence of CD68+ macrophages, suggests 
expression in resident glomerular cells, presumably either capillary 
endothelial cells or podocytes. Examination of expression by immuno-gold 
electron microscopy in diabetic rats has suggested predominant podocytic 
expression in experimental disease (Vonend et al., 2004). 
 
While patients with positive glomerular immunostaining for P2X7 had, as a 
group, earlier clinical DN than those without, this association was not 
entirely specific. Further work looking longitudinally at patients with or 
without glomerular P2X7 staining is required to determine whether this 
impacts on clinical outcomes.  
 
In summary, P2X7 is expressed constitutively in human distal tubules and is 
upregulated in glomerular and interstitial compartments in a subset of 
patients with DN; as a group, patients with glomerular P2X7 expression have 
earlier clinical disease than those without. These immunohistochemical 
findings correspond well with those seen in rodent kidney during 
experimental diabetes and hence bode well for translation of findings from 
animal models to human disease. 
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CHAPTER 4 
 
Investigating the role of P2X7 in the induction of 
murine diabetes using streptozotocin 
 
 
4.1 Introduction 
 
Streptozotocin (STZ) is commonly used to produce a phenotype of type 1 
diabetes in experimental mice and rats. Taken up into pancreatic β-cells via 
the GLUT-2 receptor, STZ causes alkylation of DNA and subsequent cellular 
necrosis and death. Administration as a repetitive low dose regime in mice 
results in reduced renal bystander toxicity and also pancreatic injury, but the 
latter is augmented by a secondary auto-immune insulinitis with an 
inflammatory infiltrate comprising lymphocytes and macrophages, with 
similarities to that seen in human type 1 diabetes (Like et al., 1978, In't Veld, 
2011). This model also has relevance to the pathogenesis of human type 2 
diabetes, where initial hyperinsulinaemia and β-cell hypertrophy is 
succeeded by β-cell loss, with many patients consequently requiring 
treatment with exogenous insulin. 
 
P2X7 has well-defined roles in inflammatory cytokine secretion from 
macrophages, and genetic deficiency or inhibition of the receptor in models 
of inflammatory disease often reduce accumulation of this cell type at the site 
of injury (Goncalves et al., 2006, Taylor et al., 2009). P2X7 is also expressed in 
T cells and has been implicated in proliferation and effector functions of 
these cells (Lang et al., 2010). P2X7 expression has been demonstrated in 
human pancreatic β-cells with upregulation observed in obese subjects and 
reduction of expression in patients with overt diabetes (Glas et al., 2009). 
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However, previous studies of the functional role of P2X7 in pathogenesis of 
diabetes in animal models have produced conflicting results (Glas et al., 2009, 
Lang et al., 2010, Chen et al., 2011). 
 
I have sought to address the question of the role of P2X7 in β-cell injury by 
studying the effect of low dose STZ on diabetes induction in mice genetically 
lacking the P2X7 receptor. Two strains of P2X7 KO mouse with differing 
profiles of residual receptor expression (GSK and Pfizer) were examined, 
with pancreatic tissue available for analysis in the Pfizer mice. 
 
4.2 Results 
 
4.2.1 GSK KO mice show partial protection against STZ-induced pancreatic 
toxicity and a less severe disease course 
 
Tail vein blood glucose (BG) was measured 3 weeks after the final injection of 
STZ and a non-fasting value of ≥16 mmol/l was considered diabetic. Physical 
and biochemical data at baseline and week 3 is summarised in Table 4.1. 
Early mortality (<3 weeks, before measurement of BG) was similar in WT STZ 
and KO STZ-injected animals (14.7% vs 10%; p=1.0). (Figure 4.1A) A higher 
proportion of WT STZ-injected animals developed diabetes than KO (83% vs 
72%; p=0.47) (Figure 4.1B). BG was significantly higher in both STZ groups 
compared to their corresponding vehicle-injected controls, but only 
marginally higher in WT STZ animals compared to KO mice (WT 23.4 ± 8.4 vs 
KO 22.2 ± 7.3 mmol/l; p>0.05, Kruskal-Wallis with Dunn's post-test; Figure 
4.1C). Glucometer readings were capped at 33.3 mmol/l, however, and 17% 
of WT STZ-injected animals had BG values >33.3 compared to 0% of the KO 
group (p=0.14; Figure 4.1D). A greater proportion of diabetic WT animals 
subsequently developed severe disease after the 3 week time-point, causing 
death or necessitating early culling (33% WT vs 15% KO; p=0.44), although a  
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Figure 4.1 Induction of diabetes with STZ in C57BL/6 WT and GSK P2X7 KO mice. A: Early mortality
(<3 weeks, prior to measurement of blood glucose). B: Percentage of WT and KO STZ-injected mice
achieving a diabetic blood glucose (> 16 mmol/l) at 3 weeks, edited for death before 3 weeks. C: Blood
glucose measured at 3 weeks. Although no significant difference was detected between WT and KO STZ-
injected animals, blood glucose measurement was capped at 33.3 mmol/l, which may have masked the
full effect. D: Percentage of WT and KO STZ-injected mice achieving a BG of >33.3 mmol/l (above range of
glucometer) at 3 weeks. E,F: Proportion of animals diagnosed diabetic at 3 weeks which maintained
sustained hyperglycaemia (16-33.3 mmol/l), became too sick (either dying or developing a BG >33.3
mmol/l) or spontaneously recovered to a BG <16 mmol/l). n: number of mice. ***: p<0.001; NS: Not
significant.
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correspondingly higher proportion of KO mice maintained a blood glucose in 
the target range (38% WT vs 62% KO; p=0.18) (Figure 4.1E,F). A similar 
proportion of both groups reverted to a non-diabetic BG on follow-up (29% 
WT vs 23% KO; p=1.0). 
 
 
4.2.2 Pfizer KO mice show marked protection against STZ-induced pancreatic 
toxicity 
 
Physical data at baseline and week 3 is summarised in Table 4.2. One animal 
from both STZ-injected groups died before the 3 week time point. Six out of 
seven (86%) WT STZ-injected mice achieved a diabetic BG compared to one 
out of six (17%) of KO STZ-injected animals (p=0.027; Figure 4.2A). BG was 
significantly higher in WT STZ than WT vehicle-injected animals (22.8 ± 7.0 
vs 8.6 ± 1.0; p<0.05, Kruskal-Wallis with Dunn's post-test) but not so for KO 
STZ compared to KO vehicle-injected mice (14.1 ± 8.6 vs 8.5 ± 1.0; p>0.05) 
(Figure 4.2B). A trend towards reduced BG values was observed in KO STZ 
mice compared to WT STZ (p>0.05). Glucometer readings were again capped 
at 33.3 mmol/l and one out of seven (14%) WT mice had a BG in excess of 
this level compared to zero out of six STZ, obscuring the full magnitude of the 
difference between groups (Figure 4.2C). 
 
To examine the possibility that P2X7 KO mice may be resistant to STZ-
induced pancreatic damage due to reduced STZ uptake into β-cells, 
expression of GLUT-2 was assessed by specific immunohistochemistry 
(Figure 4.3). GLUT-2 staining was predominantly observed at the cell 
membrane in cells within the pancreatic islets, with no difference in the 
distribution between WT and KO mice. 
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Figure 4.2 Induction of diabetes with STZ in C57BL/6 WT and Pfizer P2X7 KO mice. A: Percentage of
WT and KO STZ-injected mice achieving a diabetic BG (>16 mmol/l) at 3 weeks, edited for death before
3 weeks. B: Blood glucose measured at 3 weeks. A trend towards lower BG was seen in the KO STZ
group compared to WT STZ, and KO STZ BGs did not differ significantly from KO controls. Blood
glucose measurement was capped at 33.3 mmol/l, which may have masked the full effect. C:
Percentage of WT and KO STZ-injected mice achieving a BG of >33.3 mmol/l (above range of
glucometer) at 3 weeks. . *: p<0.05; NS: Not significant.
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4.2.3 Pfizer KO mice display preserved pancreatic islet architecture and beta 
cell density after STZ injection 
 
No macroscopic abnormalities were apparent on light microscopy of islets 
from vehicle-injected KO mice compared to WT at 3 weeks post-injection 
(Figure 4.4A and C). Islets of WT STZ-injected mice appeared markedly 
abnormal with irregular outline, increased cellularity, early vacuolar 
degenerative change and rare central core necrosis (Figure 4.4B). Islets from 
KO STZ-injected mice more closely resembled normal architecture with 
minimal degenerative changes and only mild hypercellularity (Figure 4.4D).  
 
Islet β-cell mass was assessed by specific immunohistochemistry for insulin 
(Figure 4.5). Islets from both WT and KO vehicle-injected animals showed 
uniform staining across the entire islet area (Figure 4.5A and C); a patchy 
reduction in the stained area was observed in WT STZ animals with a 
relatively preserved pattern in KO STZ mice, confirmed on semi-quantitative 
analysis of insulin-stained islet area (Figure 4.5B and D; WT STZ 2.52 ± 0.8 
units vs KO STZ 3.34 ± 0.4; p<0.05). As expected, BG and insulin-stained area 
correlated well (r2= 0.75, p<0.001). 
 
 
4.2.4 P2X7 is expressed peripherally within the healthy mouse islet with 
central translocation after treatment with STZ 
 
Expression of P2X7 within pancreatic islets was examined by specific 
immunohistochemistry (Figure 4.6). Islets from WT vehicle-injected mice 
showed peripheral decoration by P2X7-positive cells and minimal staining 
within the body of the islet (Figure 4.6A). Surrounding exocrine tissue 
displayed no staining. After STZ, the density of peripheral staining increased, 
with positive cells often layered 2 to 3 deep, with increased numbers of  
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A B
C D
WT
KO
Vehicle STZ
Figure 4.5 Analysis of beta cell mass in pancreatic tissue from WT and Pfizer P2X7 KO mice. A-D;
Specific immunohistochemistry for insulin, delineating beta cells within pancreatic islets. A,C: Islets from
both WT and KO control mice showing widespread staining across the islet; B: WT STZ-injected mice
show reduced and discontinuous staining reflecting β-cell necrosis and loss. D: KO STZ-injected mice have
relative preservation of pancreatic islet insulin staining. E: Quantification of beta cell mass by
measurement of insulin-stained islet area (5 greatest, 0 least) confirming the qualitative findings. F:
Scatter plot of blood glucose and insulin-stained area across all mice showing, as expected, these two
parameters correlate well. *: p<0.05, **: p<0.01.
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A
C
B
D
E F
Figure 4.6 Immunohistochemistry for P2X7 in pancreatic islets from WT and Pfizer KO mice.
A: Islet from WT vehicle treated mouse. The most peripheral layer of cells stained positive for P2X7
with occasional positive cells in the centre of islets. The peripheral location of P2X7-positive cells
suggests they are α-cells. B: Typical appearance of islet from STZ-injected WT mouse. The number
and depth of peripheral P2X7-positive cells was increased compared to WT with a greater number
also observed in the centre of islets. C: An islet from an STZ-injected mouse with severe diabetes (BG
>33.3 mmol/l at 3 weeks). The majority of cells in the islet stain positive for P2X7. D: Typical islet
from KO vehicle treated mouse. A few peripheral cells stain positive, implying residual expression of
receptor protein. E: Islet from KO STZ-injected mouse. The number of peripheral P2X7-positive cells
is increased compared to control. F: Islet from WT STZ-injected mouse incubated with non-immune
polyclonal rabbit immunoglobulin at an equivalent concentration to the primary antibody.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
164 
 
P2X7-positive cells within the centre of the gland (Figure 4.6B and C). These 
observations corroborate those in the NOD mouse model of type 1 diabetes, 
where co-localisation studies confirmed the P2X7-expressing cells to be α-
cells (Coutinho-Silva et al., 2007). After STZ-induced β-cell damage and death, 
α-cells undergo compensatory proliferation, explaining the appearance of 
P2X7 positive cells within the core of the islet. 
 
Sparse P2X7-positive cells were also observed around the periphery of islets 
in healthy P2X7 KO mice with an increase in number and density after STZ 
(Figure 4.6D and E). This staining is presumed to represent expression of a 
splice variant which escapes deletion and is consistent with published data 
where immunoblotting was performed on brain tissue from the Pfizer mouse 
using the same antibody (recognising the extracellular domain), and residual 
protein expression was observed (Sanchez-Nogueiro et al., 2005). 
 
 
4.2.5 Islet macrophage infiltration after STZ is diminished in Pfizer KO mice 
 
To further investigate the differences in cellularity between islets of WT and 
KO STZ-injected animals, specific immunohistochemistry for the macrophage 
antigen, Mac-2 (galectin-3), was performed. Mac-2 is a 32kD protein highly 
expressed on activated macrophages.(Ho and Springer, 1982) Significant 
macrophage accumulation was observed in islets from WT STZ-injected mice 
compared to vehicle-injected controls (mean fractional stained area: WT STZ 
0.024 ± 0.004 vs WT Vehicle 0.009 ± 0.004 arbitrary units; p<0.001) (Figure 
4.7). Macrophage infiltration was much reduced in islets from KO STZ mice 
compared to WT STZ (WT 0.024 ± 0.004 vs KO 0.013 ± 0.004; p<0.001). 
 
Specific immunohistochemistry for the T cell marker, CD3, was also 
performed (Figure 4.8). No CD3-positive cells were present in islets from WT  
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Figure 4.7 Macrophage accumulation in pancreatic islets from WT and Pfizer P2X7 KO mice.
A-D; Specific immunohistochemistry for Mac-2, delineating macrophages within pancreatic islets.
A,C: Islets from both WT and KO control mice showed minimal macrophage infiltration; B: WT STZ-
injected mice displayed evidence of significant macrophage influx. D: KO STZ-injected mice had
reduced macrophage infiltration compared to WT. E: Quantification of macrophage infiltration by
image analysis, confirming this pattern of results. . *: p<0.05; ***: p<0.001.
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E
Figure 4.8 Immunohistochemistry for CD3 in islets from WT and KO mice. No CD3-
positive cells were observed within islets from WT (A) and KO (C) vehicle-injected mice. A
small peri-vascular inflammatory infiltrate adjacent to the islet in panel A, contains
numerous CD3-positive cells (arrow). Rare solitary CD3-positive cells were observed in
islets from WT STZ-injected mice (B; arrow), while no positive cells were apparent in KO
STZ mice (D). E: Islet from WT STZ-injected mouse incubated with an equivalent
concentration of rabbit polyclonal immunoglobulin. (Magnification: x200)
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and KO vehicle injected animals; rare solitary CD3-positive cells were 
observed in islets from WT STZ injected mice, and none were seen in islets of 
KO STZ animals. T cells hence do not appear to constitute an important 
component of the inflammatory cell infiltrate in pancreatic islets following 
low dose STZ. 
 
To investigate possible differences in background T cell and macrophage 
numbers between WT and KO mice, CD3 and Mac-2 immunohistochemistry 
was also performed on spleen tissue of vehicle-injected mice (Figure 4.9). 
CD3 staining was observed predominantly within the peri-arteriolar 
lymphoid sheath in both WT and KO mice with no difference in density or 
distribution. (Figure 4.9A and B). Mac-2 positive cells were most numerous 
within the splenic red pulp, with no differences in appearance between WT 
and KO animals (Figure 4.9C and D). 
 
 
4.3 Discussion 
 
Current therapy for both type 1 and type 2 diabetes focuses on either 
replacing or augmenting endogenous pancreatic insulin secretion or 
enhancing peripheral insulin sensitivity and glucose utilisation. While 
progressive islet destruction is a feature of both forms of diabetes, no 
treatments, with the possible exception of GLP-1, exist which interrupt this 
process (Urusova et al., 2004). In this chapter I have examined the role that 
P2X7 plays in the pathogenesis of islet injury in a commonly used mouse 
model of diabetes: low dose STZ. Examining two different strains of P2X7 KO 
mouse, both showed evidence of pancreatic resistance to the effects of STZ 
with a reduced proportion of mice becoming diabetic compared to WT, albeit 
more marked in the Pfizer KO strain. This was corroborated in Pfizer mice by  
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relative preservation of islet architecture and β-cell density compared to WT 
comparators. 
 
GSK P2X7 KO mice were generated by disruption of exon 1 through insertion 
of a LacZ gene at the beginning of this region (Sim et al., 2004). It has recently 
been demonstrated that a novel splice variant of P2X7 utilising an alternative 
exon 1 (P2X7K) escapes inactivation in the GSK mouse, particularly in splenic 
lymphocytes (Nicke et al., 2009). This receptor is functional, has a greater 
sensitivity to agonist than the native P2X7A receptor and rapidly triggers 
membrane permeabilisation as measured by ethidium bromide uptake 
(Nicke et al., 2009). The Pfizer mouse was generated through targeted 
disruption of exon 13 (Solle et al., 2001). A C-terminal splice variant (∆C) 
escapes deletion in this model also, although this receptor variant is 
inefficiently trafficked to the cell membrane, transmits only small agonist-
evoked currents and exerts a dominant negative effect when co-expressed 
with P2X7A making this mouse a more ‘complete’ functional knockout (Masin 
et al., 2012). These differences in residual receptor expression are likely to 
explain the difference in protective effect observed between the two KO 
strains. 
 
An interaction between ATP and the pancreas has been recognised for more 
than 50 years, with the demonstration that extracellular ATP could stimulate 
insulin release from rabbit pancreas slices (Rodrigue-Candela et al., 1963). 
Subsequent work has demonstrated expression of both P2X and P2Y receptor 
subclasses on exocrine and endocrine cells within the mammalian pancreas, 
as well as local blood vessels and autonomic nerve terminals (Burnstock and 
Novak, 2012). P2X7 is expressed in α but not β-cells in both normal rat and 
mouse pancreas, predominantly at the periphery of the gland (Coutinho-Silva 
et al., 2003, Coutinho-Silva et al., 2007). Induction of diabetes with STZ in the 
rat results in progressive accumulation of P2X7-positive α-cells in the centre 
of the islet, a phenomenon also observed in the NOD mouse and corroborated 
170 
 
by the data in this study (Coutinho-Silva et al., 2003, Coutinho-Silva et al., 
2007). In both instances, infiltrating macrophages lacked significant P2X7 
positivity, in contrast to splenic and peritoneal macrophages which were 
typically P2X7-positive. In contrast, P2X7 appears to be widely expressed in 
human β-cells in addition to α-cells, with marked upregulation in β-cells in 
obese non-diabetic individuals, but down-regulation in patients with overt 
diabetes (Glas et al., 2009). 
 
Several studies have previously attempted to address the functional role of 
P2X7 in diabetic pancreatic injury. Lymphocytes isolated from NOD diabetic 
mice have been shown to be highly sensitive to P2X7-mediated shedding of 
CD62L and MHC Class I and also to programmed cell death (Elliott and 
Higgins, 2004). However, a P2X7 KO NOD stock did not exhibit a reduced 
incidence of diabetes compared to WT NOD mouse comparators, raising a 
question as to its importance to the initiation of diabetes in this model (Chen 
et al., 2011). P2X7-deficiency did, however, completely abrogate the 
accelerated development of diabetes seen in CD38-deficient NOD mice, 
where increased NAD-dependent cell death of CD4+ invariant T cells (iNKT) 
and Foxp3+ regulatory T cells (Tregs) promotes enhanced pancreatic injury 
(Chen et al., 2006).  
 
Mouse P2X7 can be alternatively activated by ADP-ribosylation, an NAD-
dependent process, with P2X7-deficiency presumably protecting iNKTs and 
Tregs from cell death in this model (Seman et al., 2003). The authors 
reconcile this finding with the absence of a protective effect on diabetes in 
CD38 +/+ NOD mice by suggesting that P2X7 may also contribute to 
suppression of autoreactive pathogenic T cells during development, 
promoting self-tolerance and balancing the detrimental effect on regulatory 
cell survival. The effect of P2X7 deficiency on the repertoire of immune cells 
infiltrating islets was not described in this study. CD38 has also been shown 
to participate in regulation of spontaneous release of ATP from smooth 
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muscle, further complicating the findings of this study (Durnin and Mutafova-
Yambolieva, 2011). 
 
In another study, the effect of the P2X7 antagonist, oxidized ATP (oATP), was 
tested on development of autoimmune CD8+ T cell-driven diabetes initiated 
by islet-specific expression of the LCMV-glycoprotein transgene in RIP-GP 
mice (Lang et al., 2010). oATP suppressed diabetes in 75% of mice and 
reduced numbers of activated CD8+ cells, CD4+ and CD11b+ cells within the 
spleen. The number of CD8+ cells observed infiltrating pancreatic islets was 
also reduced. oATP has also been shown to prolong graft survival in a murine 
model of pancreatic islet transplantation (Vergani et al., 2013). This was 
accompanied by a reduction in the anti-islet Th1 response and an increase in 
Tregs within the allograft. Graft survival was also prolonged when islets were 
transplanted to P2X7 KO mice, but to a lesser extent.  
 
Conversely, in a study of β-cell dysfunction due to a high sucrose / high fat 
diet, P2X7 KO mice displayed severe glucose intolerance and failure to 
appropriately upregulate β-cell mass compared to WT animals (Glas et al., 
2009). This was closely associated with reduced serum levels of IL1-RA, 
potentially exposing β-cells to increased toxic effects of local IL1β secretion. 
Islets cultured from P2X7 KO mice showed a defect in glucose-induced 
insulin release, although expression of P2X7 in β-cells of WT mice was not 
demonstrated directly. 
 
The reduction in infiltrating macrophages observed in islets of Pfizer mice in 
the present study suggests that mitigation of the inflammatory response and 
‘insulinitis’ provoked by STZ may underlie pancreatic protection, as opposed 
to direct protection of β-cells from the initial toxic insult, particularly as no 
expression of P2X7 could be demonstrated in the body of normal WT islets. 
The absence of a significant T cell infiltrate in islets from either WT or KO 
STZ-injected mice, suggest this cell type does not directly contribute to islet 
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inflammation in this model. Monocytes constitute a similar overall 
percentage of the circulating leukocyte population in P2X7 KO and WT mice 
and, together with the finding that macrophage and T cell density and 
distribution within spleen do not differ between WT and KO mice, it seems 
unlikely that effects of genetic P2X7 deficiency on monocyte development 
underlie the present experimental findings (Labasi et al, 2002). 
 
 The lack of protection afforded by P2X7 deficiency in NOD mice may be 
reconciled with our data by considering that STZ represents 'acquired' islet 
injury (as opposed to an inherent genetic susceptibility to autoimmunity), 
meaning any effect which P2X7 may have on negative selection of self-
reactive thymoctes during development is not of relevance in this model. It is 
possible that the observed reduction in macrophage infiltration may result 
from decreased P2X7-dependent secretion of recruitment signals from 
resident islet cells, in a manner analagous to that seen within the glomerulus 
(see Chapter 7). 
 
No difference in baseline random glucose was observed between WT and KO 
mice in this study, in contrast to the elevated fasting glucose seen in younger 
P2X7 KO mice in the study of Glas et al, although formal tests of glucose 
tolerance were not conducted.  While P2X7 deficiency appears to exert a 
protective role in murine STZ-induced islet toxicity, the relative contribution 
of P2X7 and innate immune mechanisms to insulin secretion, β-cell 
proliferation or apoptosis in human pancreas is not known, meaning the net 
effect of P2X7 inhibition in human disease is currently difficult to predict. The 
apparent much greater expression of P2X7 in human β-cells compared to 
mouse may also impact on this (Coutinho-Silva et al., 2007, Glas et al., 2009). 
 
In summary, the present data suggests that P2X7 deficiency ameliorates 
inflammatory attack on the islets after low dose STZ making it an interesting 
possible target in human diabetes. Further studies in isolated human islets, 
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specifically examining the effect of selective P2X7 antagonists on 
pancreatotoxic stimuli, will be crucial in advancing the translation of these 
findings. 
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CHAPTER 5 
 
Investigating the role of P2X7 in the development of 
murine diabetic nephropathy using streptozotocin 
 
5.1 Introduction 
 
There is a pressing need to develop new therapies to retard the progression 
of DN, as the world-wide prevalence of diabetes continues to increase. 
Current treatments include inhibition of the RAS together with tight 
glycaemic and blood pressure control; an increasing appreciation that innate 
immune mechanisms play an important role in disease pathogenesis 
provides a potential new avenue for intervention (Navarro-Gonzalez and 
Mora-Fernandez, 2008). Macrophages feature prominently in the glomerular 
and tubulointerstitial infiltrate observed in DN, and their functional 
importance has been proven in animal models, making them a prime target 
for manipulation (Chow et al., 2006, Chow et al., 2007). 
 
P2X7 has an integral role in IL1β and IL18 secretion from macrophages, and 
genetic deficiency or inhibition of the receptor in animal models of 
inflammatory disease often reduce accumulation of macrophages at the site 
of injury (Goncalves et al., 2006, Taylor et al., 2009). Minimal glomerular 
expression of P2X7 is observed under normal conditions, but marked 
upregulation has been described in models of both diabetic and hypertensive 
renal disease (Vonend et al., 2004). In addition, in vitro studies suggest that 
stimulation of P2X7 on mesangial cells by ATP may directly increase ECM 
synthesis, a central feature of DN, independent of any pro-inflammatory 
effect (Solini et al., 2005).  
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The current experiment has sought to investigate the functional role of P2X7 
in DN by studying renal injury in WT and GSK P2X7 KO mice after induction 
of diabetes with low dose STZ. In particular, we have examined the effect of 
P2X7 deficiency on activation of the innate immune system in DN, by 
measuring renal inflammatory cytokine production and mononuclear cell 
infiltration. We selected the low dose STZ model, both because it is well 
characterised, and because it allows study of the effects of hyperglycaemia on 
the kidney in relative isolation from confounding insults, such as the obesity 
and dyslipidaemia observed in type 2 diabetes models and vascular 
phenotype evident in genetic models such as eNOS KO (see Section 1.9 for 
further discussion of mouse models of DN). A low dose schedule avoids the 
majority of direct drug-induced nephrotoxicity observed with high dose 
induction protocols and, although it induces only mild diabetic kidney injury, 
has been used successfully elsewhere to examine mechanisms of disease in 
early DN (eg. (Chow et al., 2006). Older mice (8-12 months) were used in the 
present study to accelerate progression of DN (Wu et al., 2010a). The GSK KO 
mouse was chosen for use, both because of local availability, and because 
amelioration of renal inflammation and injury were observed in the 
nephrotoxic nephritis model when induced in this P2X7 KO strain (Taylor et 
al., 2009). 
 
5.2 Results 
 
5.2.1 GSK P2X7 KO mice are not protected from albuminuria or rise in 
creatinine at 12 weeks after STZ 
 
To ensure that groups were well-matched for degree of hyperglycaemia, only 
mice achieving and maintaining a BG of 16-33.3mmol/l after STZ injection 
were studied at the 12 week end-point; details of the proportion of mice 
falling outside of these limits are described in Chapter 4. Physical and 
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biochemical data at baseline and week 12 for the mice included in the study 
are summarised in Table 5.1. 
 
Mean BG (averaged from readings taken between weeks 3 and 12) did not 
differ between STZ-injected WT and KO groups (Figure 5.1A); BG at week 9 
was higher in the KO group (WT STZ vs KO STZ, 22.7 ± 3.4 vs 28.1 ± 4.9 
mmol/l; p=0.02), but similar at all other time-points (Figure 5.1B). A trend 
towards greater % weight loss was observed  in KO STZ compared to WT STZ 
mice (mean difference 5.9%, 95% CI -1.3 to 13.2%).  
 
At 12 weeks, the urine albumin:creatinine ratio (uACR) was elevated in WT 
STZ  mice compared to vehicle-injected controls although this did not reach 
statistical significance; a trend was seen towards higher uACR values in KO 
STZ mice compared to WT, albeit with a wide standard deviation of results in 
the latter group (WT STZ vs KO STZ; 57.0 ± 21.9 vs 158.4 ± 220.6 mg/mmol; 
95% CI of difference -44.7 - 247.4 mg/mmol; Figure 5.1C). Serum creatinine 
was significantly elevated in WT STZ mice compared to controls at this time-
point, with no observed difference between WT and KO STZ groups (Figure 
5.1D). 
 
 
5.2.2 P2X7 expression is upregulated in glomeruli of STZ diabetic mice 
 
P2X7 expression in mouse kidney tissue was examined by specific 
immunohistochemistry using a specific rabbit polyclonal anti-P2X7 antibody 
(Alomone Labs). Prominent basolateral staining was observed in a subset of 
tubules in all mice examined (Figure 5.2A), identical to that seen in both 
human  (Chapter 3) and rat (Chapter 6) kidney. This constitutive staining was 
observed in both WT and KO mice, and, in the latter, is assumed to represent 
P2X7K splice variant expression (Nicke et al., 2009). 
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WT Vehicle
(n=8)
WT STZ
(n=8)
KO Vehicle
(n=8)
KO STZ
(n=8)
Age (months) 9.1 ± 0.6 9.5 ± 0.8 9.4 ± 1.2 9.9 ± 0.4
Wk 0 weight (g) 35.0 ± 2.4 36.9 ± 4.0 37.6 ± 4.8 35.6 ± 1.7
% Weight loss 
(Wk 0 to Wk12)
-1.6 ± 5.6 11.8 ± 8.4a -3.3 ± 4.9 18.7 ± 5.1b
Wk 0 BG*
(mmol/l)
8.8 ± 1.9 8.0 ± 0.7 8.5 ± 2.5 8.7 ± 1.7
Mean BG 
(mmol/l)
(Wk 3 to Wk 12)
8.3 ± 1.1 25.9 ± 2.6a 8.7 ± 1.2 26.6 ± 2.4b
Wk 12 uACR†
(mg/mmol)
30.9 ± 14.3 57.0 ± 21.9 49.2 ± 36.6 158.4 ± 220.6
Wk 12 Serum 
Creatinine
(μmol/l)
34.8 ± 3.2 53.3 ± 10.1a 31.3 ± 3.5 57.1 ± 11.9b
Table 5.1 Summary of physical and biochemical data for GSK P2X7 KO mouse
DN experiment. a p<0.001 vs WT vehicle; b p<0.001 vs KO vehicle. *Data available for
a subset of mice: WT vehicle n=8, WT STZ n=6, KO vehicle n=8, KO STZ n=4. † KO
vehicle n=7, other groups n=8.
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Figure 5.1. Glycaemia and biochemical renal outcomes. A: Mean BG averaged across
weeks 3 to 12. Mean BG was equivalent in WT and KO diabetic groups. B: Mean BG at each
measurement time-point. KO STZ mice had higher BG at week 9, and similar levels to WT
STZ at all other time points. C: uACR at week 12. uACR was elevated in both diabetic groups
compared to controls, but failed to reach statistical signficance. A trend towards higher
uACR values was seen in KO STZ mice compared to WT, but with a wide standard deviation
of values in the former group. D: Serum creatinine at week 12. Creatinine was elevated in
both diabetic groups compared to controls, but was equivalent in WT and KO diabetic mice. .
*: p<0.05; ***: p<0.001; NS: Not significant.
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Minimal glomerular staining was seen in either WT or KO control mice 
(Figure 5.2A and C). In contrast, WT STZ-injected mice showed marked 
glomerular P2X7 expression in a capillary loop pattern, in the majority of 
glomeruli (Figure 5.2B). This capillary loop staining was not seen in KO STZ-
injected animals (Figure 5.2D). Glomerular P2X7 staining was not present at 
3 weeks after STZ injection in WT mice (data not shown). 
 
 
5.2.3 Interstitial fibrosis and glomerular hypertrophy are not influenced by 
P2X7 deficiency 
 
Cortical fibrosis was quantified by image analysis of picrosirius red-stained 
sections, viewed under double polarised light. Fibrosis was significantly 
greater in STZ-injected WT mice compared to controls (WT STZ vs WT 
vehicle; 1.2 ± 0.4 vs 0.7 ± 0.3 % surface area; p<0.01), but no difference 
existed between WT and KO diabetic groups (WT STZ vs KO STZ; 1.2 ± 0.4% 
vs 1.2 ± 0.3%; p>0.05) (Figure 5.3A-E). No correlation was found  between 
interstitial fibrosis and serum creatinine for diabetic mice (r2=0.07, p=0.32), 
suggesting that fibrosis and nephron drop-out was not the prime 
determinant of the apparent reduction in GFR in this model (Figure 5.4A). 
Similarly, there was no correlation between uACR and creatinine (r2=0.004, 
p=0.82, as analysed with removal of single outlying datapoint; Figure 5.4B 
and C). It is hence likely that the apparent reduction in GFR may be due to 
other factors, such as polyuria-driven volume depletion. 
 
Glomerular hypertrophy was assessed by measurement of mean glomerular 
area across 30 randomly-selected glomeruli for each animal. A trend was 
observed towards increased glomerular size in diabetic WT animals 
compared to controls (WT STZ vs WT vehicle; 4130 ± 851 vs 3655 ± 492 µm2; 
95% CI of difference -457.9 to 1407µm2), similar to that observed in diabetic  
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Figure 5.3 Cortical fibrosis and glomerular area in murine DN. A-D: Representative picrosirius
red-stained sections viewed under double-polarised light (x200 magnification). E: Picrosirius red-
stained cortical area, as determined by image analysis. F: Glomerular area. %SA: % surface area
stained with picrosirius red. **: p<0.01; NS: Not significant.
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Figure 5.4 Simple Pearson correlation analysis between serum creatinine (dependent variable)
and primary determinants of renal function in diabetic mice. A: Scatter plot depicting relationship
between serum creatinine and interstitial fibrosis in all diabetic mice (WT and KO), as quantified by
picrosirius red-stained surface area. No significant correlation was found between the two variables
(r2=0.07, p=0.32). B: Scatter plot depicting relationship between serum creatinine and uACR in all
diabetic mice. Outlying value is circled. C: Data as for figure B but with outlying value removed. No
correlation was observed between creatinine and uACR (r2=0.004, p=0.82). %SA: % surface area stained
with picrosirius red.
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KO mice compared to KO controls (KO STZ vs KO vehicle; 4060 ± 936 µm2 vs 
3383 ± 549 µm2; 95% CI of difference -254.6 to 1610 µm2) (Figure 5.3F). 
Glomerular size did not differ between WT and KO diabetic mice (p>0.05). 
 
Glomerular type IV collagen deposition was examined by 
immunohistochemisty using a specific rabbit polyclonal anti-type IV collagen 
antibody (Abcam) and quantified using ImagePro. Glomerular collagen was 
increased in diabetic WT animals compared to controls (WT STZ vs WT 
vehicle; 17.8 ± 2.2 vs 13.9 ± 1.5 % surface area; p<0.01), with a trend towards 
reduced levels in KO diabetic animals (WT STZ vs KO STZ; 17.8 ± 2.2 vs 15.2 ± 
2.8 % surface area; 95% CI of difference 0.1 to -5.3%); (Figure 5.5). 
 
 
5.2.4 Diminished glomerular, but not interstitial, macrophage accumulation is 
observed in GSK P2X7 KO mice 
 
Macrophage infiltration was assessed by immunohistochemistry using a 
specific rat monoclonal anti-CD68 antibody (Serotec) and quantified for 
glomerular and tubulointerstitial compartments. At 12 weeks, glomerular 
macrophage number was significantly elevated in WT diabetic mice 
compared to controls (WT STZ vs WT vehicle; 0.87 ± 0.53 vs 0.14 ± 0.15 cells 
per glomerulus; p<0.001; Figure 5.6A-E); this was significantly reduced in KO 
STZ mice (WT STZ vs KO STZ; 0.87 ± 0.53 vs 0.36 ± 0.23 cells per glomerulus; 
p<0.01). A trend towards increased interstitial macrophage accrual was 
observed in WT diabetic mice compared to WT vehicle, but this did not reach 
statistical significance (WT STZ vs WT vehicle; 40.6 ± 38.7 vs 13.3 ± 7.5 cells 
per field; p>0.05; Figure 5.6F) nor was a difference observed between WT 
and KO diabetic animals (WT STZ vs KO STZ; 40.6 ± 38.7 vs 31.3 ± 31.9 cells 
per field; p>0.05). 
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Figure 5.5 Expression of glomerular type IV collagen in murine DN. A-D: Representative
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Figure 5.6 Expression of the macrophage marker CD68 in murine DN. A-D: Representative glomeruli
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Renal cell proliferation was assessed by specific immunohistochemistry for 
Ki-67, a marker of cell proliferation. Very infrequent Ki-67-positive 
interstitial cells were observed in all mice, with no difference between groups 
(data not shown). No signficant glomerular Ki-67 staining was seen in any 
group, suggesting the observed differences in glomerular macrophage 
number were not explained by differences in intra-renal macrophage 
proliferation. 
 
5.2.5 Analysis of mRNA expression of P2X7, inflammasome components, and 
inflammatory and ECM molecules 
 
Gene expression in whole kidney tissue was studied by qPCR. P2X7 
expression was significantly upregulated in WT STZ mice compared to 
vehicle (p<0.01; Figure 5.7A); low level detectable expression in KO animals 
is presumed to represent P2X7K splice variant expression, as the primers 
used did not differentiate between P2X7A and K isoforms (it did not prove 
possible to design specific primers discriminating between the two splice 
variants, that yielded products short enough for efficient amplification by 
qPCR). 
 
No significant upregulation of expression was observed for either pro-IL1β or 
NLRP3, in either WT or KO STZ mice compared to controls (Figure 5.7C and 
D). Expression of the adaptor molecule apoptosis-associated speck-like 
protein containing a caspase recruitment domain (ASC; another component 
of the NLRP3 inflammasome), was elevated in both WT and KO STZ mice 
compared to controls, reaching statistical significance for the latter (p<0.01; 
Figure 5.7B); no difference was observed between WT and KO diabetic 
groups. A similar pattern of results was observed for caspase-1. the 
chemokines MCP-1 and osteopontin, the adhesion molecule ICAM-1, TGFβ, 
and the ECM molecules COL4A1,  
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Figure 5.7 Gene expression in murine DN. A: P2X7; B: ASC; C: NLRP3; D: proIL1β; E:
Caspase-1; F: MCP-1. Outlying values removed from analysis are marked with red circles. .
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COL1A1 and Fibronectin 1 (Figure 5.7E-L). in the case of osteopontin, 
expression was increased in KO STZ mice compared to WT STZ (p<0.05). A 
trend towards  increased expression of ICAM-1 in KO STZ mice was also 
apparent (95% CI of difference: -736 to 3992 copies). Reduced COL1A1 
expression was seen in KO STZ compared to WT STZ (95% CI of difference: 
292 to -2586 copies). 
 
 
5.3 Discussion 
 
In this study, the role of P2X7 in the development of murine DN has been 
examined, by inducing diabetes with low dose STZ in WT and GSK P2X7 KO 
mice. By 12 weeks, early renal injury was apparent in WT mice, with modest 
albuminuria and tubulointerstitial fibrosis; P2X7 deficiency did not impact on 
these core features of DN. At this time-point, P2X7 expression, as assessed by 
immunohistochemistry, was increased in glomeruli of WT diabetic mice 
compared to vehicle-injected controls. A significant reduction in glomerular, 
but not interstitial, macrophage number was observed in P2X7 KO diabetic 
mice compared to WT, suggesting that P2X7 receptor signalling contributes 
to development of early hyperglycaemia-induced glomerular inflammation. 
 
Renal macrophage infiltration is evident as early as 2 weeks after STZ 
injection in mice, and studies interfering with macrophage function (by, for 
instance, disrupting macrophage recruitment signals) have demonstrated 
important downstream effects on albuminuria, glomerular and interstitial 
fibrosis and GFR (Chow et al., 2004b, Chow et al., 2006). Although detailed 
descriptions of macrophage activation state and phenotype in human and 
animal DN are lacking, the net effect of this infiltrate appears to be 
deleterious (Lim and Tesch, 2012). The reduction in glomerular macrophage 
infiltration observed in P2X7-deficient diabetic mice would hence be 
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predicted to portend an improved outcome, although a longer duration of 
study would be required to determine this. 
 
Monocytes constitute a similar overall percentage of the circulating leukocyte 
population in GSK P2X7 KO and WT mice, suggesting reduced glomerular 
macrophage numbers observed in diabetic KO mice do not merely reflect 
global deficiency (Labasi et al., 2002).  While P2X7 has well-defined roles in 
the secretion pathway for macrophage-derived inflammatory cytokines, 
including IL1β and IL18, this, also, does not immediately explain the 
reduction in glomerular macrophages  in diabetic P2X7 KO mice (Surprenant 
et al., 1996). No difference was detected between WT and KO mice in whole 
kidney mRNA expression of the macrophage chemokine, MCP-1, while mRNA 
levels of osteopontin, also involved in macrophage recruitment, and the cell 
adhesion molecule, ICAM-1, were actually elevated in the KO group. Few 
proliferating cells were identified within the kidneys of both WT and KO 
diabetic animals with no difference between groups. 
 
IL1β/IL18 secretion, triggered by P2X7 signalling, is mediated by the NLRP3 
inflammsome, which acts as a capase-1 activation platform. A trend towards 
increased gene expression levels of the NLRP3 inflammasome-associated 
proteins ASC and caspase-1 was seen both in WT and KO diabetic mice. 
Increased expression of NLRP3 mRNA is found in a variety of non-diabetic 
human renal diseases and correlates with renal function (Vilaysane et al., 
2010). Moreover, tubular injury, inflammation and fibrosis is reduced after 
UUO in NLRP3 KO mice, together with maturation of IL1β and IL18 
(Vilaysane et al., 2010). NLRP3 inflammasome components, including NLRP3, 
ASC and caspase-1, are also upregulated in the high-fat diet mouse model of 
metabolic syndrome, although no mature IL1β or IL18 could be detected in 
renal cortex in this study (Solini et al., 2013).  Levels of mature IL1β and IL18 
in the renal cortex were not measured in the current study; while it remains 
possible that differences in maturation and secretion of these cytokines 
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underlie the observed amelioration of glomerular inflammation in P2X7 KO 
mice, the finding that pro-IL1β mRNA was not upregulated by diabetes 
makes this less likely. 
 
Albuminuria represents the earliest clinical manifestation of DN; although 
the mechanisms which lead to initiation of albuminuria have not been fully 
elucidated, VEGF-mediated increases in capillary growth and permeability, 
deleterious endothelial cell-podocyte crosstalk, RAS activation and podocyte 
injury and loss all contribute to this process (Wolf et al., 2005, Yuen et al., 
2012). P2X7 deficiency had no impact on development of early albuminuria 
in this study despite the previous observations that podocyte expression of 
P2X7 increases early in the pathogenesis of STZ-induced diabetes in the rat, 
and P2X7 agonists increase glucose uptake into podocytes in vitro (Vonend et 
al., 2004, Karczewska et al., 2011). While P2X7 does not appear to contribute 
to initiation of albuminuria, a longer period of study would be needed to 
examine its role in progression of glomerular injury to which additional 
factors, including glomerular inflammation, are of importance. A trend 
towards reduced glomerular deposition of type IV collagen, another feature 
of progressive diabetic glomerulopathy, was also apparent in KO mice at 12 
weeks. 
 
The absence of an observed effect of P2X7-deficiency on interstitial fibrosis is 
perhaps surprising in view of previous animal studies, where renal fibrosis 
after UUO was ameliorated in P2X7 KO mice, as was pulmonary fibrosis 
provoked by bleomycin (Goncalves et al., 2006, Riteau et al., 2010). In the 
former study, reduced fibrosis was accompanied by decreased interstitial 
macrophage infiltration and TGFβ expression; interstitial macrophage 
number was not significantly increased in WT diabetic mice compared to 
controls in the present study which may partly explain the lack of efficacy of 
P2X7-deficiency on interstitial fibrosis (Goncalves et al., 2006). 
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Of importance, both previous mouse studies examining the role of P2X7 in 
parenchymal fibrosis were conducted using the Pfizer P2X7 KO mouse, as 
opposed to the GSK mouse which was used in the present study. As described 
in Section 2.3.1, GSK P2X7 knockout mice were generated by disruption of 
exon 1 through insertion of a LacZ gene at the beginning of this region(Sim et 
al., 2004). It has recently been demonstrated that a novel splice variant of 
P2X7 utilising an alternative exon 1 (P2X7K) escapes inactivation in the GSK 
mouse, particularly in spleen lymphocytes (Nicke et al., 2009). This receptor 
is functional, has a greater sensitivity to agonist than the native P2X7A 
receptor and rapidly triggers membrane permeabilisation as measured by 
ethidium bromide uptake assays (Nicke et al., 2009). While a C-terminal 
splice-variant also escapes deletion in the Pfizer KO mouse, this truncated 
receptor has reduced function and acts in a dominant-negative fashion when 
co-expressed with P2X7A, making this mouse a functionally 'more complete' 
P2X7 KO (Masin et al., 2011).  
 
Although attenuated IL1β release has been described in macrophages 
isolated from both GSK and Pfizer mice, conflicting outcomes have been 
reported for the two KO strains in the mouse model of experimental 
auotimmune encephalitis, where disease was exacerbated in GSK mice and 
suppressed in Pfizer mice (Chen and Brosnan, 2006, Sharp et al., 2008). 
Differences in residual receptor expression between the two KO strains may 
explain the absence of an abrogating effect on tubulointerstitial fibrosis and 
increased mRNA expression of osteopontin seen in diabetic KO mice in this 
study, and is supported by the observation that tubular immunostaining for 
P2X7, presumably the P2X7K variant, persists in the GSK KO.  
 
Several other factors may have served to partially mask the full effect of 
P2X7-deficiency in this experiment. In order to test with specificity the 
impact of P2X7-deficiency on the renal consequences of sustained 
hyperglycaemia, it was necessary to exclude a number of mice in which 
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diabetes either failed to develop after STZ injection, became too severe, or 
resolved spontaneously. As described in Chapter 4, the proportion of mice 
developing diabetes by 3 weeks after STZ was reduced in the GSK P2X7 KO 
group (83% WT vs 72% KO). Similarly, the proportion of mice developing 
diabetes of excessive severity over the course of the study was also higher 
among WT animals (33% WT vs 15% KO). Given the finding that P2X7-
deficiency attenuates pancreatic islet injury and macrophage infiltration after 
STZ, it is reasonable to surmise that mice exhibiting more severe pancreatic 
injury, which were selected out, may also have displayed more exaggerated 
renal injury. In addition, although levels of hyperglycaemia were similar 
overall between WT and P2X7 KO mice selected for study, levels were 
significantly higher in KO animals at one measurement time-point (week 9). 
 
In summary, genetic deficiency of P2X7 imparts a marked amelioration of 
glomerular inflammation at 12 weeks after induction of diabetes with low 
dose STZ in the mouse. In combination with established treatments to 
diminish hyperglycaemia and inhibit RAS activation, targeting of P2X7 
signalling may represent an avenue by which to interrupt innate immune 
system activation in human DN and attenuate disease. 
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CHAPTER 6 
 
Investigating the role of P2X7 in diabetic 
nephropathy using  a uninephrectomised diabetic rat 
model 
 
 
6.1 Introduction 
 
In parallel to conducting experiments in STZ-diabetic mice, we chose to study 
P2X7 in a rat model of DN, again using STZ to induce diabetes. This was 
motivated both by the previous observation that P2X7 is upregulated in the 
glomerulus at an early time-point in this model, and the opportunity to test 
the effect of a selective antagonist to the P2X7 receptor, for which there are 
none currently suitable for use in the mouse (Vonend et al., 2004). We 
selected the STZ model in light of its well-characterised phenotype, primacy 
of hyperglycaemia as a driver of nephropathy, and to facilitate comparison 
with the corresponding mouse experiments. 
 
Pilot experiments revealed that STZ-induced diabetes alone produced 
inadequate evidence of renal injury necessitating the addition of a 
uninephrectomy (UNx) to accelerate disease. Using this model, a selective 
P2X7 antagonist was administered twice daily by the IP route between weeks 
8 and 12 after injection of STZ, to examine the effect on development of DN 
and, in particular, activation of the innate immune system. 
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6.2 Results 
 
6.2.1 Model optimisation 
 
Initial experiments focussed on establishing an in-house diabetic rat model 
which was both reproducible and manifested sufficient evidence of 
nephropathy to permit testing of a selective P2X7 antagonist. 
 
 
6.2.1.i STZ-induced diabetes in male Sprague-Dawley rats 
 
Male Sprague-Dawley rats weighing 200-250g (n=5/group) were 
administered a single IV dose of STZ (50mg/kg) or vehicle and followed for 
21 weeks with periodic urine collection for measurement of albuminuria as a 
marker of nephropathy. Despite persistent hyperglycaemia in the STZ-
treated group, no significant excess of albuminuria was apparent in the 
diabetic group by 21 weeks (Figure 6.1A and B). 
 
 
6.2.1.ii STZ-induced diabetes combined with right uninephrectomy in Wistar 
Han rats 
 
In order to promote more rapid development of nephropathy, rats 
underwent uninephrectomy (UNx) one week before administration of STZ. A 
different, nephropathy susceptible rat strain, the Wistar Han, was used to 
correspond with an established protocol (Dr Tim Johnson, Sheffield Kidney 
Institute, personal communication). Wistar Han rats proved more sensitive to 
the effect of STZ than Sprague Dawley, and an initial dose finding study  
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Albumin excretion (mg/hr)
Week 0 Week 4 Week 8 Week 12
Unx/Vehicle 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.00
Unx/STZ 0.02 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.09 ± 0.03
P value 0.5 0.03 0.02 0.002
Figure 6.1 Optimisation of a rat model of diabetic nephropathy. A,B: STZ-induced diabetes in
male Sprague Dawley rats (n=5/group) C,D,E: STZ-induced diabetes in uninephrectomised Wistar
Han rats (vehicle group n=4, diabetic group n=3). A: Mean blood glucose over 21 weeks. STZ-
injected animals developed marked and sustained hyperglycaemia. B: Albumin:creatinine ratio. No
increase in albuminuria was observed by 21 weeks. C: Mean blood glucose over 12 weeks. D:
Albumin excretion over the course of 12 week experiment. A significant excess of albuminuria was
present as early as 4 weeks with a further increase by 12 weeks. E: Albumin excretion rate
(mg/hr) at each collection time-point, corresponding to graph D. *: p<0.05; **: p<0.01; ***:
p<0.001; NS: Not significant.
A B
C D
E
Ve
hi
cl
e
ST
Z
Ve
hi
cl
e
ST
Z
Ve
hi
cl
e
ST
Z
Ve
hi
cl
e
ST
Z
0.000
0.025
0.050
0.075
0.100
0.125
A
lb
u
m
in
 e
x
c
re
ti
o
n
 (
m
g
/h
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
established 40mg/kg IV as an effective but sub-lethal dose for induction of 
diabetes. Uninephrectomised male rats weighing 200-250g (n=4/group) 
were followed for 12 weeks after STZ or vehicle injection with 4 weekly urine 
collection for measurement of albuminuria and terminal collection of kidney 
tissue. 
 
One STZ-injected rat spontaneously reverted to normoglycaemia 2 weeks 
post-injection and was excluded from further analysis; hyperglycaemia was 
maintained throughout in the remaining 3 diabetic animals (Figure 6.1C). A 
significant excess of albuminuria was apparent by 4 weeks in the diabetic 
group, with a further marked increase by week 12 (figure 6.1D and E). No 
increase in albuminuria was apparent in vehicle-injected uninephrectomised 
rats compared to baseline pre-nephrectomy values by 12 weeks. The 
increase in albuminuria by week 4 in diabetic animals was replicated in a 
second pilot experiment (data not shown). 
 
 
6.2.2 P2X7 is constitutively expressed in rat distal convoluted tubule and 
upregulated in the glomerulus with diabetes 
 
P2X7 expression was assessed on rat kidney tissue by 
immunohistochemistry using a rabbit polyclonal antibody to P2X7. 
Prominent tubular staining was observed in kidney from all animals tested: 
UNx diabetic rats, UNx control rats, and normal kidney obtained at the time 
of nephrectomy (Figure 6.2A and B). The stained tubules appeared most 
compatible with distal convoluted tubule (DCT), in view of their relatively 
‘open’ appearance (low cuboidal epithelium); staining appeared to be 
localised predominantly to the basolateral epithelial area. Adjacent sections 
were subsequently stained for P2X7 and Calbindin D-28K, a protein involved  
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in calcium transport along the rat DCT, with perfect correspondence of 
labelling (Figure 6.2C and D) (Rizzo et al., 2004). No significant glomerular 
P2X7 staining was observed in normal kidney or kidney from UNx control 
animals. Diffuse capillary loop staining was present in the majority of 
glomeruli in all diabetic animals examined (Figure 6.2E and Figure 6.3). 
 
 
6.2.3 Testing the effect of a selective P2X7 antagonist on evolution of diabetic 
nephropathy 
 
Once a reproducible model of DN had been established, the effect of a 
selective P2X7 antagonist, AZ11657312, was tested on evolution of disease. 
Diabetes was induced with STZ and maintained for 8 weeks before 
administering either drug (at 50mg/kg or 10mg/kg doses) or vehicle IP twice 
daily between weeks 8 and 12. Previously collected pharmacokinetic data has 
demonstrated AZ11657312 to be a high-clearance compound, with doses 
greater than 30mg/kg bd required in rats to maintain plasma levels above 
the 10x pA2 value indicative of adequate exposure (AstraZeneca, unpublished 
data). Urine, serum and kidney tissue were collected for analysis at the end of 
the experiment. 
 
 
6.2.4 Selective antagonism of P2X7 does not impact on progression of 
albuminuria or renal impairment in early experimental DN 
 
Physical and biochemical data at baseline and week 12 is summarised in 
Table 6.1. BG was carefully controlled in diabetic animals by insertion of SC 
insulin pellets to gate BG between 16-33.3 mmol/l; the profile of glycaemic 
control was similar between all 3 diabetic groups (Figure 6.4A). Similarly, 
mean BG and total insulin dose did not differ between diabetic groups  
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A B
C D
Figure 6.3 Immunohistochemistry for P2X7 in rat glomerulus. A: Glomerulus from normal
Wistar Han rat (nephrectomy specimen), negative for P2X7. B: Glomerulus from STZ-injected UNx
rat showing diffuse capillary loop staining not evident in controls rats C: Kidney from an STZ-
injected rat incubated with anti-P2X7 antibody after pre-absorbing with its cognate peptide; no
staining was seen, demonstrating the target specificity of the antibody. D: STZ-injected rat kidney
incubated with non-immune polyclonal rabbit IgG applied at the same concentration as the
primary antibody. The absence of staining excludes non-specific antigen-independent
interactions of immunoglobulin with the tissue. (x200 magnification)
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Sham/ 
Vehicle
(n=8)
UNx/ 
Vehicle
(n=8)
UNX/STZ/ 
Drug vehicle
(n=8)
UN X/STZ/ 
10mg/kg
(n=8)
UNx/STZ/ 
50 mg/kg
(n=9)
Wk 0 weight 
(g)
223.8 ± 12.5 218.8 ± 17.2 217.2 ± 13.3 215.3 ± 7.4 224.4 ± 10.3
% Weight 
gain (Wk 0 to 
Wk12)
84.0 ± 15.8 84.9 ± 18.7 18.5 ± 8.6a,b 23.3 ± 6.1 25.0 ± 10.8
Wk 0 BG
(mmol/l)
4.8 ± 0.8 5.8 ± 0.8 5.1 ± 0.6 5.7 ± 1.5 6.0 ± 1.1
Mean BG
(mmol/l)
4.6 ± 0.7 4.9 ± 0.6 30.6 ± 0.9a,b 30.7 ± 0.9 29.7 ± 1.4
Mean no. 
insulin
pellets
N/A N/A 3.0 ± 1.5 3.6 ± 1.3 3.9 ± 1.5
Kidney 
weight : 
body weight
(mg/kg)
2.70 ± 0.29 3.95 ± 0.23c 8.17 ± 0.85a,b 7.88  ± 0.89 7.24 ± 0.98
Wk 12 AER
(mg/hr) *
8.9 ± 2.3 16.0 ± 9.3 50.2 ± 20.3d 42.5 ± 17.9 82.3 ± 50.3
Wk 12 
Serum 
Creatinine
(μmol/l)
43.7 ± 4.4 48.9 ± 3.3 66.5 ± 5.6a,b 71.0 ± 9.1 64.7 ± 7.4
Table 6.1 Summary of physical and biochemical data for rat P2X7 antagonist DN study. a:
p<0.001 vs sham/ vehicle; b: p<0.001 vs UNx/vehicle; c: p<0.01 vs sham/vehicle d: p<0.05 vs
sham/vehicle. *Data presented with outlying values removed, leaving final group numbers:
sham/vehicle n=8, Unx/vehicle n=8, Unx/STZ/drug vehicle n=7, Unx/STZ/AZ11657312 10mg/kg
n=6, Unx/STZ/AZ11657312 50mg/kg n=9.
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(FIgure 6.4B). While urine albumin excretion increased progressively from 
week 4 in diabetic animals, no significant difference was apparent between 
either drug-treated group and drug vehicle group at week 12 (Figure 6.4C). 
Serum creatinine was also elevated in diabetic animals compared to both 
sham-operated and UNx control groups, but did not differ between the three 
diabetic groups (Figure 6.4D). 
 
Kidney weight : body weight (KW:BW) was increased in UNx/STZ rats 2.1x 
compared to UNx/controls (p<0.001) and 3x compared to sham/controls 
(p<0.001) (Figure 6.4E). A stepwise trend towards decreased KW:BW was 
seen in antagonist-treated rats (mean reduction 50mg/kg vs drug vehicle 
groups, 0.933, 95% CI, -0.01 to 1.88). No significant difference in glomerular 
area was observed among any of the groups studied. No significant 
interstitial fibrosis was present at 12 weeks in any diabetic or control group 
as assessed by picrosirius red staining (Data not shown). 
 
6.2.5 Analysis of renal macrophage accumulation 
 
Macrophage infiltration was assessed by immunohistochemistry for CD68 
and quantified for glomerular and tubulointerstitial compartments (Figure 
6.5). Interstitial macrophage number was significantly increased in diabetic 
UNx rats compared to both sham-operated and UNx controls (p<0.05 for both 
comparisons) (Figure 6.5A-E). A trend towards reduced interstitial 
macrophage number was seen in 50 mg/kg (95% CI for difference: 1.5 to -
15.9 cells per field) but not 10 mg/kg (95% CI for difference: 11.3 to -6.1 cells 
per field) P2X7 antagonist-treated rats compared to the drug vehicle group. 
Macrophage number was significantly reduced in 50mg/kg compared to 
10mg/kg antagonist-treated rats (p<0.05). Glomerular macrophage number 
was not increased in diabetic rats compared to controls, and was similar 
across all 5 groups (Figure 6.5F). 
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A B
C D
*
*
*
E F
Figure 6.5 Assessment of macrophage infiltration by immunohistochemistry for CD68 (ED-1). A-D:
Representative images of the tubulointerstitium (x200 magnification). A: Sham/vehicle-treated rat
kidney with minimal macrophage infiltration apparent. B: UNx/STZ/drug vehicle-treated diabetic rat
kidney with interstitial macrophage accumulation (arrows). C: Unx/STZ rat treated with 10mg/kg P2X7
antagonist; appearance was similar to rats treated with drug vehicle. D: 50mg/kg P2X7 antagonist-
treated rat kidney; interstitial macrophage accumulation was attenuated in the majority of animals. E:
Quantification of interstitial macrophage infiltration. F: Quantification of glomerular macrophage
infiltration. *: p<0.05.
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6.2.6 Analysis of mRNA expression of P2X7,  inflammatory and ECM 
molecules 
 
mRNA expression of P2X7, pro-fibrotic and inflammatory cytokines and ECM 
molecules was examined in homogenised whole kidney tissue by qPCR. 
(Table 6.2) P2X7 was upregulated significantly in UNx/STZ rats compared to 
sham/vehicle controls (p<0.05), with an trend towards increased expression 
compared to UNx/vehicle animals. (Figure 6.6A) A step-wise trend towards 
reduced  P2X7 expression was seen in 10mg/kg (mean reduction vs UNx/STZ 
4228 copies, 95% CI -7110 to 15570) and 50mg/kg (mean reduction 6649 
copies, 95% CI -4369 to 17670) P2X7 antagonist-treated rats. 
 
No significant upregulation of expression was observed in UNx/STZ rats 
compared to controls for TGFβ, COL4A1, COL1A1 or fibronectin-1, with 
expression similar across all groups for these mRNAs. pro-IL1β and MCP-1 
expression was also similar across all 5 groups.  
 
Expression of the macrophage chemokine, osteopontin, was increased 
significantly in UNx/STZ rats compared to both non-diabetic groups (Figure 
6.6B). A trend towards reduced expression was observed in 10mg/kg 
antagonist-treated rats (mean reduction vs UNx/STZ 110,100 copies, 95% CI 
-24170 to 244300), while expression in the 50mg/kg treated group did not 
differ from drug vehicle. Expression of the cell adhesion molecule, ICAM-1, 
was also significantly elevated in UNx/STZ rats compared to sham/vehicle 
(p<0.01), with an upward trend compared to UNx/vehicle (mean increase 
1385 copies, 95% CI -162.5 to 2933) (Figure 6.6C). The pattern of ICAM-1 
expression observed in P2X7 antagonist-treated rats appeared the inverse of 
that for osteopontin, with a trend towards increased expression in the 
10mg/kg group (mean increase vs UNx/STZ 958 copies, 95% CI -590 to 
2505) and no difference in 50mg/kg group compared to UNx/STZ. 
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Figure 6.6. qPCR data from rat P2X7 antagonist experiment. A: P2X7, B:
Osteopontin. C: ICAM-1. Circled datapoints represent outlying values excluded from
analysis. *: p<0.05; **: p<0.01; ***: p<0.001.
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6.2.7 P2X7 is upregulated in both glomeruli and peri-tubular capillaries at 12 
weeks in a rat model of lean type 2 diabetes 
 
The Goto-Kakasaki rat represents a model of lean type 2 diabetes, 
accompanied by mild and slowly evolving DN, and is discussed in Section 
1.10.3.a.  P2X7 expression was examined by specific immunohistochemistry 
in 12 week old GK rats and age-matched Wistar controls (Figure 6.7). Distal 
tubular P2X7 expression was observed as previously in control animals, with 
minimal glomerular staining (Figure 6.7A and C). In addition to tubular 
staining, GK rats exhibited diffuse capillary loop P2X7 positivity, similar to 
that observed at 12 weeks after STZ, as well as marked staining of peri-
tubular capillaries (Figure 6.7B, D and E). A trend towards increased P2X7 
mRNA expression was seen in GK rat kidney compared to Wistar control 
kidney (Figure 6.7G). 
 
 
6.3 Discussion 
 
In this experiment, it was sought to test the effect of a selective P2X7 
antagonist on the evolution of nephropathy in the uninephrectomised STZ rat 
model of diabetes. At 12 weeks, this model manifests early DN, with evidence 
of renal enlargement and increased albumin excretion compared to sham-
operated and single kidney controls, but no glomerular hypertrophy, 
mesangial expansion, interstitial fibrosis or transcriptional upregulation of 
ECM proteins. While P2X7 expression is upregulated in the diabetic 
glomerulus at 12 weeks, inhibition with a selective receptor antagonist 
between weeks 8 and 12 did not modify urinary albumin excretion or final 
serum creatinine. With the higher, 50mg/kg twice-daily antagonist dose, a 
trend towards reduced interstitial macrophage accumulation and KW:BW 
was observed. 
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AZ11657312 is a highly potent, competitive antagonist at the P2X7 receptor. 
It was selected from a small molecule drug discovery program, where 
compounds were screened for inhibitory activity against BzATP-induced 
pore formation in HEK cells stably transfected with human or rodent P2X7 
receptors. In vivo efficacy has previously been demonstrated, at a dose of 30-
60mg/kg bd, on ankle swelling and mechanical hyperalgesia in the 
streptococcal cell wall (SCW) rat model of rheumatoid arthritis, and on 
development of interstitial fibrosis in the rat UUO model (AstraZeneca, 
unpublished data). Although AZ11657312 is absorbed orally, IP dosing was 
chosen to maximise bioavailability, with doses separated by ~10-14 hours. 
The chosen dosing schedule, between week 8, when a separation in albumin 
excretion between diabetic animals and controls has become clearly evident, 
and week 12, has relevance to management of human diabetes, where 
therapy is typically only commenced after signs of DN have become apparent. 
 
The observed lack of impact of P2X7 blockade on albumin excretion is 
consistent with the experimental findings in GSK P2X7 KO mice and suggests 
that P2X7 does not contribute mechanistically to the early development of 
albuminuria. This is despite upregulation of P2X7 expression in the 
glomerulus at 12 weeks in both mice and rats with STZ-induced diabetes, and 
also GK lean type 2 diabetic rats. Although not formally co-localised, the 
pattern of glomerular P2X7 immunostaining is strongly suggestive of an 
endothelial cell locus of expression as the pattern is reminiscent of that 
observed with the endothelial cell marker CD31, and not the podocyte 
antigen, WT-1 (Pusztaszeri et al., 2006, Siu et al., 2006). While this expression 
does not appear to directly impact on the integrity of the glomerular 
filtration barrier by week 12, it is conceivable that inducible P2X7 expression 
may contribute to subsequent glomerular inflammation and disease 
progression, as occurs in diabetic mice. A longer duration of treatment with 
the receptor antagonist would be required to test this hypothesis. 
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Interstitial, but not glomerular, macrophage infiltration was observed in 
diabetic rats by 12 week, and a trend towards reduced macrophage numbers 
was observed in 50mg/kg antagonist-treated animals. mRNA for MCP-1, an 
important chemokine regulating glomerular macrophage recruitment, was 
not elevated, consistent with the lack of macrophages in this compartment. 
mRNA for osteopontin, important in co-ordination of interstitial macrophage 
migration, was upregulated in diabetic rats, with a trend towards reduced 
mRNA levels evident in 10mg/kg antagonist-treated animals. A trend 
towards increased expression of ICAM-1 mRNA, important in leucocyte 
adhesion, was also observed in 10mg/kg antagonist-treated rats, and may 
represent a reciprocal compensatory phenomenon. These findings are 
comparable to those seen in P2X7 KO mice, where glomerular macrophage 
infiltration was suppressed compared to WT. Although no significant 
interstitial fibrosis was apparent by 12 weeks in diabetic rats, one may 
predict that a reduction in interstitial macrophage infiltration may portend 
milder disease, were later time-points to be assessed (Chow et al., 2004b). 
 
In summary, this study suggests, but does not conclusively prove, that 
inhibition of P2X7 by administration of a selective receptor antagonist 
ameliorates the interstitial inflammatory response observed in early DN in 
the rat. While longer-term studies are required to confirm efficacy against 
progressive disease, these data provide encouragement for the development 
of P2X7 antagonists as an adjunct to current standard therapy in human 
diabetic disease. 
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CHAPTER 7 
 
Investigating the effects of diabetic and purinergic 
stimuli on P2X7 expression and MCP-1 secretion by 
resident glomerular cells in vitro 
 
 
7.1 Introduction 
 
Diabetic nephropathy (DN) is primarily characterised by its glomerular 
phenotype, histologically comprising GBM thickening and progressive 
mesangial sclerosis and manifesting clinically as proteinuria (Tervaert et al., 
2010). All resident glomerular cell types are affected by the prevailing 
metabolic and haemodynamic disturbances: podocyte injury and loss occurs 
early, denuding areas of the GBM and provoking architectural disturbance in 
neighbouring epithelial cells; endothelial cells show swelling and thinning of 
the glycocalyx; and mesangial cells proliferate and elaborate excessive 
extracellular matrix (ECM) components (Gnudi, 2012). An early and 
prominent influx of macrophages into glomeruli is observed in experimental 
DN as early as day 3, preceding classical histological changes and preventable 
with insulin (Young et al., 1995). Interrupting this macrophage accumulation, 
either by depletion or interfering with critical adhesion molecules or 
chemokine signals, has been shown to attenuate glomerular injury, proving a 
critical role for this cell type in the evolution of DN (Lim and Tesch, 2012). 
 
Although numerous inflammatory molecules have been linked to renal 
leukocyte recruitment in DN (reviewed in Chapter 1), the chemokine MCP-1 
currently has the strongest evidence for an important functional role (Chow 
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et al., 2006, Lim and Tesch, 2012). MCP-1 is synthesised by all resident 
glomerular cell types as well as mononuclear cells (Kim and Tam, 2011). 
Hyperglycaemia induces an upregulation of MCP-1 protein production and 
release in both mesangial cells and podocytes in vitro (Ihm et al., 1998, Han et 
al., 2004). In addition to its role as a chemoattractant, MCP-1 has been 
demonstrated to mediate effects on podocyte mobility and albumin 
permeability, podocyte apoptosis and mesangial cell synthesis of ECM 
proteins, potentially positioning it as a central player in the pathogenesis of 
diabetic glomerulopathy (Park et al., 2008, Lee et al., 2009, Nam et al., 2012). 
 
Previous studies of P2X7 in DN have demonstrated upregulation of mRNA 
and protein in all glomerular cell types, although predominantly the 
podocyte, at an early stage of disease development (Vonend et al., 2004). 
P2X7 has also been directly linked to the synthesis of ECM proteins in rat 
podocytes cultured under hyperglycaemic conditions in vitro (Solini et al., 
2005). When studied in experimental nephrotoxic nephritis, a model of 
inflammatory glomerular disease, genetic P2X7 deficiency or inhibition 
markedly reduced the influx of macrophages into glomeruli and almost 
entirely abolished urinary excretion of MCP-1 (Taylor et al., 2009). When 
studied in astrocytes and microglia, application of the P2X7 agonist BzATP 
resulted in increased expression of MCP-1 (Panenka et al., 2001, Fang et al., 
2011). 
 
In view of these observations together with data from my experiments using 
the GSK P2X7 KO mouse (Chapter 5), showing a reduction in glomerular 
macrophage infiltration after induction of diabetes with STZ compared to WT 
animals, it was hypothesised that the diabetic milieu may upregulate P2X7 
expression in glomerular cells and provoke a consequent increase in MCP-1 
release.  Hence to test this hypothesis, it was chosen to study the effect of 
hyperglycaemia on P2X7 expression and MCP-1 secretion from both human 
podocytes and mesangial cells in vitro. 
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7.2 Results 
 
7.2.1 Characterisation of podocytes 
 
Conditionally-immortalised human podocytes (a gift of Prof. Moin Saleem) 
were allowed to proliferate at 33oC in a medium approximating human 
euglycaemia (4mM D-glucose). Cells were then transferred to 37oC for 2 
weeks to inactivate the temperature-sensitive SV40 T transgene and trigger 
subsequent differentiation to a mature form.  Efforts were made to 
characterise the differentiated cells prior to further study to ensure they 
were adequately recapitulating the anticipated mature phenotype. 
 
Cells grown at 33oC showed a cobblestone morphology (typical for epithelial 
cells) but after transfer to 37oC and arrest of proliferation underwent a 
gradual change in appearance with irregular enlargement of the cell body 
and appearance of long spindle-like cytoplasmic processes (Figure 7.1). The 
majority of cells underwent these changes, consistent with the original 
published report of their behaviour, although occasional small rafts of 
undifferentiated cells were observed. (Saleem et al., 2002) Expression of the 
slit-diaphragm protein nephrin was confirmed in mature cells by specific 
immunofluorescence: a diffuse cytoplasmic staining pattern was observed in 
differentiated cells as opposed to a peri-nuclear distribution in proliferating 
cells, suggesting cellular redistribution of the protein during the maturation 
process. Podocin was also examined by specific immunofluorescence and 
showed an increase in cytoplasmic staining intensity during the maturation 
process although unexpected nuclear staining was also prominent at all time-
points. Expression of SV40 large T antigen was examined by Western blot; 
expression level appeared unchanged across all-time points examined 
suggesting incomplete inactivation of the transgene by temperature 
modulation. 
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7.2.2 Secretion of MCP-1 from human podocytes exposed to hyperglycaemia 
is inconsistent between experiments 
 
The capacity of mature podocytes to secrete MCP-1 was first tested by 
stimulating them with the inflammatory cytokine TNFα (10 ng/ml) for 48 
hours. TNFα provoked a 5-fold rise in MCP-1 secretion, as measured in 
conditioned media by specific ELISA, compared to unstimulated cells. (Figure 
7.2A) Fully differentiated podocytes were subsequently cultured for 48 hours 
in hyperglycaemic (30mM D-glucose) or euglycaemic (4mM) media, or with 
an osmotically equivalent concentration of the metabolically inactive 
stereoisomer L-glucose (26mM L-glucose + 4mM D-glucose). Although an 
increase in MCP-1 secretion was observed with hyperglycaemia, the 
magnitude of the response was variable between experiments (Figure 
7.2B,C), as was the proportion of non-adherent cells observed at the point of 
supernatant collection. No significant increase in MCP-1 was observed after 
culture in 30mM D-glucose for 96 hours, while MCP-1 secretion from cells 
incubated with L-glucose was significantly reduced compared to 4mM D-
glucose controls by this time (Figure 7.2D).  
 
A single experiment was performed with the selective P2X7 antagonist 
A438079 (10µM)  added to cultures with or without hyperglycaemic medium 
for 48 hours (Figure 7.2E). A significant increase in MCP-1 release was 
observed in the presence of A438079 from cells grown in both 4mM D-
glucose and 30mM D-glucose, although hyperglycaemia alone did not 
increase MCP-1 levels compared to euglycaemia in this experiment. A438079 
did not influence the secretion of MCP-1 induced by culture with TNFα for 48 
hours (Figure 7.2F). 
 
In view of the difficulties in establishing a reproducible response of the 
podocytes to hyperglycaemic challenge in terms of MCP-1 secretion, no  
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Figure 7.2 Podocyte MCP-1 secretion under hyperglycaemic and inflammatory stress. A:
Stimulation with TNFα (10ng/ml) for 48 hours provoked a 5-fold rise in MCP-1 secretion compared to
basal 4mM D-glucose conditions. B,C: Two illustrative experiments of stimulation with 30mM D-glucose
or osmotic control for 48 hours showing the observed increase in MCP-1 secretion was inconsistent in
magnitude. D: No excess of MCP-1 was observed when cells were cultured in 30mM D-glucose for 96
hours although MCP-1 secretion was reduced from cells cultured in L-glucose compared to 4mM D-
glucose controls. E: A438079 (10µM) provoked a rise in MCP-1 secretion under both normal and high
glucose conditions, although hyperglycaemia itself did not increase secretion in this experiment. F:
A438079 (10µM) had no effect on the increased MCP-1 secretion provoked by TNFα (10ng/ml). N=3-
4/group in all experiments. D: D-glucose; L: L-glucose. *: p<0.05; ***: p<0.001; NS: Not significant.
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further investigations were undertaken of the role of the P2X7 receptor in 
this cell line. 
 
 
7.2.3 Secretion of MCP-1 from transformed human mesangial cells exposed to 
hyperglycaemia is inconsistent between experiments 
 
A transformed human mesangial cell line (tHMC) was available (see Section 
2.16.2.i) which had been used with success locally for other applications, 
hence initial studies of the mesangial MCP-1 response to hyperglycaemia 
were performed using these. In the same manner as for podocytes, an initial 
stimulation was performed with TNFα to confirm whether tHMC secrete 
MCP-1 in respone to a robust inflammatory stimulus. TNFα provoked an 8-
fold rise in MCP-1 secretion compared to unstimulated cells (Figure 7.3A). As 
with the podocyte line, mesangial cells were then incubated for 48 hours in 
high or low glucose or L-glucose as an osmotic control. Over four 
experiments the magnitude of MCP-1 response to hyperglycaemia proved 
highly variable (Figure 7.3B). In those experiments where a significant 
increase in secretion in response to hyperglycaemia was observed, no 
difference was seen as compared to the L-glucose control, suggesting any 
such effect was a direct consequence of changes in tonicity of the culture 
milieu. For these reasons, no further investigations were undertaken with 
this cell line. 
 
 
7.2.4 Hyperglycaemia induces a reproducible rise in MCP-1 secretion, but not 
IL1β, from primary human mesangial cells, independent of its osmotic effect 
 
In view of the inconsistent response to hyperglycaemia observed with 
transformed mesangial cells, further experiments were undertaken with  
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Figure 7.3 MCP-1 secretion from transformed and primary HMCs under hyperglycaemic and
inflammatory stress. A: Stimulation of transformed HMCs with TNFα (10ng/ml) for 48 hours provoked
an 8-fold rise in MCP-1 secretion compared to basal glycaemic conditions alone. B: A representative trial
of MCP-1 secretion from transformed HMCs under hyperglycaemic conditions. The rise in MCP-1
secretion in response to hyperglycaemia was variable and when present, did not differ from the effect of
the osmotic control. C: Stimulation of primary HMCs with TNFα (10ng/ml) for 48 hours provoked a 90-
fold rise in MCP-1 secretion compared to basal glycaemic conditions alone. D: Culture of primary HMCs in
30 mM D-glucose provoked a robust increase in MCP-1 secretion that was not reproduced by an
equivalent concentration of L-glucose, suggesting the response was independent of the hypertonic effect
of hyperglycaemia. N= 3-4/group in all experiments. ***: p<0.001; NS: Not significant.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
220 
 
commercially-available human primary mesangial cells (pHMC). The ability 
of these cells to secrete MCP-1 when exposed to a robust inflammatory 
cytokine stimulus (TNFα 10ng/ml) was again assessed. TNFα provoked a 90-
fold rise in MCP-1 secretion compared to unstimulated cells. (Figure 7.3C). 
On incubation of cells with 30mM D-glucose for 48 hours, in all experiments a 
rise in MCP-1 of 25-50% was observed compared to cells grown in 4mM D-
glucose (Figure 7.3D). No rise in MCP-1 was elicited with an osmotically 
equivalent concentration of L-glucose. 
 
To ascertain whether pHMCs are capable of significant IL1β release, cells 
were exposed to TNFα 10ng/ml for 48 hours and IL1β was measured in 
supernatant by specific ELISA. No IL1β was detectable in supernatants from 
either TNFα stimulated or unstimulated cells. In a single experiment, IL1β 
was also undetectable after cells were cultured in either 30mM D-glucose or 
an osmotically equivalent concentration of L-glucose for 48 hours. 
 
Given the importance of ATP as a stimulus for IL1β maturation and release 
from macrophages, IL1β was also measured in pHMC supernatants in a single 
experiment following 30 minutes exposure to 5mM ATP, after pre-culture in 
either 4mM or 30mM D-glucose media or 4mM D-glucose media 
supplemented with TNFα (10ng/ml) for 48 hours. Again, no IL1β was 
detectable in cell culture supernatants of any group. pHMC hence do not 
appear capable of significant mature IL1β secretion under the culture 
conditions used in this study.  
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7.2.5 P2X7 is constitutively expressed in pHMC with cellular redistribution 
on exposure to hyperglycaemia 
 
P2X7 expression in pHMC was examined using Western blotting of cell 
lysates and specific immunofluorescence staining of fixed cells. Using a 
monoclonal anti-P2X7 primary antibody, a band of the anticipated molecular 
weight (72kD) was observed in lysates from cells grown for 48 hours in both 
4mM and 30mM D-glucose media (Figure 7.4A). A trend towards increased 
P2X7 expression, as quantified by band densitometry, was apparent in cells 
grown under hyperglycaemic conditions (Figure 7.4B) P2X7 was also present 
but not upregulated in cells stimulated with TNFα 10ng/ml (data not shown). 
 
Intensity of cytoplasmic staining for P2X7 by immunofluorescence (using the 
same monoclonal anti-P2X7 antibody) appeared greater in cells cultured in a 
hyperglycaemic milieu than low glucose conditions (Figure 7.4C,D). 
Occasional peripheral ring-like figures, presumed to represent coalescence of 
P2X7 molecules into pore-like structures were also observed (Figure 7.4E), 
as have been described elsewhere, suggesting that hyperglycaemia can 
provoke cellular redistribution of the pre-formed protein (Solini et al., 2005). 
 
 
7.2.6 P2X7 contributes to regulation of MCP-1 secretion from pHMC exposed 
to hyperglycaemia 
 
The effect of a small molecule selective P2X7 antagonist, A438079, on MCP-1 
secretion from pHMC exposed to hyperglycaemia was tested. At 10µM 
concentration, A438079 reduced hyperglycaemia-induced MCP-1 secretion 
by 43.9 ± 61.0% aggregated over 9 separate experiments (p=0.057; paired t-
test), although some variability in response was observed between 
experiments. (Figure 7.5A,B). This effect was sustained across the range of  
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Figure 7.4 P2X7 expression in primary HMCs. A,B: Specific immunoblot for P2X7 with an actin loading
control (A) and P2X7 expression quantified by densitometry (B). P2X7 was expressed under basal culture
conditions, with a trend towards upregulated expression after culture in hyperglycaemic medium. C,D,E:
Specific immunofluorescence for P2X7. C: P2X7 expression under basal glucose conditions. D: P2X7
expression under hyperglycaemic conditions. Intensity of cytoplasmic staining for P2X7 appeared
increased under high glucose conditions with an increased incidence of organised peripheral ring-like
structures (E, arrow).
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Figure 7.5 P2X7 contributes to regulation of hyperglycaemia-induced MCP-1 secretion from
primary HMCs. A,B,C: Effect of the small molecule selective P2X7 antagonist A438079 on
hyperglycaemia-induced MCP-1 release. A: An example of an experiment where A438079 (10µM) was
added to cells grown either in 4mM or 30mmM D-glucose or L-glucose as an osmotic control. In this
instance, A438079 suppressed hyperglycaemia-induced MCP-1 release to basal levels. B: Over 9
independent experiments, an average reduction in MCP-1 secretion of 43.9 ± 61.0% was observed, with
inhibition observed in 6/9 trials and no effect or increased secretion in 3/9. C: No apparent dose-
dependence was seen over a range of concentrations of A438079 from 5 to 50 µM, with all proving
equally effective (all comparisons to 30mM D-glucose group). D: Assessment of A438079 cytotoxicity
using MTS assay. A438079 had no effect on cell viability as assessed over the 5 to 50µM concentration
range. E: Effect of A438079 on TNFα-induced MCP-1 release. A438079 (10 µM) partially inhibited TNFα
stimulated MCP-1 release (18.6 ± 3.0% reduction). F: The P2X7 agonist BzATP (100µM) provoked an
additive increase in MCP-1 secretion under high glucose, but not low glucose, conditions. N=3-4/group D:
D-glucose; L: L-glucose. *: p<0.05; **: p<0.01; ***: p<0.001; NS: Not significant.
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concentrations of A438079 tested (5-50μM) (Figure 7.5C).  A438079 also 
produced a proportionally smaller but significant reduction in MCP-1 
secretion after stimulation with TNFα 10 ng/ml (18.6 ± 3.0% reduction 
compared to TNFα alone) (Figure 7.5E). No evidence of cytotoxicity was 
observed with A438079, as measured by MTS assay, over a range of 
concentrations from 5 to 50 µM (Figure 7.5D). The P2X7 agonist BzATP had 
no effect on MCP-1 secretion when added to cells incubated in 4mM D-
glucose, but provoked a significant additive increase in MCP-1 secretion 
when applied to cells incubated in 30mM D-glucose (114.1% increase 
compared to baseline vs 30mM D-glucose alone, p<0.05, pooled data from 
two trials) (Figure 7.5F). 
 
 
7.2.7 The ATP-hydrolysing enzyme apyrase enhances MCP-1 secretion from 
pHMC. 
 
Apyrase efficiently hydrolyses ATP to yield AMP and inorganic phosphate. 
ATP is the dominant agonist of P2X7 and indeed all P2X family receptors. 
Given the observed partial P2X7-dependence of pHMC MCP-1 secretion, 
apyrase was added to cultures in the expectation that MCP-1 secretion would 
be attenuated as agonist at the P2X7 receptor (ATP) would be degraded. 
 
Addition of apyrase (5 U/ml) to cultures led to an increase in MCP-1 
secretion, most marked under hyperglycaemic conditions (78.8 ± 65.4% 
increase compared to 30mM D-glucose alone) (Figure 7.6A) The rise in MCP-
1 under hyperglycaemic conditions was dependent on the concentration of 
apyrase added (Figure 7.6B). 
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Figure 7.6 ATP may regulate hyperglycaemia-induced MCP-1 secretion via multiple
P2 receptors. A,B: Incubation of HMCs with the ATP hydrolysing agent apyrase, in the
presence or absence of hyperglycaemia. A; Apyrase (5U/ml) induced a rise in MCP-1
secretion under both normal and high glucose conditions. B: The effect of a range of
concentrations (0.5 – 5U/ml) were examined; a trend towards increased MCP-1 secretion
with increasing apyrase concentration became statistically significant at 5U/ml. C: The
P2Y2/4 agonist, UTPγS, at 10μM produced a small but non-significant rise in MCP-1
release under low glucose conditions but the opposite effect under high glucose conditions.
D: D-glucose. *: p<0.05; **: p<0.01; ***: p<0.001; NS: Not significant.
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7.2.8 Hyperglycaemia-induced MCP-1 secretion may be regulated by multiple 
competing purinoceptor signals 
 
The observed enhancement of MCP-1 release with the addition of the ATP-
hydrolysing enzyme apyrase raises the possibility that ATP or adenosine may 
provoke differential effects on MCP-1 secretion from HMCs, presumably as a 
result of activity at multiple receptors. ATP is the dominant agonist at all P2X 
receptors and several P2Y receptors including P2Y2 and P2Y11. To 
investigate this further, cells were cultured in the presence of 5-BDBD, a 
potent P2X4 receptor antagonist, and UTPγS, an agonist at the P2Y2 and 
P2Y4 receptors, both of which have been implicated in inhibitory effects on 
ECM production in rat MCs (Solini et al., 2005). Expression of both P2X4 and 
P2Y2 has previously been demonstrated in pHMC cultures (Solini et al., 
2007). 
 
UTPγS (10µM) produced a trend towards increased MCP-1 release under 
normoglycaemic conditions (7.6% increase vs 4mM D-glucose, p>0.05) but a 
trend towards reduced MCP-1 secretion under hyperglycaemic conditions 
(10.3% reduction compared to basal secretion vs 30mM D-glucose, p>0.05, 
pooled data from 2 trials.) (Figure 7.6C). 
 
P2X4 expression in pHMC was examined using Western blotting of cell 
lysates. Using a polyclonal anti-P2X4 primary antibody, a band of the 
anticipated molecular weight (62kD) was observed in lysates from cells 
grown for 48 hours in both 4mM and 30mM D-glucose media (Figure 7.7A). A 
trend towards increased P2X4 expression, as quantified by band 
densitometry, was apparent in cells grown under hyperglycaemic conditions 
(Figure 7.7B). Addition of 5-BDBD (10µM) to cultures provoked an additional 
increase in MCP-1 release under high glucose, but not low glucose, conditions 
(85.9% increase compared to 30mmM D-glucose alone, p<0.05, pooled data  
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Figure 7.7 P2X4 is antagonistic to P2X7 with respect to
hyperglycaemia-induced MCP-1 secretion. A,B: Specific immunoblot for
P2X4 with an actin loading control (A) and P2X4 expression quantified by
densitometry (B). P2X4 was expressed under basal culture conditions,
with a trend towards upregulated expression after culture in
hyperglycaemic medium. C: Incubation with the selective P2X4 antagonist.
5-BDBD, at 10μM produced an additive rise in MCP-1 secretion under
hyperglycaemic conditions, but did not augment MCP-1 release in
normoglycemia. D: D-glucose. *: p<0.05; **: p<0.01.
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from two trials), suggesting that signalling via P2X4 and P2X7 is antagonistic 
with respect to MCP-1 release (Figure 7.7C).  
 
 
7.3 Discussion 
 
Renal infiltration by macrophages plays an important role in the 
pathogenesis of DN and represents a novel facet of disease to target 
therapeutically. Based on data presented elsewhere in this thesis (Chapters 4 
and 5), expression of P2X7 appears to be required for development of the 
expected inflammatory response observed in both the pancreas after 
induction of diabetes with STZ, and in the kidney during hyperglycaemia. In 
this chapter, I have examined the production of the key macrophage 
chemokine MCP-1 by different resident glomerular cells in response to 
hyperglycaemia and the P2X7-dependence of this response in primary HMCs. 
While conditionally-immortalised human podocytes and transformed HMCs 
both exhibited a marked increase in MCP-1 secretion in response to 
stimulation with TNFα, confirming their potential to upregulate and secrete 
this cytokine under inflammatory stress, neither cell line displayed a robust 
or reproducible response to hyperglycaemia. Consequently, neither line was 
suitable for further investigation of P2X7 in this context. 
 
Conversely, primary HMCs exhibited a reproducible increase in MCP-1 
secretion when cultured in high glucose, which was independent of osmotic 
stress, making these cells an excellent model for further study. Using this 
model, I have demonstrated that glucose-induced MCP-1 release is, at least in 
part, dependent on the P2X7 receptor. Surprisingly, hydrolysis of ATP with 
apyrase produced the opposite direction of response to P2X7 blockade, 
suggesting involvement of other P1 or P2 receptors in the modulation of 
MCP-1 release. Selective blockade of P2X4 also enhanced MCP-1 release, 
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suggesting this may be one such receptor antagonising the effect of P2X7. The 
implication is that competing signals through P1 or P2 receptors may ‘fine 
tune’ local MCP-1 release depending on current levels of receptor expression, 
local concentration of ATP or ectonucleotidase activity. The role of adenosine 
in regulating MCP-1 release from pHMCs was not tested in this study, but 
represents an important focus for future research, particularly as CD73, an 
important source of local adenosine production, is upregulated in the kidneys 
of mice with DN (Tak et al., 2013). 
 
Expression of P2X7, albeit at low levels, has previously been demonstrated at 
both mRNA and protein levels in human and rat MCs (Solini et al., 2005, 
Solini et al., 2007). P2X7 mRNA can be upregulated in rat MCs through 
stimulation by TNFα, although not reportedly by hyperglycaemia (Harada et 
al., 2000, Solini et al., 2005). When present, P2X7 is typically reported to form 
ring-like structures at the periphery of the cell visualised by specific 
immunofluoresence; the incidence of such structures is enhanced in 
fibroblasts by hyperglycaemia, mirroring the findings in this study (Solini et 
al., 2000).  P2X7 has previously been shown to mediate ATP-induced 
apoptosis in rat MCs, although this does not appear to be true in human MCs 
where P2X4 has a more prominent role at least under basal conditions 
(Schulze-Lohoff et al., 1998, Harada et al., 2000, Solini et al., 2007). 
 
Unlike in macrophages where P2X7 has a clear role in the inflammatory 
cascade and cytokine release, the role of P2X7 in secretion of inflammatory 
molecules from MCs has not been studied. MCs do not represent a major 
source of IL-1, the cytokine most tightly linked to P2X7, although 
upregulation of IL1β mRNA in MCs has been shown in the rat model of anti-
GBM nephritis and small detectable increases in IL1β secretion have been 
observed in response to hyperglycaemia in HMCs in vitro (Tesch et al., 1997, 
Wu et al., 2010b). MCs do, however, represent an important source of other 
inflammatory mediators including TNFα, MCP-1 and MIP-1α (Wu et al., 
230 
 
2010b). IL1β itself represents an important inducer of MCP-1 secretion from 
MCs, while IL1-RA, the endogenous IL-1 antagonist, almost entirely 
suppresses leukocyte infiltration in experimental models of 
glomerulonephritis (Lan et al., 1993, Chikaraishi et al., 2001). 
 
In this study, negligible IL1β release could be detected from MCs, whether 
cultured for 48 hours in normal or high glucose or in the presence of TNFα, 
or after 30 minute application of 5mM ATP following preculture in TNFα-
supplemented medium, a potent combination inducing IL1β maturation and 
release from macrophages (Franchi et al., 2009). Although this does not 
entirely exclude the possibility of low level hyperglycaemia-induced, P2X7-
dependent IL1β release acting in a paracrine fashion to upregulate MCP-1, it 
seems probable that P2X7 regulates MCP-1 synthesis or release via an 
independent mechanism. Experiments performed in astrocytes have 
suggested that P2X7 acts to increase MCP-1 expression via activation of the 
mitogen-activated protein kinases (MAPK) ERK1/2 and p38, discrete from 
the caspase-1 pathway associated with IL1β release (Panenka et al., 2001). 
 
Work examining ECM protein production from rat MCs exposed to 
hyperglycaemia has demonstrated how competing signals through P2 
receptors may provoke opposing effects (Solini et al., 2005). The authors 
demonstrated that a range of P2X and P2Y receptor subtypes are expressed 
in MCs and extracellular ATP levels rose after exposure to hyperglycaemia. In 
this system, stimulation with ATP and BzATP (presumed to be acting via the 
P2X7 receptor) led to a dose-dependent increase in ECM production under 
both normal and high glucose conditions while the P2Y agonist, UTP, led to a 
reduction in ECM synthesis. The data presented in this thesis suggests a 
similar balance of competing purinoceptor signals may exist in the control of 
MCP-1 secretion by MCs, with a suggestion of functional antagonism between 
P2X7 and P2X4. Physiological antagonism between P2X7 and P2X4 has been 
described in the normal control of renal arterial resistance in the rat, 
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although in vitro studies of P2X4 in renal tubular epithelial cells have 
suggested they transduce a pro-inflammatory response after high glucose 
stimulation, contrary to the present findings in mesangial cells (Chen et al., 
2013, Menzies et al., 2013). 
 
P2X4 shares structural and functional similarities with P2X7, including the 
ability to undergo pore-like transformation, and is frequently co-expressed 
with P2X7, although its affinity for ATP is considerably higher (Guo et al., 
2007). Previous descriptions of interaction between P2X4 and P2X7 have 
been co-operative, for instance in the facilitation of cytokine release and 
apoptosis from murine macrophages, while receptor subunits of the two 
receptors may be capable of forming heteromeric channels (Guo et al., 2007, 
Kawano et al., 2012, Sakaki et al., 2013). Although no statistically significant 
effect was noted with UTPγS, a P2Y2/4 agonist, it should be noted that BzATP 
possesses antagonistic properties at P2Y1 and P2Y4 receptors in addition to 
agonism at P2X7 and hence the possibility of a role for P2Y receptors in the 
modulation of MCP-1 release is not excluded (Vigne et al., 1999, Wildman et 
al., 2003). 
 
In summary, P2 receptors appear to play a clear role in the regulation of 
MCP-1 release from MCs in vitro, and, by corollary, organisation of the 
glomerular inflammatory response to hyperglycaemia. Future efforts to 
delineate the P2 receptor dependency of inflammatory cytokine release from 
other resident renal cell types will be needed to ascertain whether 
pharmacological manipulation of individual or multiple P2 receptors in vivo 
would be anticipated to have a net beneficial effect. The data presented is 
consistent with the observation that renal macrophage recruitment is 
attenuated when P2X7 is deficient, and provides a putative mechanism for 
this phenomenon. 
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CHAPTER 8 
 
Discussion 
 
 
8.1 Summary of key findings and evaluation of the experimental 
hypotheses 
 
The work described in this thesis has been conducted to test a central 
research question: "Does P2X7 contribute to the pathogenesis of diabetic 
nephropathy?". The following novel findings have emerged from this 
research: 
 
 P2X7 is constitutively expressed in distal convoluted tubule in human, 
rat and mouse kidney, with glomerular upregulation apparent in all 
three species when diabetes is present. 
 
 P2X7 is required for development of insulinitis after low dose STZ in 
the mouse, with partial protection against induction of diabetes 
observed in Pfizer P2X7 KO animals. 
 
 P2X7 contributes mechanistically to the glomerular inflammatory 
response observed after low dose STZ in the mouse. 
 
 P2X7 is expressed in human mesangial cells in vitro and contributes to 
chemokine production after exposure to hyperglycaemia. Competing 
purinoceptor signals appear able to modulate this response. 
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With reference to the main research question, it also serves to highlight those 
findings which have proved either negative or equivocal: 
 
 Genetic P2X7 deficiency in the mouse did not ameliorate albuminuria, 
interstitial fibrosis or loss of GFR at the early (12 week) time-point 
studied, and mRNA levels of the chemokine osteopontin were actually 
increased. 
 
 No statistically significant effect was observed on any measured 
parameter when uninephrectomised diabetic rats were treated with a 
selective P2X7 antagonist between weeks 8 and 12, although a trend 
towards reduced interstitial macrophage infiltration was apparent in 
high-dose (50mg/kg) antagonist-treated animals. 
 
Taken together, these findings suggest that P2X7 has an important role in 
facilitating activation of the innate immune system in experimental diabetes 
induced with STZ. While this function may, in part, derive from the well-
characterised role of P2X7 in IL1β/IL18 maturation and release from 
inflammatory cells (Surprenant et al,. 1996), the in vitro data obtained in 
mesangial cells suggests that P2X7 activation may directly or indirectly 
influence production of other cytokines crucial to the inflammatory response, 
such as MCP-1, by resident renal cell types. The similar histological patterns 
of receptor expression observed in all three species studied suggest that 
these findings may potentially translate to human disease. 
 
 
8.2 P2X7 and albuminuria 
 
While both rat and mouse models of DN histologically displayed early 
disease, increased albumin excretion was present in diseased animals, and 
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was unaffected by P2X7 deficiency or inhibition. Hence, it appears that P2X7 
activation does not contribute to the mechanism by which albuminuria is 
initiated despite its early glomerular upregulation in diabetes. The effect of 
P2X7 deficiency on podocyte detachment and apoptosis, an important early 
event in diabetic glomerulopathy, was not directly examined in this study, 
and would merit further investigation; reduced glomerular cell apoptosis has 
previously been demonstrated in the GSK P2X7 KO mouse in the high fat diet 
model of metabolic syndrome (Solini et al., 2013).  Previous studies have 
demonstrated that renal macrophage infiltration drives progressive disease 
in both glomerular and interstitial compartments in DN; given the reduced 
accumulation of glomerular macrophages observed in diabetic P2X7 KO mice, 
it is tempting to speculate that P2X7 may contribute to this disease 
amplification loop, but longer term study of models displaying a more severe 
disease phenotype would be required to confirm this (Chow et al., 2006, 
Chow et al., 2007). 
 
 
8.3 P2X7, interstitial fibrosis and splice variant receptor expression in 
KO mice 
 
A moderate amount of interstitial fibrosis, typically associated with advanced 
DN, was observed in the mouse model of STZ-induced DN, and was not 
ameliorated in GSK P2X7 KO mice. The quantity of interstitial fibrosis 
appeared somewhat disproportionate to the degree of glomerulopathy; the 
absence of an increase in interstitial macrophage number in WT diabetic 
mice is also surprising, as local inflammation is an important driver of 
tubulointerstitial injury in this model (Chow et al., 2004b). These findings 
may reflect the use of older, 8-12 month old mice in the study, but may also 
imply the contribution of other mechanisms of interstitial injury. While STZ 
has been shown to cause minimal direct nephrotoxicity when administered 
in a low dose protocol (with hyperglycaemia fully corrected by insulin 
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treatment), this has not been replicated in aged mice where the threshold of 
injury may be lower (Chow et al., 2006). Similarly, tolerance of severe 
polyuria and relative hypovolaemia may be altered in older mice, also 
predisposing to tubular injury. 
 
However, the lack of impact of P2X7 deficiency on tubulointerstitial fibrosis 
remains surprising. A previous study investigating the effect of P2X7 
deficiency on tubulointerstitial fibrosis, using the UUO model in Pfizer P2X7 
KO mice, showed reduced fibrosis, TGFβ expression and interstitial 
macrophage accumulation (Goncalves et al., 2006). Similarly, pulmonary 
fibrosis after bleomycin was ameliorated in the Pfizer mouse (Riteau et al., 
2010). Interstitial fibrosis measurements were not reported in the study of 
high fat diet-induced metabolic syndrome in GSK P2X7 KO mice (Solini et al., 
2013). 
 
As discussed previously (Chapter 5), neither available P2X7 KO mouse 
represents a true 'global' receptor knockout. The GSK mouse retains a 
functional exon 1 splice variant (P2X7K) which displays increased sensitivity 
of pore-formation to BzATP, is insensitive to the P451L single nucleotide 
polymorphism (SNP), and is the receptor subtype that mediates NAD-
dependent ADP-ribosylation; P2X7K is absent in the Pfizer mouse (Xu et al., 
2012). While P2X7K has a relatively restricted tissue distribution compared 
to P2X7A, it is known to be present in T lymphocytes and spleen; expression 
in kidney has not been studied (Nicke et al., 2009). Although no significant 
glomerular P2X7 expression was observed in GSK P2X7 KO mice, residual 
receptor expression was demonstrated by immunohistochemistry in a subset 
of renal tubules in this study, however the precise receptor variant was not 
characterised. It is likely that persistent tubular expression of the functional 
P2X7K splice variant underlies the lack of protection against 
tubulointerstitial fibrosis seen in the GSK KO mouse in this model of DN. 
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Pfizer P2X7 KO mice also express a splice variant receptor which escapes 
deletion (Masin et al., 2011). This ΔC-terminal splice variant receptor has 
reduced function and, when co-expressed with P2X7A, exerts a dominant-
negative effect. Immunohistochemistry for P2X7 performed on pancreas 
from Pfizer KO mice, using an antibody raised against the distal C-terminus of 
P2X7 (APR-004, Alomone Labs), revealed positive staining in a distribution 
similar to that seen in WT mice, albeit with reduced frequency of positive 
cells. The staining pattern in WT mice recapitulated published data obtained 
using a different antibody (Roche Bioscience) also recognising the C-terminal 
domain (Coutinho-Silva et al., 2007). APR-004 does not recognise the ΔC-
terminal splice variant, but has previously been used to demonstrate residual 
receptor expression within brain tissue of the Pfizer KO mouse, while 
confirming absence of expression in macrophages (Sanchez-Nogueiro et al., 
2005, Masin et al., 2011).  Taken together, these findings strongly suggest the 
existence of at least one additonal, uncharacterised, splice variant which 
escapes deletion in the Pfizer KO mouse, further complicating interpretation 
of data obtained in experiments using this strain. 
 
 
8.4 P2X7 and glomerular macrophage infiltration 
 
The reduction in glomerular macrophage numbers observed in GSK P2X7 KO 
mice prompted subsequent in vitro studies using resident glomerular cells; 
these experiments suggest that P2X7 may regulate secretion of MCP-1 from 
mesangial cells under hyperglycaemic conditions. MCP-1 has a key role in 
mediating monocyte/macrophage infiltration in acute and chronic 
glomerular inflammatory conditions, and also in experimental DN (Wenzel et 
al., 1997, Fujinaka et al., 1997, Chow et al., 2006). Amelioration of murine 
nephrotoxic nephritis by genetic P2X7 deficiency in the GSK KO mouse, was 
associated with almost complete suppression of urinary MCP-1 secretion, 
disproportionate to the reduction in glomerular macrophage number, 
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suggesting a possible causal relationship as opposed to a bystander effect 
(Taylor et al., 2009). IL1β is a potent inducer of MCP-1 secretion from human 
mesangial cells (Lee et al., 2003). IL1β could not be detected by ELISA in cell 
culture supernatants, when cells were exposed to either TNFα or 
hyperglycaemia for 48 hours, with or without a subsequent 30 minute 
exposure to 5mM ATP. The combination of priming with TNFα followed by a 
short exposure to ATP represents a robust stimulus to pro-IL1β maturation 
and release in macrophages, and would be anticipated to demonstrate IL1β 
release from mesangial cells if capable of doing so (Franchi et al., 2009). The 
possibility still remains, however, that low level IL1β release (below the 
threshold of detection by ELISA) acts in an autrocrine or paracrine fashion to 
stimulate MCP-1 release and underlies the association between P2X7 and 
MCP-1 production. 
 
While mRNA expression of MCP-1 in whole kidney tissue lysates was 
increased in WT diabetic mice, no reduction was observed in GSK KO 
animals, and transcriptional levels of osteopontin, another chemokine, were 
actually elevated in the KO group. This may, in part, be explained by the 
observed differences in outcome between glomerular and interstitial 
compartments, as discussed above, and also residual P2X7 receptor 
expression at these two sites. A clearer appreciation of the effect of P2X7 
deficiency on chemokine expression in this model may have been gained 
either by analysing transcriptional changes in isolated glomerular mRNA, or 
by performing specific immunohistochemistry and separately assessing 
staining in glomerular and interstitial compartments. 
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8.5 P2X7 and pancreatic injury 
 
The serendipitous observation that GSK P2X7 KO mice appeared protected 
from the induction of diabetes with STZ was explored more closely in the 
Pfizer P2X7 KO; in this mouse, protection from diabetes was clear-cut, with 
reduced islet inflammation and macrophage infiltration. In contrast to human 
disease, few T lymphocytes were seen accumulating in islets in this mouse 
model, although macrophages also form part of the islet inflammatory 
infiltrate in human type 1 diabetes, and interest has grown in targeting 
innate immune pathways to slow pancreatic destruction (Foulis, 2008, 
Mandrup-Poulsen et al., 2010).  
 
IL1β, the release of which from macrophages is partly dependent on P2X7 
activation, has attracted particular attention; β-cells are highly sensitive to 
IL1β-induced apoptosis, and IL1β is also able to polarise T cells towards a 
pro-inflammatory phenotype (such as TH1 or TH17) (Mandrup-Poulsen et al., 
2010). A recent clinical trial compared the effect of either the IL1 receptor 
antagonist anakinra, or the monoclonal anti-IL1 antibody canakinumab, 
against placebo in patients with newly diagnosed type 1 diabetes. 
Monotherapy with these drugs did not prove effective in retarding disease 
progression, although hope remains that such a strategy may be clinically 
useful if combined with simultaneous manipulation of the adaptive immune 
response (Moran et al., 2013). 
 
As discussed in the context of DN, it is likely that P2X7 may also induce local 
inflammation and tissue injury via IL1β-independent mechanisms. Like 
mesangial cells, β-cells also secrete MCP-1, raising the possibility that P2X7 
activation may drive macrophage recruitment via increased secretion of this 
chemokine (Chen et al., 2001). P2X7 may also mediate direct ATP-induced 
cell death in β-cells, similar to the effect of ADP acting via the P2Y13 receptor 
(Tan et al., 2010). Notably, ATP stimulation also inhibits the suppressive 
239 
 
potential and stability of regulatory T cells via the P2X7 receptor,  while P2X7 
has been shown to have a role in driving T cell lineage decisions in the 
thymus (Schenk et al., 2011, Frascoli et al., 2012). This pleiotropic effect on 
the immune system renders P2X7 an important candidate for further study, 
suggesting manipulation of P2X7 may yield benefits beyond simple 
downsteam inhibition of IL1β. 
 
As discussed in Chapter 4, Pfizer P2X7 KO mice fed a high sucrose/high fat 
diet exhibited severe glucose intolerance and failure to appropriately 
increase β-cell mass, accompanied by reduced circulating IL1-RA levels (Glas 
et al., 2009). This suggests pancreatic P2X7 signalling may be either 
beneficial or deleterious depending on the mechanism of islet injury or time-
point of disease (Glas et al., 2009). This, combined with differences in P2X7 
expression between human and rodent islets, make the clinical effects of 
P2X7 antagonism in human disease difficult to predict and mandate further 
study in human tissue before considering a clinical trial of a selective P2X7 
inhibitor. 
 
 
8.6 Potential translational relevance of findings 
  
How may the findings in this study translate to opportunities in the 
treatment of human disease? Current therapy in DN centres on good 
glycaemic and blood pressure control and use of ACE inhibitors primarily to 
reduce glomerular hypertension and albuminuria. Targeting of innate 
immune mechanisms and, more specifically, macrophage activation, 
represents a potential avenue for adjunctive therapy to delay progression of 
disease. Selective antagonism of P2X7 may provide one option by which to 
achieve this, particularly since orally-active selective human P2X7 
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antagonists are already available and have proved well tolerated in clinical 
studies to date (Arulkumaran et al., 2011).  
 
Evidence of benefit in pre-clinical studies would need to be strengthened 
prior to considering clinical translation, for instance through examining the 
effect of long-term P2X7 receptor antagonism in a mouse model which 
exhibits convincing evidence of established DN (eg. STZ diabetic eNOS KO 
mice). The present study has also brought into focus the functional 
importance of P2X7 receptor splice variant expression, and the expression 
profile for receptor variants and relative potency of antagonists at these 
isoforms in both rodents and humans should be considered when planning 
any future human study. 
 
 
8.7 Limitations of the work, potential experimental refinements and 
future research 
 
Limitations of the animal models employed to examine the functional role of 
P2X7 in DN have been discussed throughout this thesis. A number of 
modifications and refinements to the experimental protocols may, however, 
have yielded more clear-cut answers to the experimental hypotheses. 
 
 
8.7.1 Choice of mouse and genetic background 
 
The C57BL/6 background is relatively resistant to the renal consequences of 
diabetes and work to understand the genetic basis for this is on-going 
(Brosius et al., 2009). Use of aged male mice in this study enhanced the 
severity of disease, although the DN phenotype after 12 weeks would still be 
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regarded as 'mild'. Although the model proved sufficient to delineate an effect 
of P2X7 deficiency on glomerular macrophage accumulation, it was not 
possible to conclude whether ‘harder’ signs of established DN, such as 
development of typical glomerular lesions, are similarly ameliorated. Back-
crossing the KO mouse onto a more susceptible genetic background (eg. 
DBA/2) may have helped provide a more robust disease phenotype, and this 
is currently being performed in the laboratory with the Pfizer mouse to 
permit study of P2X7 in a mouse model of uraemic vascular calcification 
(Gurley et al., 2006). 
 
C57BL/6 is also notable for carrying the P451L single nucleotide 
polymorphism in P2X7 which confers drastically reduced sensitivity to ATP-
induced pore formation and knock-on effects on P2X7-mediated apoptosis 
and cytokine release (Adriouch et al., 2002). Testing the effect of the P2X7 KO 
against a mouse already carrying a hypofunctional receptor may thus have 
led to underestimation of treatment effect. 
 
Finally, as discussed at length, the GSK P2X7 KO mouse does not represent a 
true global receptor KO. While the Pfizer KO also expresses splice variants 
which escape deletion, the functional difference between the animals is 
emphasised by the differing degrees of resistance to diabetes induction 
apparent in this study. Any future experiments should employ the Pfizer KO 
in preference to the GSK. 
 
 
8.7.2 Choice of mouse model 
 
While STZ-induced diabetes remains a useful tool due to the production of a 
relatively ‘pure’ hyperglycaemic phenotype, renal disease is strain-
dependent, generally mild, and potentially confounded by direct renal 
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tubular toxicity. Newer genetic models of disease, in particular eNOS KO mice 
combined with low dose STZ, present a more robust and severe phenotype, 
even on a C57BL/6 background (Kanetsuna et al., 2007). 
 
Using this model it would be feasible to test the effect of P2X7 deficiency with 
or without co-administration of an ACE inhibitor to simulate a proposed 
treatment regimen in humans. Demonstration of an additive effect would 
provide strong pre-clinical evidence for P2X7 inhibition in human disease. A 
similar protocol could be undertaken in db/db mice with co-existent eNOS 
deficiency, to test the hypothesis in a model of accelerated nephropathy in 
type 2 diabetes. 
 
 
8.7.3 Downstream mechanisms of P2X7 signalling in DN 
 
Although this study has produced several findings regarding the mechanism 
by which P2X7 signalling contributes to pathogenesis of DN, refinements to 
the experimental protocol could have yielded further insights. In the mouse 
study of DN, Isolation of glomeruli, either by sieving of renal tissue or laser-
capture micro-dissection, would have allowed analysis of transcriptional 
changes in the glomeruli alone, and overcome problems interpreting data in 
the light of diverging responses of glomerular and interstitial compartments 
to the effect of P2X7 gene deletion. This is particularly pertinent in view of 
the apparent differences in residual receptor splice variant expression 
between glomeruli and tubules in the GSK KO mouse. 
 
The association between P2X7 and inflammatory cytokine release from 
resident glomerular cells could also be further dissected. The extended 
pattern of inflammatory and pro-fibrotic cytokines released under conditions 
of hyperglycaemia, with or without P2X7 blockade, could be assayed using a 
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high-sensitivity bead-based multiplex assay, to determine the specificity of 
the observed relationship with MCP-1. This approach could also be 
complemented by transcriptional analysis of a similar range of mediators. 
The caspase-1/IL1β dependence of P2X7-mediated MCP-1 release could be 
further explored by repeating experiments in the presence of a caspase-1 
inhibitor. Similar approaches could be used to investigate the role of the large 
pore pathway and ERK signalling in P2X7-induced MCP-1 release, by using 
selective inhibitors of panx-1 and ERK-1or -2 respectively.  Similar studies 
undertaken in an alternative podocyte cell-line would resolve whether these 
responses are common to other resident renal cells. Finally, additional work 
using modulators of adenosine signalling (eg adenosine deaminase) would 
determine whether the observed increase in hyperglycaemia-induced MCP-1 
release from pHMCs with apyrase is, in fact, adenosine dependent. 
 
 
8.7.4 P2X7, islet inflammation and diabetes 
 
The finding that P2X7 deficiency protects mice against induction of diabetes 
with STZ may be relevant to the pathogenesis of human type 1 diabetes but 
requires further investigation. Administration of low dose STZ to P2X7 KO 
mice chimaeric for WT bone marrow would help elucidate the relative 
contribution of P2X7 signalling in peripheral immune cells to this protective 
effect. Similar studies using a genetically engineered cell-type specific P2X7 
KO,  harnessing for instance, the insulin gene promoter to isolate P2X7 gene 
silencing in β cells, would provide complementary information on the role of 
P2X7 in resident islet cells. 
 
 A further experiment could assess the effect of selective pharmacological 
inhibition of P2X7 on induction of STZ diabetes in the rat, with the caveat that 
this is less dependent on an autoimmune insulinitis than low dose STZ in the 
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mouse. In vitro studies, ideally using islets extracted from normal healthy 
human pancreas, would help delineate the consequences of P2X7 activation 
on cytokine and chemokine release and cell survival, and the effect of P2X7 
receptor blockade on the response to injurious stimuli, including STZ and 
hyperglycaemia, could be studied. 
 
 
8.8 Conclusion 
 
P2X7 is not significantly expressed in the normal glomerulus, but is 
upregulated in this location at an early timepoint in rodent models of both 
type 1 and type 2 diabetes as well as human disease. P2X7 contributes to 
both glomerular and pancreatic islet inflammation after STZ, with partial 
protection against STZ diabetes observed in Pfizer P2X7 KO mice. P2X7 
appears to regulate secretion of the pro-inflammatory chemokine, MCP-1, 
from primary human mesangial cells under diabetic conditions, as part of a 
wider spectrum of purinoceptor responses. 
 
These findings place P2X7 firmly at the heart of the innate immune response 
observed in experimental diabetes and DN. The human biopsy tissue study 
and human cell culture data presented in this thesis, correspond well with 
the results from animal models, boding well for future translational efforts.  
 
Further pre-clinical studies, primarily designed to test the effect of P2X7 
signalling on major long-term renal outcomes in DN (eg. glomerulosclerosis, 
interstitial fibrosis and loss of GFR), are required before receptor antagonists 
can be trialled in human disease, together with exhaustive characterisation of 
receptor splice variant expression in human immune cells and kidney. 
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